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Abstract——The endothelins comprise three structur-
ally similar 21-amino acid peptides. Endothelin-1 and -2
activate two G-protein coupled receptors, ETA and ETB,
with equal affinity, whereas endothelin-3 has a lower
affinity for theETA subtype.Genes encoding thepeptides
are present only among vertebrates. The ligand-receptor
signaling pathway is a vertebrate innovation and may
reflect the evolution of endothelin-1 as the most potent
vasoconstrictor in the human cardiovascular system
with remarkably long lasting action. Highly selective
peptide ETA and ETB antagonists and ETB agonists
together with radiolabeled analogs have accurately
delineated endothelin pharmacology in humans and
animal models, although surprisingly no ETA agonist
has been discovered. ET antagonists (bosentan,
ambrisentan) have revolutionized the treatment of
pulmonaryarterialhypertension,with thenextgeneration
of antagonists exhibiting improved efficacy (macitentan).
Clinical trials continue to explore new applications,
particularly in renal failure and for reducing proteinuria
in diabetic nephropathy. Translational studies suggest
a potential benefit of ETB agonists in chemotherapy
and neuroprotection. However, demonstrating clinical
efficacy of combined inhibitors of the endothelin
converting enzyme and neutral endopeptidase has
proved elusive. Over 28 genetic modifications have
been made to the ET system in mice through global or
cell-specific knockouts, knock ins, or alterations in
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gene expression of endothelin ligands or their target
receptors. These studies have identified key roles
for the endothelin isoforms and new therapeutic targets
in development, fluid-electrolyte homeostasis, and
cardiovascular and neuronal function. For the future,
novel pharmacological strategies are emerging via
small molecule epigenetic modulators, biologi-
cals such as ETB monoclonal antibodies and the
potential of signaling pathway biased agonists and
antagonists.
I. Historical Introduction
The vasoconstrictor actions of a factor obtained from
the culture media of bovine aortic endothelial cells
was first characterized in 1985 by Hickey et al. (1985)
and was proposed to have the chemical composition of a
peptide, because trypsin abolished the observed activ-
ity. The structure of this endothelium-derived constrict-
ing factor was identified in 1988 by Yanagisawa et al.
(1988) from the supernatant of porcine aortic endothe-
lial cells and named endothelin (now called endothelin-
1 or ET-1). This remarkable paper ignited worldwide
interest in both academia and the pharmaceutical
industry by showing that ET-1 was the most potent
vasoconstrictor identified to date, producing extremely
powerful contraction of a range of mammalian blood
vessels in vitro, including human arteries and veins.
The response was unusually long lasting and difficult to
wash out (Fig. 1). In the anesthetized denervated rat, in
vivo ET-1 caused a rise in arterial pressure, and this
pressor response was typically sustained for more than
1 hour. In the same year, the sarafotoxins, a family of
peptides with high degree of sequence similarity to ET-
1, were identified from the venom of a snakeAtractaspis
engaddensis or burrowing asp (Kloog et al., 1988;
Takasaki et al., 1988). In accord with the actions of
ET-1 in vivo, the symptoms of envenomation included
very powerful contraction of the coronary arteries suffi-
cient to cause the heart to stop. In humans, two further
peptides, endothelin-2 (ET-2) and endothelin-3 (ET-3),
were identified (Inoue et al., 1989) to complete the family
of endogenous endothelin agonists. Pharmacological
preparations such as rat aorta and rabbit pulmonary
artery were initially identified that exhibited differ-
ences in the rank order of affinities for the three
endogenous ET isoforms, suggesting the presence of
two receptor subtypes. A year later, two novel G protein-
coupled receptors (GPCRs) were identified: ETA (Arai
et al., 1990)whereET-1 andET-2weremore potent than
ET-3 (ET-1 = ET-2 . ET-3), and ETB (Sakurai et al.,
1990), where all three isoforms were equally effective
(ET-1 = ET-2 = ET-3).
Yanagisawa et al. (1988) correctly predicted the bio-
synthesis of a 39-amino acid intermediate "Big endo-
thelin" from proendothelin by proteolytic cleavage at
paired basic residues and the subsequent production
of the mature 21-amino acid peptide by a previously
unknown processing pathway involving a putative
"endothelin converting enzyme." The predicted endo-
thelin converting enzyme-1 (ECE-1) was discovered
(Takahashi et al., 1993, Xu et al., 1994). A second
enzyme, ECE-2 (Emoto and Yanagisawa, 1995), was
also identified. Thus within 7 years, all the essential
components of the ET pathway had been revealed (Figs.
2 and 3).
Key milestones in the development of pharmacolog-
ical agents were the first ETA-selective peptide antag-
onists, BQ123 (Ihara et al., 1992a) and FR139317
(Aramori et al., 1993). ETB agonists were identified,
including the linear or modified ET-1 sequences
[Ala1,3,11,15]-ET-1 (Saeki et al., 1991), BQ3020; (Ihara
et al., 1992b), and IRL 1620 (Takai et al., 1992) and the
snake venom toxin sarafotoxin 6c (Williams et al.,
1991). The first selective peptide ETB antagonist was
KCl10nM
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20 min
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0.01   0.1     1        10     Cl
0.03   0.3      3 30
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Fig. 1. Long lasting vasoconstrictor response to 10 nM ET-1 in human mammary artery is maintained for over 2 hours but can be reversed by the
physiologic antagonist nitric oxide derived from a nitric oxide donor (A) or by the ETA antagonist PD156707 but not the ETB antagonist BQ788 (B).
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BQ788 (Ishikawa et al., 1994). It was very clear that the
clinical goal was the discovery of orally active, small
molecule ET receptor antagonists that would block the
potent and long lasting vasoconstrictor actions of ET in
the human cardiovascular system.Within 5 years of the
discovery of ET-1, the first ETA/ETB antagonist with
oral bioavailability was identified by Clozel et al.,
(1993). Its successor bosentan (Tracleer; Actelion,
Allschwil, Switzerland), also a mixed ETA/ETB antago-
nist, was the first in class to be introduced into the
clinic, initially for the treatment of pulmonary arterial
hypertension (PAH) (Rubin et al., 2002).
An ETA-selective antagonist ambrisentan (Letairis,
Volibris; Gilead, Foster City, California) was approved
for clinical use in PAH in 2007 (Vatter and Seifert,
2006), followed by the more ETA-selective antagonist
sitaxentan (Thelin; Pfizer, Groton, Connecticut) (Benza
et al., 2007; Galie et al., 2009). However, in 2010
sitaxentan was voluntarily withdrawn by Pfizer
(Groton, Connecticut) owing to cases of idiosyncratic
hepatitis, resulting in mortality from acute liver failure
(Don et al., 2012). Bosentan was the structural basis for
the development of macitentan, approved for clinical
use in 2013 and representing the next generation of
antagonists, being more potent, with longer receptor
occupancy as well as undergoing conversion to an active
metabolite, properties contributing to greater pharma-
codynamic and pharmacokinetic efficacy (Patel and
McKeage, 2014). Despite the success of both mixed
receptor and ETA-selective antagonists, the second
pharmacological strategy of reducing ET-1 levels by
inhibiting ECE has yet to be proven successful in the
clinic.
The aim of this review is to focus on key concepts in
the pharmacology of ETs, their receptors, and the
interaction of the signaling pathway with agonists,
antagonists, and synthetic enzyme inhibitors, particu-
larly in humans, in vitro and in vivo. Remarkably all
ET peptides, receptors, and synthetic enzymes have
been deleted in mice with many components selectively
deleted or overexpressed in specific cell types. The
resulting phenotypes have provided insights into their
role in the ET signaling pathway, which are evaluated
in this review. The third aim is to summarize advances
in the clinical pharmacology of ET agents. To date
nearly 28,000 endothelin-related papers and reviews
have been published. The following should be consulted
for more detailed information on ET pharmacology,
physiology, and pathology: antagonists (Kohan et al.,
2012; Clozel et al., 2013; Maguire and Davenport, 2015),
the heart (Drawnel et al., 2013; Chester and Yacoub,
2014; Nasser and El-Mas 2014), kidney (Kohan et al.,
2011a,b; Hyndman and Pollock, 2013; Boesen, 2015;
Culshaw et al., 2015), vasculature (Sandoval et al.,
2014), hypertension (Schiffrin, 2001; Rautureau and
Schiffrin, 2012; Speed and Pollock, 2013; Laffin and
Bakris, 2015), atherosclerosis and diabetes (Pernow
et al., 2012), cancer (Rosanò et al., 2013a; Irani et al.,
2014), and PAH (Moorhouse et al., 2013; Miyagawa and
Emoto 2014). The International Union of Pharmacology/
British Pharmacological Society (IUPHAR/BPS) cu-
rated database, Guide to PHARMACOLOGY, provides
detailed information on pharmacological parameters
for ET ligands (Davenport et al., 2015).
II. Endothelins and Sarafotoxins
A. Endothelin-1 and Big Endothelin-1
The structure of ET-1, considered the parent com-
pound of the family, is shown in Fig. 2 comprising 21
amino acids with a free amino terminus and C-terminal
carboxylic acid. Within the endothelins and sarafotox-
ins residues 1, 3, 8, 10, 11, 15, 16, 18, 20, and 21 are
21
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Fig. 2. Schematic diagram showing the sequences of ET, Big ET
precursors and sarafotoxin peptides. Amino acids that differ between
ET-1 and mature peptides or between Big ET-1 and precursors are shown
in blue. Labeling of [125I] radioligands at Tyr residues are shown by a
filled red circle. Residues that are thought from X-ray crystallography to
be aligned as a stripe as a result of a secondary helical structure
secondary helical structure are indicated with a star (Janes et al., 1994;
Orry and Wallace, 2000). These residues have also been shown
experimentally to be crucial for binding (Huggins et al., 1993). Arrows
indicate the site for cleavage of Big ETs to mature peptides: between
Trp21-Val22 amino acids for Big ET-1 and ET-2 and between Trp21-Ile22
for ET-1 and for Big ET-3.
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always conserved (Huggins et al., 1993). The ETs are
unusual compared with other bioactive peptides be-
cause the amino acid residues are linked by two
disulfide bonds. A number of three-dimensional nuclear
magnetic resonance (NMR) structures have been pro-
posed for ET-1 but these have not produced a consensus
for its conformation and are difficult to interpret
(Wallace and Janes, 1995). ET-1 is one of a very few
vasoactive peptides that have been successfully crys-
talized and the X-ray structure has been solved (Janes
et al., 1994). This differs from the various NMRmodels,
particularly in the C-terminal helical tail that is crucial
for receptor interaction, and the proposed structure is
supported by binding data. A major reason for the
variability in NMR is that these use ET-1 in organic
solvents, whereas X-ray studies were carried out on
crystals from an aqueous solution that better reflects
the in vivo environment.
The structure of ET-1 is unusual among the mamma-
lian bioactive peptides in possessing two intramolecular
disulfide bonds between Cys residues crosslinked at
positions 1 and 15 and 3 and 11 (Fig. 2). Experimentally,
residues at positions 10, 13, 14, 17, 18, and 21 are
crucial for binding (Huggins et al., 1993; Janes et al.,
1994; Orry and Wallace, 2000), with loss of Trp21 for
example completely abolishing activity. These residues
are located consecutively, separated by two amino acids,
which is consistent with a secondary helical structure.
X-ray crystallography also suggests there is a helical
structure, and these residues are aligned as a stripe
(Fig. 2).
Radioligand binding studies using [125I]-Big ET-1
demonstrated unequivocally that at physiologic concen-
trations, despite the presence of the mature sequence
within the molecule, Big ET-1 does not bind to either
receptor subtype (Russell et al., 1998). Molecular mod-
eling shows that the accessibility for binding of amino
acids 1–5 are greatly reduced in Big ET-1 compared
with ET-1 and that residues 16–21 are also affected as a
result of the folding back of the C terminus of Big ET-1.
In addition, Big ET-1 is resistant to proteolytic cleavage
by enzymes that are able to metabolize the mature
peptide (Peto et al., 1996). As a result, inhibition of the
processing of Big ET-1 to ET-1 is an attractive target for
lowering endogenous levels of the mature peptides
through selective ECE inhibition.
1. Endothelin-1 Synthesis within Endothelial Cells.
ET-1 is the most abundant isoform in the human
cardiovascular system and the primary source is
thought to be vascular endothelial cells, although the
peptide is produced by other cell types, including
epithelial cells, for example in the lungs, kidney, and
colon; macrophages and monocytes, enteric glia cells in
the periphery, as well as choroid plexus and certain
neurons and reactive glial cells in the central nervous
system. However, most of the information about ET-1
Prepro-ET-1 mRNA Prepro-ET-2 mRNA Prepro-ET-3 mRNA
Prepro-ET-1 Prepro-ET-2 Prepro-ET-3
Big-ET-1 Big-ET-2 Big-ET-3
ET-1 ET-2 ET-3
ETA Receptor ETB Receptor 
Agonist AgonistAntagonist AntagonistAntagonist
None S6c
IRL1620
BQ3020
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FR139317
PD156707
Furin Furin Furin
ECE-1ECE-1, ECE-2 KELL, ECE-1
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ECE 
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(EDNRA) (EDNRB)
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Inactive Metabolites
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Fig. 3. Schematic diagram illustrating synthesis of ET peptides and interaction with receptors. ET isoforms are synthesized by a three-step process:
Messenger RNA encodes a prepro-peptide that after a proteolytic cleavage initial of the signal peptidase to yield the propeptide is further cleaved by furin
to Big ET precursors. Synthesis of ET-1 has been studied in the most detail. Transformation to the mature, biologically active ET-1 is mainly by the action
of ECE-1 at pH 7 but also by ECE-2 at pH 5.5 within endothelial cells. On release from endothelial cells, about one in five molecules of Big ET-1 escape
conversion but further processing to ET-1 may occur by smooth muscle ECE or via alternative pathways catalyzed by chymase for ET-1. It is inferred that
ET-2 from endothelial cells is synthesized by a similar pathway. ET-3 is not released from human endothelial cells but is also synthesized in other cells by
ECE-1 with evidence for an additional pathway, KELL. ET-1 is metabolized by NEP to inactive metabolites. ETs mediate their actions via two GPCRs ETA
or ETB and the recommended agonists and antagonists that are most widely used are indicated together with ECE inhibitors.
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synthesis has been determined from studying endothe-
lial cells that form a single layer of cells lining every
blood vessel in the cardiovascular system that have a
mass comparable with other endocrine glands. ET-1 has
been detected in endothelial cells in all types of vessel,
from large conduit arteries, resistance arteries (contrib-
uting to themaintenance of blood pressure), large veins,
and venules. ET-1 is likely to be present and have a role
in controlling perfusion in every organ in the body.
ET-1 is synthesized and released continuously
from endothelial cells, and levels of pre-proendothelin
(preproET-1) are modulated predominantly at the level
of transcription, with evidence implicating numerous
transcription including, activator proton 1 (AP-1), nu-
clear factor kappa B, FOXO1, VezF1, HIF-1, and
GATA2. Both physical and chemical stimuli contribute
to alterations in levels of preproET-1 mRNA in physi-
ologic and pathophysiological conditions [e.g., shear
stress, hypoxia, thrombin, and vasoactive factors such
as angiotensin II (ANGII)] (for a detailed review of ET-1
gene regulation, see Stow et al., 2011). In the vascula-
ture, shear stress is critical in determining the balance
between ET-1 and NO production, and, at least in mice
in vivo, shear stress alteration in endothelial gene
expression appears to involve AMP-activated protein
kinase stimulation of the anti-inflammatory transcrip-
tion factor Krüppel-like factor 2 (Young et al., 2009).
Hypoxia, for example in tumors, also has an important
role in increasing expression of endothelial genes in-
cluding ET-1 that possess hypoxic responsive elements
in their promotors, contributing to disease progression
(Spinella et al., 2014). One of the most important
regulators of ET-1 production in endothelial cells is
transforming growth factor (TGF) b. It has been dem-
onstrated in bovine aortic endothelial cells in culture
that TGFb signaling via the ALK5/Smad 3 pathway
results in an increase in preproET-1 via an AP-1 site
and/or smad binding element (Castañares et al., 2007),
resulting in a mature cell phenotype.
2. ECE-1 Synthetic Pathway. ET-1 is synthesized in
a three-step process (Figs. 3 and 4). The ET-1 gene
encodes a 212-amino acid precursor, preproET-1. Re-
moval of the 17-amino acid signal by a signal peptidase
generates proET-1, which in turn is cleaved at both the
C and N terminals by furin enzymes, which remove
35 and 122 amino acids, respectively, to yield Big ET-1
(Xu et al., 1994; Turner and Murphy, 1996). PC7 has
also been proposed as a second convertase (Blais et al.,
2002); however, deleting furin in endothelial cells sub-
stantially reduced generation of ET-1 (Kim et al., 2012).
Furins activate a wide range of proteins by cleaving
basic amino pairs of Arg and Lys, and this stage is not
tractable to selective inhibition of the ET pathway.
In contrast, the final conversion is affected by an
unusual but selective hydrolysis of Trp21-Val22 by activity
of ECE-1. ECE-1 belongs to the type II membrane-bound
zincmetalloprotease family and exhibitsmaximal activity
at pH 7.0 for the cleavage of Big ET-1. ECE-1 comprises a
short cytoplasmic N-terminal tail, a membrane-spanning
region, and a large extracellular domain containing a zinc-
binding motif essential for enzymatic activity. Four iso-
forms,ECE-1a–d (Schweizer et al., 1997;Valdenaire et al.,
1999), derived from a single gene by differential splicing of
mRNA transcripts, have been identified in humans. The
enzymes differ only in the amino acid sequence of the
extreme N terminal and show comparable efficiency of
conversion of Big ET-1 (Jeng et al., 2002). They do differ in
their subcellular localization, although the relative levels
of the isoform mRNA species vary between human
tissues: ECE-1c mRNA is generally the predominant
isoform. ECE-1a and ECE-1c were localized at the cell
surface; ECE-1b was intracellular and showed significant
colocalization with a marker protein for the trans-Golgi
network (Schweizer et al., 1997). The fourth isoform
(ECE-1d) was also identified, with converting activity
comparable with that of the other three isoenzymes. In
contrast to ECE-1b, ECE-1d is expressed at the cell
surface, although less strongly than ECE-1a (Valdenaire
et al., 1999).
ECE-1 is widely expressed in human tissues (Rossi
et al., 1995; Davenport et al., 1998; Davenport and Kuc,
2000) and intriguingly is upregulated in a number
of cancers (Smollich et al., 2007; Whyteside et al.,
2014). Term embryos of ECE-1 knockout (KO) mice
(ECE-12/2) (section V.B.1) exhibited similar craniofa-
cial and cardiac abnormalities to those seen in ET-1-
and ETA-deficient embryos. Unexpectedly, in view of
the lowered efficiency of ECE-1 in generating ET-3 from
Big ET-3, epidermalmelanocytes and enteric neurons of
the distal gut were also absent in these animals, similar
to the developmental phenotype seen in ET-32/2 and
ETB KO mice (Yanagisawa et al., 1998b).
ET-1 is unusual for vasoactive peptides in being
synthesized by a dual pathway (Fig. 4). ECE-1 has been
visualized in small secretory vesicles of the constitutive
pathway, fromwhere ET-1 is thought to be continuously
released to maintain normal vascular tone (Haynes and
Webb, 1994). ET-1 has also been localized together with
ECE-1 and ECE-2 in specialized Weibel-Palade storage
granules that are unique to endothelial cells and that
are an integral component of the regulated pathway.
These structures degranulate after external physiologic
or pathophysiological stimulus (chemical or mechani-
cal), releasing ET-1 to produce further vasoconstriction
(Russell et al., 1998; Russell and Davenport, 1999a). Big
ET-1 that has escaped conversion to ET-1 within
endothelial cells can be detected in the plasma. ECE-1
has also been localized to smooth muscle cells in human
blood vessels and converts Big ET-1 in vitro and is
upregulated in atherosclerosis (Maguire et al., 1997;
Maguire andDavenport, 1998). Given the larger volume
of the smooth muscle compared with the single layer
of endothelium, smooth muscle ECE may be a more
important source of ET-1 in pathophysiological
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conditions. Plasma levels of ET-1 are typically ;5 pmol/l,
suggestive of a locally released rather than a circulating
peptide (Davenport et al., 1990). In comparison Big ET-1
is detected at ;1 pmol/l in plasma (Suzuki et al., 1991).
3. ECE-2 Synthetic Pathway. ECE-2 also belongs to
the type II membrane-bound zinc metalloprotease
family and shares 59% sequence similarity to ECE-1
(Emoto and Yanagisawa, 1995; Yanagisawa et al., 2000;
Lorenzo et al., 2001). In common with ECE-1, there are
also four ECE-2 isoforms possessing a conserved cata-
lytic unit and differing only in their N terminal. The
isoforms differ in their localization, and this may be the
reason for the variation in the N terminal; ECE-2b was
found to be highly expressed in neuroendocrine tissues
(brain, pituitary, and adrenal medulla), whereas the
other isoforms were in peripheral tissues (Ikeda et al.,
2002). In contrast to ECE-1, the optimum pH for ECE-2
activity is acidic (pH 5.5), which would favor an in-
tracellular localization and a potential role under low
pH conditions, for example in ischemia. This difference
provides an experimental method for distinguishing
between the activities of the two enzymes. In agree-
ment, ECE-2 was found to be localized to the acidified
environment of vesicles of the secretorypathway inhuman
endothelial cells but was not detected in Weibel-Palade
storage granules (Fig. 4; Russell and Davenport, 1999b).
Although ECE-2 efficiently converts Big ET-1, it is
important to emphasize that the enzyme is able to
process other biologically active peptides. In a study
testing ECE-2 for activity against 42 peptides, 10 were
processed including conversion of ANGI to ANG1–7
(a vasodilator) and the inactivation of bradykinin.
Selective pharmacological inhibition of ECE-2 activity
may therefore be difficult to interpret because other
vasoactive pathways could be altered in addition to ET-
1 (Mzhavia et al., 2003). ECEs have also been reported
to beneficially degrade intracellular beta-amyloid pro-
duced within the endosomal/lysosomal pathway and
autophagosomes (Pacheco-Quinto and Eckman, 2013).
Intriguingly, knocking out the ECE-2 gene in mice
(section V.B.1) was without any alteration of the
phenotype: mice show normal development, life span,
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Fig. 4. ET-1 is synthesized in human endothelial cells by a dual secretory pathway. ET-1 is continuously released from the small vesicles of the
constitutive pathway to interact with ET receptors to contribute to vasomotor tone. ET-1 is also released from the regulated pathway in response to
external stimuli from Weibel-Palade bodies that are unique to endothelial cells. In the human vasculature, ET-1 released abluminally from endothelial
cells, interacts mainly with ETA receptors on the underlying smooth muscle, with a small population of ETB receptors also mediating constriction in
some but not all vessels. In animals, vasoconstriction can be via ETB or a mixture of both depending on the vascular bed. The ET-1/ETA complex
undergoes internalization to the endosome before recycling of the receptor to the cell surface and provides a mechanism whereby ETA antagonist can
reverse an ET-1 response. Some ET-1 may also interact with endothelial ETB receptors in an autocrine manner and limit the constrictor response by
the release of vasodilators such as nitric oxide. ET-1/ETB complex is internalized and degraded to the lysosome; as a result ETB antagonists are unable
to displace receptor bound ligand. Low levels of ET-1 and Big ET-1 that has escaped conversion can also be detected in the plasma. Big ET-1 can also
undergo further conversion by smooth muscle ECE to the mature peptide.
364 Davenport et al.
and fertility (Yanagisawa et al., 2000). However, a
combined double KO, ECE-1(2/2)/ECE-2(2/2) resulted
in more severe or additional abnormalities than those in
the ECE-1 single knockout embryos, suggesting a signif-
icant developmental role for ECE-2. Importantly,whereas
levels of ET-1 were reduced, ET-1 was still detectable in
the double KO animals, emphasizing the potential for
contribution from other pathways to ET-1 synthesis.
4. Peptidic Converting Enzyme/Neutral Endopeptidase
Inhibitors: Phosphoramidon. There are two important
aspects of its properties that need to be considered in
interpreting the action of phosphoramidon on the
endothelin synthetic pathway. Phosphoramidon is
not selective for ECE-1, because it was originally
developed to inhibit a related enzyme neutral
endopeptidase/neprilysin (NEP), and it will also increase
levels of vasodilators such as atrial natriuretic peptide
(ANP) and inactivate other peptides, including the en-
kephalins and tachykinins. To confirm ECE activity in a
particular cell or tissue preparation in vitro, the action of
another NEP inhibitor, thiorphan, must be compared
with that of phosphoramidon. Thiorphan does not inhibit
ECE-1, and the formation of ET-1 in the presence of this
compound is generally accepted as providing evidence of
ECE activity. Although using two compounds increases
complexity, both reagents have been used in experimental
medicine studies to characterize Big ET-1 conversion in
vivo (see for example, Plumpton et al., 1995; Webb, 1995;
Hand et al., 1999) as well as in animal models. A second
complication in interpreting pharmacological assays is
that NEP also metabolizes ET-1 to inactive fragments via
a two-stage process, opening of the Ser5-Leu6 bond
followed by cleavage at the amino side of Ile19 (Skolovsky
et al., 1990), and inhibition in tissues derived fromkidney,
whereNEP is particularly abundant, may therefore cause
an unanticipated rise in ET-1 (Turner and Tanzawa,
1997).
Finally, phosphoramidon is a protein and does not
cross the plasma membrane, therefore its use either in
cell-based assays, in vitro or in vivo, will only report
on extracellular ECE activity not intracellular ET-1
synthesis (Parnot et al., 1997). This is important
because mature ET-1 can be detected together with
ECE within Weibel-Palade bodies and secretory vesi-
cles of endothelial cells and it is likely many inhibitors
will not alter intracellular synthesis.
5. Small Molecule, Selective Converting Enzyme-1
Inhibitor: PD159790. Despite the identification of
ECE-1 as a rate limiting enzyme in the synthesis of
ET-1, there has beenmuch less development of selective
small molecule inhibitors that could potentially reduce
levels of ET-1 in pathophysiological conditions com-
pared with the considerable effort to discover receptor
antagonists. PD159790 was developed to be selective
for ECE-1 compared with NEP (Ahn et al., 1998).
The compound has been validated experimentally by
altering the pH of endothelial cells in culture: at the
optimum for ECE-1 activity, pH 6.9, PD159790
inhibited Big-ET-1 conversion but not at the optimum
for ECE-2, pH 5.4 (Russell and Davenport, 1999a). In
addition, the compound had no effect on the alternative
pathway for ET-1 metabolism via chymase generation
of ET-1(1-31) (Maguire et al., 2001).
6. Small Molecule Converting Enzyme/Neutral En-
dopeptidase Inhibitors: Daglutril (SLV306) and SOL1.
No small molecule-selective ECE inhibitor has been
tested in the clinic, but compounds have been developed
to inhibit both ECE and NEP. Such compounds would
be predicted to be antihypertensive by inhibiting the
formation of the vasoconstrictor ET-1 as well as in-
creasing vasodilators such as ANP that would normally
be inactivated by NEP-mediated metabolism.
The ECE/NEP inhibitor SLV338 has been tested in a
number of animal models characterized by elevated
levels of ET and therefore potentially tractable to
inhibition of ET synthesis, such as in ischemic areas of
the brain after stroke. SLV338 was tested for 27 weeks
in spontaneously hypertensive, stroke-prone rats. The
compound significantly lowered the incidence of stroke
and improved survival in a blood pressure-independent
manner comparedwith untreated animals, suggesting a
new target for primary stroke prevention (Wengen-
mayer et al., 2011). Sharkovska et al. (2011) showed
that SLV338 was able to preserve kidney function and
reduce mortality in a rat model of severe acute ischemic
renal failure. In a chronic renal failure model using
Nv -nitro-L-arginine methyl ester (L-NAME) to inhibit
nitric oxide synthesis for 4 weeks, which increases
levels of ET; SLV338 did not reduce blood pressure,
but importantly abolished renal tissue damage (inter-
stitial fibrosis, glomerulosclerosis, and renal arterial
remodeling). In a rat model of experimental renovascu-
lar hypertension (2-kidney, 1-clip), SLV338 was equally
effective as losartan at preventing cardiac remodeling
(Kalk et al., 2011). These results are potentially impor-
tant because there are currently few drugs for the
treatment of chronic renal failure.
Daglutril (SLV306) was the first in class, orally
active, dual ECE/NEP inhibitor to enter clinical trials
(Tabrizchi, 2003; Dickstein et al., 2004; Parvanova
et al., 2013), where it was reported to be well tolerated
without the disadvantages of side effects of edema and
liver toxicity observed with some ET receptor antago-
nists. SLV306 is a prodrug, hydrolyzed to an active
metabolite, KC-12615. In proof of principle studies in
volunteers, oral SLV306 significantly increased endog-
enous plasma ANP concentrations, while reducing the
rise in blood pressure after infusion of Big ET-1 (Seed
et al., 2012). Initial studies in animal models of diabetes
showed that SLV306 was comparable to captopril, an
ACE inhibitor, in reducing proteinuria and preventing
nephrosclerosis (Thöne-Reinke et al., 2004). In this
model, changes in the ET system in the kidney are
thought to mediate renal damage by cell proliferation
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and interstitial inflammation. A limitation of inhibitors
of the renin-angiotensin system for treating hyperten-
sive patients with type 2 diabetes is that they become
less effective as the condition advances. SLV306 was as
effective as captopril in decreasing renal interstitial
matrix content as well as protein and albumin excretion
(Thöne-Reinke et al., 2004) and could have an additional
benefit in targeting the ET pathway to improve renal
function. However, in a small randomized, crossover,
double-blind, placebo-controlled trial in patients with
type 2 diabetic nephropathy, Daglutril on top of losartan
did not alter albuminuria that had been predicted from
animal studies or renal hemodynamics (Parvanova et al.,
2013). This may have been the result of the compara-
tively short duration of the trial (8 weeks). Importantly,
ambulatory blood pressure was reduced, particularly at
night when there is a greater risk associated with high
blood pressure in this patient group. There was the
expected corresponding significant rise in levels of
plasmaBig ET-1, suggesting inhibition of ECE, but there
was no change in proANP that would have been expected
as a consequence of NEP inhibition. SLV306 has also
been evaluated in a small study of patients with
congestive heart failure who underwent right-sided
heart catheterization. The results are difficult to in-
terpret because, although pulmonary pressure and right
atrial pressure decreased significantly with a maximum
effect observed between 6 and 8 hours, there was no clear
concentration response relationship between the three
doses tested (Dickstein et al., 2004).
SOL1 has been described as a dual ECE/NEP non-
peptide inhibitor, although it is less effective at inhibit-
ing ECE-1 compared with NEP at neutral pH in vitro.
However, the compound was effective in inhibiting the
Big-ET-1-induced rise in blood pressure in DOCA salt
hypertensive rats (10 mmol×kg21) (Nelissen et al., 2012)
and chronic treatment reduced macrophage infiltration
(Lemkens et al., 2012a). SOL1 normalized impaired
endothelium-derived hyperpolarizing factor responses
in spontaneously hypertensive rats, although there was
no effect on blood pressure (Lemkens et al., 2012b).
7. Chymase—A Pathophysiological Synthetic Pathway?
A surprising finding in the double ECE-1/ECE-2 KO
mice was the presence of mature ET peptides, suggest-
ing other proteases could synthesize ETs (Yanagisawa
et al., 2000). Chymase is a serine protease associated
with inflammatory responses, including those in the
vasculature, and has been implicated in a range of
cardiovascular diseases, particularly after release from
mast cells. The enzyme is an alternative synthetic
pathway for angiotensin II as well as ET-1. Chymase
converts Big ET-1 to an intermediate ET-1(1–31), by
cleaving the Tyr31–Gly 32 bond, which in turn is
converted to the mature peptide by NEP (Fecteau
et al., 2005; D’Orleans-Juste et al., 2008). Pharmaco-
logically ET-1(1–31) has no selectivity between ETA and
ETB receptors in human heart, and vasoconstriction
was fully blocked by an ETA-selective antagonist,
reflecting the predominance of the ETA receptor on
vascular smooth muscle (Maguire et al., 2001; Maguire
and Davenport, 2004).
In ligand binding assays in human heart, ET-1(1–31)
had a similar affinity for both receptor subtypes, but
this affinity was approximately 100 times lower than for
ET-1. In functional assays in human arteries, ET-1(1–31)
caused vasoconstriction (although again less effective
thanET-1 itself) that was blocked by anETA antagonist.
This action was unaffected by the ECE inhibitors
PD159790 or phosphoramidon, although the appear-
ance of the mature peptide, ET-1, was detected in the
bathing medium (Maguire et al., 2001) and may there-
fore contribute to some of the observed functional
response to ET-1(1-31). Interestingly, involvement of
chymase activity in conversion of Big ET-1 was con-
firmed in rat aorta (artery) but not vena cava (vein)
(Watts et al., 2007).
How important is the chymase pathway compared
with ECE? The results from in vitro pharmacology
experiments using human vessels, including coronary
arteries, clearly demonstrated the potential for vaso-
constriction for the putative chymase product (Maguire
et al., 2001). In contrast to humans that have only one
chymase, mice express several isoforms, so results are
more difficult to interpret in this species. However,
mouse mast cell protease 4 is thought to be most similar
in activity to human chymase. Levels of ET-1 were
reduced by 40% in mouse mast cell protease 4 KOs
(Houde et al., 2013), and pressor responses to Big ET-1,
but not to ET-1, were reduced (Semaan et al., 2015).
Studies on isolated arteries from the kidneys of diabetic
mice showed that Big ET-1 vasoconstriction produced
by the chymase-dependent pathway measured by chy-
mase inhibition was significantly greater in diabetic
compared with control kidneys. It was speculated that
this pathway might therefore contribute to end-stage
renal disease (Harrison-Bernard et al., 2013).
A potential source of chymase is degranulation of
mast cells that may occur under pathophysiological
conditions, and a working hypothesis is that this
would provide an alternative pathway for ET-1 syn-
thesis in disease. However, paradoxically, injection of
ET-1 was found to be toxic to mast cell-deficient mice,
suggesting that mast cell degranulation releases
proteases that metabolize ET-1 to reduce endogenous
ET-1 levels and pathophysiology in vivo (Maurer
et al., 2004).
ET-1(1–31) levels were increased to several times
higher concentrations, and for longer, than ET-1 in
the plasma of patients with acute myocardial infarction
(Oka et al., 2014). In contrast, although Big ET-1 levels
were elevated in patients with chronic heart failure
compared with controls, there was no change in
ET-1(1–31) (Leslie et al., 2004). There are currently
insufficient data to determine whether changes in
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ET-1(1–31) are associated with clinical and experimental
pathophysiological conditions.
8. Is Dual Vasopeptidase Inhibition a Pharmacolog-
ically Flawed Concept? Although volunteer and clin-
ical studies with SLV306 have provided, to a certain
extent, proof of mechanism of action, the results have
been disappointing in proving efficacy of ECE/NEP
inhibition in heart failure and diabetes. It is possible
that inhibition of ECE may switch Big ET-1 conversion
to an alternative pathway such as chymase, particularly
in disease. In animal models with normal renal function
this does not appear to be the case. In a positron
emission tomography study, [18F]-Big ET rapidly accu-
mulated unchanged in the kidney and there was
little evidence of conversion by an alternative pathway
(Johnström et al., 2010). The study by Parvanova et al.
(2013) was well designed and powered but failed to meet
the primary criteria of reducing albuminuria despite
promising data from animal studies. The authors specu-
lated that although the reduction in ET produced benefi-
cial effects, the increase in ANP could have increased
preglomerular vasodilatation, thus maintaining glomeru-
lar perfusion and filtration despite lowered blood pres-
sure. Although the efficacy of a specific inhibitor of ECE-1
has not been tested in the clinic, the clinical evidence is
against dual inhibition of ECE/NEP as a therapeutic
strategy to inhibit the ET pathway.
B. Endothelin-2 and Big Endothelin-2
1. Synthesis of Endothelin-2. In humans and other
mammals including monkeys, cats, dogs, and cattle,
ET-2 differs from ET-1 by two amino acids, Trp6 and
Leu7. Synthesis of ET-2 is thought to be essentially
similar to that of ET-1 (Fig. 2). Preproendothelin-2 is
formed after transcription of the EDN2 gene. After
removal of the signal sequence, proendothelin is cleaved
by furin, to Big ET-2, a 38-amino acid peptide. In-
terestingly, ECE-1 and ECE-2 were about 10% less
efficient in vitro in converting Big ET-2 to mature
peptide compared with conversion of Big ET-1, despite
sharing the same scissile bond (Trp21-Val22) (Emoto and
Yanagisawa, 1995). The ET-2 synthetic pathway has
been studied in detail in human renal adenocarcinoma
cells because these produce high levels of ET-2. Synthesis
was inhibited by phosphoramidon and ECE confirmed by
sequencing (Yorimitsu et al., 1992, 1995; Shinmi et al.,
1993).
In vivo, Gardiner et al. (1992a) showed that Big ET-2
was converted to produce cardiovascular actions (dose-
dependent pressor effect, bradycardia, renal and mes-
enteric vasoconstriction), similar to Big ET-1. All these
responses were blocked by phosphoramidon, but
the ECE/NEP inhibitor had no effect on the actions
of the mature peptide. Similar results were obtained in
the anesthetized, ganglion-blocked rat, where intrave-
nous bolus doses of Big ET-2 were compared with Big
ET-1 where the cardiovascular actions of both peptides
were prevented, as expected, by phosphoramidon but
not thiorphan (Mattera et al., 1993).
2. Expression. The cellular and organ distribution of
ET-2 has not been as extensively studied as ET-1, but a
pattern is emerging of a more restricted organ distri-
bution. Big ET-2 was detected at higher levels in human
plasma than Big ET-1 (Matsumoto et al., 1994),
although the concentration of ET-2 (;0.9 pmol/l) is a
one-fifth of that of ET-1 (Davenport andMaguire, 2006).
Big ET-2 concentration was ;2 pmol/l of plasma
(Suzuki et al., 1991). The most likely source in the
plasma is overspill from endothelial cells: both ET-2
mRNA and Big ET-2 have been detected (Howard et al.,
1992; O’Reilly et al., 1993a,b). ET-2 mRNA and/or
peptide have been detected in a number of human
tissues: vasculature, heart, lung, kidney, intestine,
and ovaries (Howard et al., 1992; Marciniak et al.,
1992; Plumpton et al., 1993; Karet and Davenport,
1996; Palanisamy et al., 2006). Similarly, in the rat,
although all 16 organs examined had measurable
mRNA for ET-1, ET-2 mRNA was restricted to heart,
lung, ovary, stomach, and intestine (Uchide et al., 1999,
2000). High levels were expressed by regions of the
intestine (duodenum, jejunum, ileum, colon, and rec-
tum) as well as the ovary, but not testes (De La Monte
et al., 1995; Takizawa et al., 2005). Pituitary glands and
medulla oblongata had higher ET-2 mRNA levels than
ET-1 (Masuo et al., 2003), suggesting a possible role
in these tissues that requires further exploration,
although most brain regions had lower or undetectable
levels of ET-2 (cerebellum and cerebrum). An alterna-
tive strategy using a transgenic mouse line that ex-
presses codon-improved Cre recombinase (iCre) under
regulation of the endothelin-2 gene (edn2) to map ET-2
expression showed expected expression from previous
studies in ovary, stomach, and intestine with a punctate
expression in the corneal epithelium, liver, lung, pitu-
itary, uterus, and heart. Interestingly, in the mouse
embryo, expression was localized in developing hair
follicles and the dermis (Cacioppo et al., 2015).
The tertiary structure of ET-2 was found to be
essentially the same as ET-1 by NMR and any differ-
ences in pharmacology would be attributable to changes
in the characteristics of the two side-chains of Trp6 and
Leu7 (Arvidsson et al., 1998). However, in humans and
other mammalian preparations both peptides are equi-
potent. Studies comparing radiolabeled [125I]-ET-2 with
[125I]-ET-1 binding in cultured rat aortic smoothmuscle
cells that express ETA receptors found identical affinity
constants (KD = 0.1 nM) and similar maximum receptor
density values (46 and 54 fmol per million cells, re-
spectively). Both ligands had the same association rate
constants of 0.01 minute21 and similar slow dissocia-
tion rates (Roubert et al., 1991), although Devesly et al.
(1990) reported ET-2 dissociated more rapidly at 37°C
than ET-1 in Swiss 3T3 fibroblasts that also express
ETA. In human smooth muscle from aorta and coronary
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artery that express mainly ETA receptors, saturation
binding assays were monophasic, Hill slopes close to
unity, and KD values were 0.7 nM for [
125I]-ET-2 and
0.4 nM for [125I]-ET-1 (Bacon and Davenport, 1996).
Antagonists such as FR139317 were equally effective at
competing for [125I]-ET-2 as for [125I]-ET-1 binding. In
agreement, in functional assays, ET-2 had a similar
potency as a vasoconstrictor to ET-1 in all human
isolated vessels tested (saphenous vein, aorta, coronary,
internal mammary artery, and pulmonary arteries
(Maguire and Davenport, 1995). ET-2 was also found
to be equipotent with ET-1 in animal preparations, for
example, rat portal vein (Guimaraes et al., 1992).
3. Vasoactive Intestinal Contractor and Big Vasoactive
Intestinal Contractor. In rodents, ET-2 differs fromET-1
by three amino acids (Fig. 1; Asn4, Trp6, and Leu7) (Bloch
et al., 1991) and is also called vasoactive intestinal
contractor (VIC) because it was originally identified by
its ability to contract isolated mouse ileum (Ishida et al.,
1989). The synthetic pathway is the same as ET-2:
preproVIC, a 175 amino acid precursor protein, via a
38-amino acid Big VIC, which in turn is cleaved to VIC
and a C-terminal fragment, which is sensitive to phos-
phoramidon inhibition (Saida et al., 1989, 2000, 2002;
Yorimitsu et al., 1992).
These amino acid substitutions have no effect on the
pharmacology of VIC, with the peptide having the same
affinity for both receptor subtypes. [125I]-VIC had a
similar autoradiographical distribution in human, por-
cine, and rat tissues compared with [125I]-ET-1 and
[125I]-ET-2 (Davenport and Morton, 1991; Davenport
et al., 1991). No differences were found in the ability of
unlabeled VIC, ET-1, ET-2, or ET-3 to compete for
[125I]-VIC in ligand binding assays or in vasoconstrictor
responses in the guinea pig longitudinal smooth muscle
(Yoshinaga et al., 1992). In other ETB (Cozza et el.,
1992; Lin and Lee, 1992) or predominantly ETA prep-
arations, VIC was equipotent with ET-1 and ET-2
(Douglas and Hiley, 1990; Schoeffter and Randriantsoa,
1993). VIC had a lower potency than ET-1 in cultured
human smooth muscle cells (Iwashima et al., 1997).
4. Distinct Physiologic/Pathophysiological Role for
Endothelin-2. Although the pharmacology of ET-2 is
similar to ET-1 and both peptides may be released from
the same cells, such as the endothelium, and exist in the
same tissue compartments, there is increasing evidence
that ET-2 does not simply duplicate ET-1 but has a
distinct physiologic and potentially pathophysiological
role. This difference may be achieved by a change in
levels of gene expression and through differences in
synthesis.
Deletion of the ET-2 gene in mice produces a different
phenotype to that affected by disrupting the ETA/ET-1
or the ETB/ET-3 pathways. The ET-2 phenotype was
characterized by severe growth retardation, hypoglyce-
mia, ketonemia, and increased levels of starvation-
induced genes as well as severe hypothermia, but
surprisingly intestinal function was normal (Chang
et al., 2013; section V.A.3). After selective deletion of
the ET-2 gene in epithelial cells, mice showed no
abnormalities in growth and survival, but major
changes were observed in lung morphology leading to
increased levels of carbon dioxide (hypercapnia) and a
deficiency of oxygen (hypoxemia) in the blood. It is not
yet clear whether this phenotype is a consequence of
internal starvation as a consequence of reduction in
ET-2 expression or whether ET-2 may have a critical
function in the pulmonary system. ET-2 mRNA local-
ized to epithelial cells, whereas receptor mRNA was
mainly present in mesenchyme, suggesting a paracrine
function for ET-2 (Chang et al., 2013). PAH remains the
major clinical indication for ET antagonists (Liu et al.,
2013), where the importance of dysregulation of vascu-
lar cell growth is increasingly recognized. Selective
deletion of ET-2 may provide new clues to the progres-
sion of this disease and the role of ET-2 in PAH
warrants further investigation.
Evidence is emerging that ET-2 plays a key role in
ovarian physiology, with ET-2-mediated contraction
proposed as a final signal facilitating ovulation (Meidan
and Levy 2007; Ko et al., 2012; Ling et al., 2013). ET-2
expression is higher than ET-1 in ovaries (Uchide et al.,
1999). ECE-1 and ET-2 were found to be transiently
expressed in rat ovaries during ovulation (Ko et al.,
2006), and inmice, induced superovulation resulted in a
surge of ET-2 mRNA expression after 11 hours that
coincided with the time of follicular rupture and then
subsequently declined (Palanisamy et al., 2006). The
precise mechanism of rupture and ovulation are un-
determined, but ET-2 caused contraction of the smooth
muscle layer surrounding each follicle (Ko et al., 2006).
In support, tezosentan (a mixed ETA/ETB receptor
antagonist), reduced ovulation and resulted in mature
unruptured follicles despite gonadotropin superovula-
tion. Although differences are reported between species
in the action of ET-2 in ovarian physiology (see Ling
et al., 2013), overall the results suggest ET-2 has both a
spatial and temporal role in mediating follicular rup-
ture, without which normal ovulation cannot proceed.
Further studies on ET-2 signaling pathways in ovula-
tion are needed and may lead to the identification of
new drug targets for associated with infertility such as
Luteinized Unruptured Follicle Syndrome.
ET-2 also has a distinct chemokine role, functioning
as a chemoattractant for neutrophils at low levels,
although inhibition of migration occurs at high concen-
trations (Elferink and deKoster, 1996). The peptide was
also found to be as effective as the inflammatory
chemokine CCL2 in stimulating chemotaxis in macro-
phages, mediated via ETB receptors through the MAPK
pathway (Yen et al., 1997; Grimshaw et al., 2002b).
ET-1 has been shown to affect many stages of cancer
development, including proliferation, angiogenesis,
migration, invasion, and apoptosis (Grant et al., 2003;
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Bhalla et al., 2009), but there is increasing evidence
for a role for ET-2. The peptide has been isolated from
renal adenocarcinoma cell lines (Ohkubo et al., 1990).
ET-2 is absent from breast tissue, but under hypoxic
conditions, cultured cells from HTH-K mice human
breast tumor cell lines show enhanced expression
of ET-2, ETA, and ETB but not ET-1 and ET-3
(Grimshaw et al., 2002a,b). ET-2 may be the principle
isoform increased in hypoxic tumors with increased ET-
2 in cancers such as those found in the skin, where
expression is three times higher in basal cell carcinoma
compared with normal skin (Tanese et al., 2010). Further
studies are required to determine whether the ET-2
pathway is a potential target in cancer therapy
(Grimshaw et al., 2004).
C. Endothelin-3, the Receptor Subtype Selective
Isoform and Big Endothelin-3
ET-3 is the only endogenous isoform that, at physio-
logic concentrations, can distinguish between the two
receptor subtypes, because it has the same affinity at
ETB receptors as ET-1 and ET-2 but has much lower or
little affinity for ETA than the other isoforms (Fig. 2). It
was an early discovery in the field by Matsumoto et al.
(1989) that ET-3 was the most abundant ET peptide in
rat brain, mainly localized to neurons and glia of the
neostriatum, hypothalamic nuclei, hippocampus, and
Purkinje cells of the cerebellum and medulla oblongata
(Giaid et al., 1991). This led to the proposal that ET-3
was the "brain" endothelin peptide, particularly because
the ETB subtype comprises;90% of the ET receptors in
human normal cerebral cortex (Harland et al., 1995)
(section III.C).
KO mice also emphasize the importance of the ET-3/
ETB pathway in the development of the enteric nervous
system (Kurihara et al., 1999), a complex network of
neurons and glia in the gut controlling intestinal
motility, secretion, and blood flow. A mutation in ETB
is a common cause of Hirschsprung disease (section
V.B.3), in which enteric nervous system precursors and
neural crest-derived epidermal melanoblasts fail to
colonize the intestine and skin.
1. Endothelin-3 Synthesis and Kell. Controversy
remains concerning the precise contribution of ECE-1
to ET-3 synthesis. ECE-1-deficient mice recapitulated
the combined phenotype of both ET-1/ETA- and ET-3/
ETB-deficient mice. Tissue ET-3 levels were lower than
in wild-type animals, suggesting that ECE-1 was an
important converting enzyme for both Big ET-1 and Big
ET-3 in vivo, at least in mice (Yanagisawa et al., 2000).
However, Big ET-3 has been reported to be poorly
converted by ECE-1 when tested as the purified enzyme
or in isolated tissue preparations (D’Orléans-Juste
et al., 1991; Telemaque and D’Orléans-Juste, 1991;
Shimada et al., 1994; Turner and Murphy, 1996), owing
to differences in the scissile bond Trp21-Ile21 in Big-ET-3
compared with Trp21-Val21 in Big ET-1 and in the
C-terminal sequence. However, Big ET-3 in vivo pro-
duces vasoconstriction, for example, in the chronically
instrumented rat (called proendothelin-3 by Gardiner
et al., 1992a,b), suggesting the existence of further
converting enzymes. The Kell blood group comprises
20 different antigens borne by the protein Kell, a
93-kDa membrane bound glycoprotein expressed by
erythrocytes with homology to the type II membrane-
bound zinc metalloprotease family that includes ECE-1
and ECE-2 (Clapéron et al., 2005). A recombinant,
nonphysiologic form of Kell has been shown to effi-
ciently cleave Big ET-3, suggesting the existence of a
specific converting enzyme for the synthesis of ET-3
(Lee et al., 1999).
Clapéron et al. (2005) expressed the Kell K2 antigen
under more representative physiologic conditions in
erythroid and nonerythroid cells lines. Kell K2 effi-
ciently cleaved Big ET-1 as well as Big ET-3 (Big ET-2
was not tested), but unlike ECE-1, the enzyme was
inhibited efficiently by thiorphan as well as phosphor-
amidon. It was not selective for ET synthesis because it
also cleaved tachykinins. The relative contributions of
Kell versus ECE-1/ECE-2 to the synthesis of mature
peptides remain unclear but may explain the disap-
pointing results of targeting the latter (see section
V.B.1), and further studies are required to comprehen-
sively delineate the synthetic pathways contributing to
the production of the mature endothelin peptides.
2. Expression. ET-3 (typically ;0.3 pmol/l) and an
order of magnitude higher level of Big ET-3 (;6 pmol/l)
are detectable in human plasma (Matsumoto et al.,
1994). Changes associated with disease have not been
extensively investigated, but concentrations of Big ET-3
increased significantly in hemodialysis patients (to-
gether with Big ET-1 and Big ET-2) but with only
a moderate rise in corresponding active peptides
(Miyauchi et al., 2012). Human endothelial cells do not
synthesize ET-3, but one possible source of circulating
Big ET-3 could be the adrenal gland, where this peptide
has been visualized in secretory cells of the medulla
using selective antisera, although mature ET-3 could
not be detected (Davenport et al., 1996). If released,
further processing of Big ET-3 could occur within the
vasculature by smooth muscle cell ECE (Davenport
et al., 1998). ET-3 has been detected in other tissues,
including heart (Plumpton et al., 1993), endometrium
(O’Reilly et al., 1992; Cameron et al., 1993) using HPLC
fractionation combined with radioimmunoassay, brain,
and pituitary using sandwich enzyme-linked immuno-
sorbent assay—interestingly the pituitary was stated
(but not shown) to have higher levels of ET-3 than ET-1
(Takahashi et al., 1991). In other species, high concen-
trations of immunoreactive ET-3 were found in the
intestine, lung, pituitary gland, and brain (greater than
100 pg/g wet tissue) in rats; in agreement with humans,
only pituitary gland expressed higher levels than ET-1
(Matsumoto et al., 1989). Northern analysis showed that
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preproET-3 mRNA was expressed in the eye, subman-
dibular gland, brain, kidney, jejunum, stomach, and
spleen (Shiba et al., 1992). Big ET-3was also localized by
immunocytochemistry (with Big ET-1 and Big ET-2) to
mast cells and macrophages in the rat gastrointestinal
tract (Liu et al., 1998). Because ET-3 does not activate
ETA receptors at physiologic concentrations, the expres-
sion should correlate with higher densities of ETB
receptor—and this is true to a certain extent for the
brain and pituitary (compare in Fig. 7).
D. Snake Venom Peptides, the Sarafotoxins
The sarafotoxins are a family of four isoforms (S6a,
S6b, S6c, S6d; Fig. 2) with a high degree of sequence
similarity to ET-1, identified from the venom of the
snake Atractaspis engaddensis (Kloog et al., 1988;
Takasaki et al., 1988). The main differences are in
residues 5, 6, 7, and 17, which are Asp, Met, Thr, and
Gln. The venoms evolved to immobilize mammalian
prey and can be fatal in humans. Symptoms are a rapid
rise in blood pressure consistent with systemic vaso-
constriction, as observed with ET-1 and changes in
electrocardiogram consistent with coronary vasocon-
striction or direct inotropic actions on the heart accom-
panied by changes in the electrocardiogram associated
with atrioventricular block and cardiac arrest (Kurnik
et al., 1999). The most widely studied are S6b and S6c.
Sarafotoxin 6b has similar affinities for both endothelin
receptors with a profile similar to ET-1/ET-2, although
less potent, whereas S6c is used as a moderately
selective ETB agonist (Maguire et al., 1994, 1996;
Maguire and Davenport, 1999). A fifth isoform, bibro-
toxin, was isolated from the venom of the burrowing asp
Atractaspis bibroniwith an amino acid sequence similar
to S6b but with the substitution of Ala4 instead of Lys4
and similar pharmacology (Becker et al., 1993).
III. Receptor Structure, Distribution,
and Function
ETs activate two receptor subtypes (Davenport,
2002), ETA (Arai et al., 1990) and ETB (Sakurai et al.,
1990), that belong to Class 1 (Family A or rhodopsin-
like) of the G protein-coupled, 7 transmembrane-
spanning domains receptors (GPCR). Although ET
receptor-like genes are found outside the vertebrates
in the cephalochordate amphioxus, suggesting a long
lineage in eukaryote evolution, genes encoding peptides
are only present among vertebrates: jawless verte-
brates (lampreys and hagfishes), cartilaginous vertebrates
(sharks, rays, and chimaeras), and bony vertebrates (ray-
finned fishes and lobe-finned vertebrates including tetra-
pods). It is therefore likely that the receptor-ligandsignaling
pathway is a vertebrate innovation consistent with the role
of the development and regulation of the cardiovascular
system (Braasch and Schartl, 2014).
The sequencing of the human genome is virtually
complete andmost if not all genes encodingGPCRs have
been identified (Foord et al., 2005; Davenport et al.,
2013). The receptors most closely related in structure to
ETA and ETB are GPR37 (endothelin receptor type
B-like or Parkin-associated endothelin receptor-like
receptor) and GPR37L1. Neither of these receptors
was activated by any of approximately 20 ET peptides,
Big ET precursors, or known ET receptor ligands
(such as BQ123 and BQ3020) that were tested at high
concentration. Two other peptides, prosaptide and
prosaposin, have been identified as cognate ligands for
GPR37 and GPR37L1 (Meyer et al., 2013). In addition,
none of the ET ligands had any activity against the
remaining ;80 GPCRs in the screen that are currently
classified as orphans, because their endogenous ligand
is not yet known.
Studies continue to be published suggesting the
existence of further ET receptor subtypes: for example,
ETB isoforms were proposed with ETB1 present on
endothelial cells and ETB2 on smooth muscle cells, but
the evidence is against this. In competition binding
assays, ETB receptors expressed by human isolated
endothelial compared with smooth muscle cells in
culture could not be distinguished by a range of ET
ligands (Flynn et al., 1998). Radiolabeled ETB ligands
were always found to bind with a single affinity and
Hill slopes close unity in saturation binding assays
(Molenaar et al., 1992, 1993; Nambi et al., 1994) and to
produce monophasic curves in competition binding
assays versus [125I]-ET-1 in human native (Peter and
Davenport 1995a,b; Russell and Davenport, 1996) or
recombinantETB receptors (Nambi et al., 1994; Reynolds
et al., 1995). In global ETB receptor knockout mice both
the direct constrictor (smooth muscle) and indirect
vasodilator (endothelium) responses to the ETB agonist
sarafotoxin 6c were abolished (Mizuguchi et al., 1997).
Current evidence only supports the existence of two
subtypes, ETA and ETB, according to NC-IUPHAR
nomenclature (Davenport, 2002). No further Family A
GPCRs have been identified that might bind ET
peptides.
A. Endothelin A Receptors
1. Structure. The human ETA receptor has 63%
sequence similarity with the human ETB receptor over
a 420-residue match length. The amino acid sequences
of human ETA differ from other species, for example by
9% from rat ETA and by 12% for the ETB. The ETA gene
spans more than 40 kilobases and contains eight exons
and seven introns. It is located on chromosome 4 and
encodes a 427-amino acid protein (Hosoda et al., 1992).
The amino acid sequence of the human ETA receptor is
shown in Fig. 5. The receptor sequence displays a high
degree of conservation between human and animal
species, including pig, dog, sheep (95%), rat (93%), and
mouse (92%). The main differences are in the N
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terminus, rather than within the transmembrane do-
mains that contribute to binding, and reflect that ET-1
structure is conserved across mammalian species.
Figure 5 shows the amino acids that have been mutated
and reported to alter the binding of ET ligands. The
choice of amino acids tomutate is determined usually by
modeling the three-dimensional structure and identify-
ing amino acids that are likely to have groups associated
with the binding of ligand to the receptor. For example,
an extensive study mutating 18 amino acids identified
that Gly97, Lysl40, Lys159, Gln165, and Phe315, located in
transmembrane regions 1, 2, 3, 3, and 6, respectively,
reduced binding of radiolabeled ET-1. Interestingly
mutation of Tyr263, Arg326, and Asp351 preserved ET-1
binding but reduced that of the antagonist bosentan. All
of these three residues are conserved in the ETB subtype,
consistent with bosentan displaying little selectivity for
either ETA versus ETB.
Posttranslational modifications, phosphorylation,
palmitoylation, and glycosylation can further modulate
the function of GPCRs (Fig. 5). Mutation of a cluster of
five Cys residues present in the cytoplasmic tail did
not alter binding but prevented palmitoylation of the
receptor, resulting in a failure of ET-1 to stimulate
the transient increase in the cytoplasmic calcium.
Posttranslational modification by palmitoylation would
seem to be essential for functional activity of ETA
(Horstmeyer et al., 1996). Truncation of the entire N
Fig. 5. Schematic diagram of the human ETA receptor. Experimental mutations altering receptor function are shown in red. Potential sites for
translational modifications are shown as phosphorylation (yellow), glycosylation (gray), and palmitoylation (purple). Diagrams generated using http://
tools.gpcr.org/ (Isberg et al., 2014).
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terminus that included a possible glycosylation site
abolished binding activity, but it is unclear whether this
is the result of a structural change or whether glycosyla-
tion is important (Hashido et al., 1992). Phosphorylation
is crucial for ligand induced desensitization in ETB
receptors, with rapid deactivation after ET-1 stimulation
and most activity lost within 5 minutes. In contrast, ETA
did not undergo ligand-induced phosphorylation and
continued to signal with little reduction in activity after
5minutes, consistentwith long-lasting constrictor activity
(Cramer et al., 1997).
2. Receptors Mutations. ETA receptor knockoutmice
bearmorphologic abnormalities nearly identical to ET-1
and ECE-1 knockout mice. Homozygous mice died at
birth of respiratory failure secondary to severe cranio-
facial abnormalities (Hosoda et al., 1994; section V.B.2).
ETA receptors are essential for development, and
mutations will be lethal or detrimental. Deletions in
the ETA receptor in mice mimic the human conditions
collectively termed CATCH 22 or velocardiofacial syn-
drome. These include severe craniofacial deformities
and defects in the cardiovascular outflow tract. Great
vessel malformations highly similar to those seen in
neural crest-ablated chick embryos and human congen-
ital cardiac defect also occur.
3. Splice Variants. At least three alternatively
spliced ETA receptor transcripts have been reported
in human tissues, including aorta, heart atria, and
lung. Deletions of exon 3 (producing a protein with
two membrane-spanning domains), exon 4 (producing
a protein with three membrane-spanning domains),
and exon 3 plus exon 4 (producing a protein lacking
the third and fourth domain) have been identified, but
these did not bind ET-1 when expressed in cells
(Miyamoto et al., 1996; Bourgeois et al., 1997; Zhang
et al., 1998). The significance of alternative splicing of
ETAmRNA is unclear but could reduce the abundance
of active receptor and reduce functions such as
contractility. For example, mRNA encoding the pre-
dicted truncated receptor with the deletion of exon 3
and 4 was more abundant in human melanoma cell
lines and melanoma tissue than the wild type (Zhang
et al., 1998).
B. Endothelin B Receptors
1. Structure. Human ETB gene (EDNRB) comprises
7 exons and 6 introns, is located on chromosome 13, and
encodes a 442-amino acid protein. The ETB receptor has
an unusually long N terminus (Fig. 6) that can be
cleaved by a metalloprotease to remove the first 64
amino acids while still retaining ET-1 binding capacity.
It is thought that amino acids associated with the first,
second, third and seventh transmembrane spanning
domains and associated extracellular loops are mainly
involved in ligand binding where interestingly most of
the naturally occurring or experimental mutations that
affect ET ligand binding and ligand receptor selectivity
coincide. The carboxyl terminus, as with other GPCRs,
is important for intracellular signaling.
Like ETA receptors, ETB receptors have a surprising
number of potential post-translational modifications
(Fig. 6). There are 13 phosphorylation sites comprising
Tyr, Ser, Cys residuesmainly located in the C terminus.
There is a potential glycosylation site at Asn59 in the
N terminus but no evidence yet that this is important
for binding, although in other GPCRs at least one
glycosylation site is often critical for receptor expression
at the cell membrane and for function (Okamoto et al.,
1998). In addition, there are four sites for possible
palmitoylation. The clustering of Cys residues is con-
served across many GPCRs, and the degree of C-terminal
palmitoylation may act as a selector for coupling with
different G proteins and different pathways of intracellu-
lar signaling (Stannard et al., 2003a,b). For example, ET
mitogenic activity that stimulates extracellular signal-
regulated kinases (ERK/MAP kinases) critically depends
on palmitoylation (but not on phosphorylation) of ET
receptors (Cramer et al., 2001). Okamoto et al. (1998)
showed that substitution of three residues Cys402, Cys403,
or Cys405 with Ser gave an unpalmitoylated mutant that
retainedbindingand surface expressionbut didnot couple
to G proteins, suggesting a critical role in signaling.
2. Receptor Mutations. Homozygote ETB knockout
mice exhibit a different andnonoverlapping phenotype to
ETA-deficient animals with survival for up to 8 weeks.
The enteric nervous system precursors and neural
crest-derived epidermal melanoblasts fail to colonize
the intestine, causing an aganglionic megacolon and a
pigmentary disorder in their skin. ET-3 knockouts
display an identical phenotype (section V.B.3; Kurihara
et al., 1999). This phenotype is similar to Hirschsprung
disease (estimated at 1/5000 live births), a multigenetic
disorder, where one of the causative genes includes
mutations in ETB receptor expression (Tanaka et al.,
1998). Hirschsprung disease can also be associated with
Waardenburg syndrome (where in addition to colonic
aganglionosis the patients have sensorineural hearing
loss, hypopigmentation of skin and hair, and pigmentary
disturbances of the irides) that is also linked to muta-
tions in the ETB and ET-3 genes. The effect of some ETB
receptor mutations in Hirschsprung disease have been
tested experimentally. For example, A183G, W276C,
R319W, M374I, and P383L had reduced intracellular
signaling and reduced receptor density resulting in a loss
of function, although all mutants bound ET-1 with high
affinity (Fig. 6; Abe et al., 2000), suggesting ET agonists
such as IRL 1620 could rescue function, whereas others
such as the C109Rmutation failed to translocate into the
plasma membrane and had low ET-1 affinity.
A naturally occurring 301-base pair deletion of the
ETB gene resulting in a lack of ETB expression,
elevation of plasma ET levels, and aganglionic mega-
colon was identified in "spotting lethal" rats. ETB
deficiency caused early onset of renal impairment
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characterized by reduced sodium excretion and de-
creased glomerular filtration rate (Hocher et al., 2001;
Taylor et al., 2003). A missense mutation in the ETB
gene is also associated with Lethal White Foal Syn-
drome, an equine version of Hirschsprung disease
(Metallinos et al., 1998).
3. Splice Variants. Alternative splice variants of
ETB receptors have been reported in humans but they
do not seem as important as for other transmitters such
as dopamine. Elshourbagy et al. (1996) identified a
variant where substitution of 42 amino acids of the
intracellular carboxy terminus of the ETB receptor was
replacedwith an alternative 36-residue sequence, resulted
in a receptor retaining binding but lacking any potential
palmitoylation sites so that ET-stimulated inositol phos-
phate accumulation was abolished. Messenger RNA
encoding the variant was not particularly abundant,
except in skeletal muscle where it represented more than
40% of the totalmRNA. Shyamala et al. (1994) described a
variant encoding a 10 amino acid increase in the length of
the second cytoplasmic domain that exhibited limited
distribution in heart, lung, brain, and placenta, but there
was no change in binding characteristics or downstream
signaling, and therefore the physiologic or pathophysio-
logical significance is unclear. Tanoue et al. (2002) de-
scribed a mutant ETB gene associated with Hirschsprung
disease where the transcript lacked a 134-base pair
nucleotide sequence corresponding to exon 5 that may
Fig. 6. Schematic diagram of the human ETB receptor. Naturally occurring mutation reported in patients with Hirschsprung disease (blue),
experimental mutations altering receptor function (red). Potential sites for translational modifications as shown as phosphorylation (yellow),
glycosylation (gray), and palmitoylation (purple). Green indicates both a phosphoraylation and site experimentally mutated. Diagrams generated using
http://tools.gpcr.org/ (Isberg et al., 2014).
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not have been translated or rapidly degraded as a possible
cause of the disease. An alternative transcript of the rat
ETB in brain has also been reported (Cheng et al., 1993).
C. Distribution of Endothelin Receptors
The distribution of mRNA encoding the two receptors
is shown in Fig. 7, measured in adult mouse tissues, a
species widely used for cell-specific disruption of the ET
genes. The pattern emphasizes that ET receptor mRNA
is likely to be detected in all tissues or organs receiving a
blood supply, reflecting the ubiquitous expression of
ETA on vascular smooth muscle and ETB on endothelial
cells. Highest relative expression of ETA mRNA is
associated with the heart and lungs with relatively
low expression in the CNS. ETA mRNA was the fifth
most abundant GPCR in heart atria and 11th in
ventricle, emphasizing the importance of the ET path-
way in the cardiovascular system (Regard et al., 2008).
By radioligand binding, the brain regions measured
have high expression of ETB receptors and in the
periphery the lung is also a particularly ETB rich tissue.
The relative ratio of the two subtypes, measured by
competition binding in human tissues, is shown in Fig.
8. The human brain contains a high density of ET
receptors (see Schinelli, 2006 for review), with ETB
accounting for 90% of total ET receptors in the cerebral
cortex (Harland et al., 1995), localized to neuronal
regions, particularly levels III and IV. The small
proportion of ETA receptors detected were largely re-
stricted to the smooth muscle of the cerebral vascula-
ture (pial arteries and intracerebral vessels) and
leptomeninges, with much lower but detectable levels
in the gray and white matter. ETB receptors were not
detected in the vascular structures or leptomeninges.
Functional studies in rat cerebellum suggested glial
cells expressed the ETB subtype, whereas some re-
sponses of neurons were ETA mediated (Davenport
and Morton, 1991; Morton and Davenport, 1992).
Smooth muscle cells of the small pial arteries and
arterioles that penetrate into the human brain only
express ETA receptors (Adner et al., 1994; Yu et al.,
1995; Lucas et al., 1996; Harland et al., 1995, 1998;
Pierre and Davenport, 1995, 1998a,b, 1999) that play a
major role in the maintenance of cerebral blood flow.
ET-1 potently constricts brain vessels, including cere-
bral (Adner et al., 1994) and pial arteries (Hardebo
et al., 1989; Thorin et al., 1998; Pierre and Davenport,
1998b, 1999). The latter are particularly sensitive
to ET-1 and provide the therapeutic rationale for
blocking the actions of the peptide, which is thought to
be a mediator of cerebrovascular disorders including
delayed vasospasm associated with subarachnoid
hemorrhage and stroke. In contrast to the periphery,
both ligand binding (Yamaga et al., 1995) and functional
studies suggest that human brain endothelial cells
isolated from capillaries (diameter ,10 mm) that form
A
B
Fig. 7. Relative expression of mRNA encoding ETA (Ednra) or ETB (Ednrb) receptors in 41 adult tissues. (Graphs constructed using data from Regard
et al., 2008).
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the blood-brain barrier and from larger microvessels
express ETA receptors linked to phospholipase C and
IP3 accumulation (Stanimirovic et al., 1994; Spatz et al.,
1997) possibly functioning to increase capillary perme-
ability, leading to edema (Purkiss et al., 1994). These
studies used a comprehensive range of agonists and
antagonists to show ETA-mediated responses, but this
intriguing finding has not been explored further. In-
terestingly, there are numerous reports of upregulation
of expression of ETB receptors in cerebrovascular
smooth muscle in rat models of, for example, global
ischemic stroke (Johansson et al., 2012), subarachnoid
hemorrhage (Vikman et al., 2006), or cerebrovascular
remodeling associated with diabetes (Kelly-Cobbs et al.,
2011), although effectiveness of ETA or dual receptor
antagonists in human cerebrovascular disease appears
to be limited.
In human peripheral tissue, the lungs have the
highest density of ET receptors (;9600 fmol/g protein)
measured to date compared with other peripheral
tissues and even higher than the brain (;5000 fmol/g
protein) (Henry et al., 1990; McKay et al., 1991;
Marciniak et al., 1992; Knott et al., 1995; Russell and
Davenport, 1996). ETA receptors predominate on
smooth muscle of pulmonary arteries and resistance
vessels where the subtype mediates vasoconstriction
(Hay et al., 1993; Maguire and Davenport, 1995),
although McCulloch et al. (1996) suggested a contribu-
tion from ETB receptors in resistance vessels. The
majority of ETB receptors in the lungs are present on
the endothelium, but this receptor is also localized to
airway smooth muscle and mediates bronchoconstric-
tion (Adner et al., 1996; Takahashi et al., 1997; Hay
et al., 1998), although Fukuroda et al. (1994a) detected
an ETA component in isolated human bronchi responses
to ET-1. Lower levels of receptors are detectable in
parenchyma, airway submucosal glands, and small
conduit arteries (Russell and Davenport, 1995). Plasma
levels of ET-1 are increased in PAH and correlate with
the severity of disease, as well as its prognosis (Rubens
et al., 2001). ET-1 levels are also increased in explanted
lungs (Giaid et al., 1993), as is the density of both
subtypes in distal pulmonary arteries of patients with
PAH (Davie et al., 2002). In PAH, this increase in ET-1
is thought to cause sustained vasoconstriction and
stimulates cellular proliferation, cell migration, fibro-
sis, and hypertrophy (see Vachiery and Davenport,
2009).
In human heart, both receptor subtypes are expressed
by the myocardium of atria and ventricles (Bax et al.,
1993; Molenaar et al., 1992, 1993; Peter and Davenport,
1995a,b, 1996a; Pönicke et al., 1998) and septum, al-
though the ETA receptor predominates. In myocytes ETA
comprise 90% of the receptors. In contrast ETB receptors
are more abundant in the atrioventricular conducting
system (Molenaar et al., 1993). ET-1 is a potent positive
inotropic agent (Davenport et al., 1989; Moravec et al.,
1989). In vivo the endogenous ligand ET-1 has a tonic
positive inotropic effect in normal subjects that can be
blocked by BQ123 and is independent of any effect on the
peripheral vasculature (MacCarthy et al., 2000). In the
right ventricle of human hearts from PAH patients, there
was a significant increase in the ratio of ETA to ETB
receptors compared with normal hearts as well as a
significant increase in the medial layer of small pulmo-
nary arteries. The latter provide the rationale for efficacy
of ET antagonists, although the increase in ETA in the
ventricle is likely to be an adaptive response to left heart
failure to cause a beneficial increase in cardiac output.
This would be blocked in the setting of ET antagonism
(Kuc et al., 2014). Interestingly, the density of the ETA
subtype is increased by 50% in the left ventricle of patients
with ischemic heart disease, whereas ETB receptor
density is unaltered compared with nonfailing hearts
(Peter and Davenport, 1996b).
D. Function of Endothelin Receptors in the
Cardiovascular System
1. Endothelin A Receptor Constriction in the Human
Cardiovascular System. The two receptor subtypes
exhibit contrasting cardiovascular actions under nor-
mal physiologic conditions. ET-1 is the most abundant
isoform in the human cardiovascular system. On re-
lease from the endothelium, primarily directed ablumi-
nally, the peptide causes vasoconstriction, mainly via
ETA receptors that are the principle subtype in the
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vascular medial layer (comprising mainly smooth mus-
cle cells) in large conduit arteries and veins as well as
small resistance vessels (Fig. 4). Electron microscope
autoradiography has confirmed unequivocally the pres-
ence of high densities of ETA but low densities of ETB
receptors in smooth muscle cells with few receptors of
either subtype associatedwith the surrounding collagen
(Russell et al., 1997).
In some, but not all, human vessels, ETBmRNA and a
low density of ETB receptors (usually ,15%) have been
detected in the medial layer from certain vessels (Fig. 8,
Davenport et al., 1993, 1995a,b). Extensive pharmaco-
logical characterization of human isolated vessels
shows that ETB agonists such as BQ3020 do not have
any activity up to a concentration of 10 mM. Occasion-
ally some vessels were found to respond to the more
potent sarafotoxin 6c, but themagnitude of the response
was much less than for ET-1. ET-3 was at least two
orders of magnitude less potent than ET-1 consistent
with activating ETA rather than ETB receptors. Finally
all antagonists tested to date, such as BQ123, cause a
parallel and rightward shift of the ET-1 concentration
response curve in all vessels examined with Schild
slopes close to unity (Maguire and Davenport, 1995,
Pierre and Davenport, 1998a,b). Although there is a
consistent pattern of ETA-mediated constriction in
human vessels, in animals the relative contribution is
more complex, with vasoconstriction via ETA, ETB, or a
mixture of both depending on species or vascular beds.
For example, BQ3020 and sarafotoxins 6c are potent
constrictors of rat renal and mesenteric beds; BQ123
does not fully block these responses.
In agreement with in vitro studies in humans, in-
fusion of BQ123 caused vasodilatation in volunteers
when the ETA antagonist was infused into the brachial
artery (Haynes and Webb, 1994), a finding repeated in
other clinical studies. These observations are consistent
with blocking the action of ET-1 that is being continu-
ously released from the endothelium on vascular
smooth muscle ETA receptors. This was significant as
antagonists of other vasoconstrictors, such as ANGII, do
not alter blood flow in normotensive individuals. In
marked contrast, infusion of an ETB-selective antago-
nist BQ788 caused systemic vasoconstriction in healthy
volunteers, showing that the main consequence of
activation of endothelial ETB receptors by tonically
secreted ET-1 was the physiologic basal release of nitric
oxide (Verhaar et al., 1998).
The pharmacological action of ET-1 is very unusual
compared with other vasoactive mediators such as
ANGII. It remains the most powerful constrictor of
human vessels discovered with a remarkably long-
lasting action. For example, after intracisternal injec-
tion of 10 pmol ET-1 into dogs, the diameter of the
basilar artery was 76% of the control after 3 days (Asano
et al., 1989). No human vessel has been reported that
does not respond to ET-1, suggesting the peptide is the
"universal" vasoconstrictor. ET-1 is thought to play a
major physiologic role in regulating vascular function
and the flow of blood in most, if not all, organ systems,
including heart, kidney, lungs, and liver. Other cell
types that synthesize the peptide can also modulate
vascular reactivity, including perivascular neurons in
the periphery, perivascular astrocytes in the CNS, and,
under pathophysiological conditions such as atheroscle-
rosis, macrophages and monocytes. Overproduction of
ET in pathophysiological conditions from the endothe-
lium and other cellular sources can lead to constriction
of vessels in conditions such as PAH, leading to vascular
remodeling. This is exacerbated particularly where
there is reduced production of opposing vasodilators
such as nitric oxide, prostacyclin, and endothelium-
derived hyperpolarizing factor. Activation of the ETA
receptor can drive proliferation in multiple cell types
and contributes to fibrosis and inflammation.
It has often been reported that ET-1 binds irrevers-
ibly to ETA receptors. This raises a critical question
about the tractability of ETA receptors as therapeutic
targets in, for example, cerebral vasospasm, where
antagonists if they are to be effective are required to
reverse an established constrictor ET response (Pierre
and Davenport, 1999). However, although dissociation
of [125I]-ET-1 from cloned ETA receptors was slow
compared with other ligands with a half-life of the
about 6 hours (as would be expected for long-lasting
constrictor responses), binding was not irreversible
(Blandin et al., 2000). Similarly, about 20% of specific
[125I]-ET-1 binding had dissociated from native ETA
receptors in human aorta after 20 minutes (Maguire
et al., 1996). Established ET-1 responses can be re-
versed in vitro and in vivo by receptor antagonists
(Warner et al., 1994; Pierre and Davenport, 1999).
2. Does Endothelin B Receptor-Mediated Constriction
Change in Human Vascular Disease? Detailed phar-
macological studies have investigated whether there is
functional evidence for an upregulation of ETB recep-
tors in human isolated coronary arteries. Constrictor
responses to sarafotoxin 6c were variable, with 40% of
healthy arteries and 50% of vessels containing an
atherosclerotic lesion not responding to the ETB. Where
vessels did respond, there was no difference in the
maximum responses obtained in healthy and diseased
tissues. There was also no change in ETB receptor
density in the medial layer of atherosclerotic compared
with control arteries (Maguire and Davenport, 2000).
These results were supported by clinical studies. BQ123
caused coronary vasodilation and improved endothelial
dysfunction in patients with atherosclerosis or its risk
factors (Halcox et al., 2001). In a further 39 patients,
ETB antagonism caused coronary microvascular con-
striction and not dilatation, without affecting epicardial
coronary tone or endothelial function. Combined ETA and
ETB blockade, however, dilated coronary conduit and
resistance vessels and improved endothelial dysfunction
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of the epicardial coronary arteries (Halcox et al., 2007).
Thus the results of both in vitro and in vivo studies show
that ETA receptors contribute to basal constrictor tone
with no evidence for constrictor ETB receptors in human
atherosclerosis. Animal studies where ETB receptors are
increased in pathophysiological conditions, in for example
rat coronary arteries, are not representative of humans
(Skovsted et al., 2014).
Of particular relevance is what happens in PAH, the
current target of ET antagonists. McCulloch et al.
(1996) found ET-1 caused a biphasic response in
pulmonary resistance arteries (150–200 mm internal
diameter) with constrictor responses to low concentra-
tions of ET-1 (,1 nM) blocked by an ETB antagonist, but
at higher concentrations, greater than 1 nM, ET-1
responses were blocked by an ETA but not an ETB
antagonist, suggesting that at levels of ET-1 in the
pathophysiological range ETA receptors will be acti-
vated. Davie et al. (2002) quantified the ratio of the two
receptor subtypes in small arteries (500–1000 mm) from
PAH patients and healthy controls. Although overall
ET receptor density in distal arteries was twofold
greater than in controls, there was no change in any
vessel in the ratio of ETA to ETB. These results suggest
that ETB-mediated constrictor responses occur at low
ET concentrations, but in the absence of a change in
subtype ratio it is unlikely there would be increased
ETB constrictor response in this patient group.
3. Endothelin B Receptor Vasodilatation. Although
the vascular endothelium represents only 1% of theweight
of the vessel wall it is distributed as a monolayer
throughout all vessels in the body. The paradox that the
potent vasoconstrictor ET-1 was also a vasodilator was
quickly recognized after its discovery and was partic-
ularly evident from early in vivo studies (Wright and
Fozard, 1988), because vasodilator responses can be
lost during the preparation of vessel for in vitro
research. ET-1, released from endothelial cells, func-
tions in an autocrine manner to feed back onto
endothelial ETB receptors to release vasodilators,
principally nitric oxide, but also prostacyclin or endo-
thelium derive hyperpolarizing factor depending on
the vascular bed. This feedback mechanism limits the
constrictor actions of ET via smooth muscle ETA
receptors and has an essential physiologic role in
cardiovascular homeostasis. ET-1 is continuously re-
leased from the endothelial constitutive pathway. Low
levels of ET-1 promote vasodilatation, whereas higher
and pathophysiological concentrations increase blood
pressure and total peripheral vascular resistance. In
ET-1+/2 heterozygous mice, levels of ET-1 in plasma
and lung tissue were lower than wild type, and the
animals developed elevated blood pressure and mild
hypertension rather than the fall in blood pressure
that might have been expected (Kurihara et al., 1994)
but explainable by ETB-mediated dilatation as the
predominant action of ET-1 in the wild-type mice.
In healthy volunteers, low doses of ET-1 infused into
the brachial artery cause vasodilatation consistent with
ETB-mediated release of vasodilators, but this was
followed by sustained vasoconstriction of the forearm
vascular bed at higher doses because the peptide
accessed the smooth muscle ETA receptors (Kiowski
et al., 1991). High concentrations of ET-3 also cause
vasodilatation (Haynes et al., 1995a,b). Blocking ETB
receptors using BQ788 caused vasoconstriction in
healthy volunteers, showing that the main consequence
of activation of endothelial ETB receptors by tonically
secreted ET-1 was the physiologic basal release of nitric
oxide (Verhaar et al., 1998). Similarly, ETA receptor
antagonism caused vasodilatation in the peripheral
circulation of volunteers and patients with chronic
heart failure, whereas selective ETB receptor antago-
nism caused vasoconstriction in each group. ETB re-
ceptor antagonism may therefore cause potentially
deleterious vasoconstriction in chronic heart failure
(Love et al., 2000). Only nitric oxide, from a range of
potential vasodilators tested as physiologic antagonists,
was found to fully reverse ET-1-mediated constrictions
in human epicardial coronary arteries (Wiley and
Davenport, 2000, 2001a) and also inhibited ET-1 bind-
ing (Wiley and Davenport, 2001b). It is well established
that nitric oxide inhibits ET-1 synthesis, for example in
cultured endothelial cells (Ohkita et al., 2002) and
synthetic ECE-1 enzyme (Kuruppu et al., 2014).
Thus ETB-mediated release of nitric oxide and other
vasodilators is crucial in acting as a counterregulatory
pathway to limit ETA-mediated vasoconstriction
through stimulation of vascular cyclic GMP. In patho-
physiological conditions where there is endothelial cell
dysfunction resulting in a loss of vasodilators, the
vasoconstrictor and other pathophysiological effects of
ET-1, such as cell proliferation, will be potentiated. In
addition, Big ET-1 levels are raised in some condition
such as heart failure (Love et al., 2000), and alternative
pathways for ET-1 synthesis fromBig ET-1, for example
by the vascular smooth muscle, would result in ET-1
binding immediately to ETA receptors and thus negat-
ing activation of the endothelial ETB feedback pathway
that opposes vasoconstriction.
4. Endothelin B Receptor Clearing Receptors. In
addition to vasodilatation, endothelial ETB receptors
function as clearing or scavenger receptors to internal-
ize the ligand-receptor complex and remove ET-1 from
the circulation (Fig. 4; Gasic et al., 1992; Fukuroda
et al., 1994b). Systemic and selective blockade of ETB
receptors results in a significant rise in circulating ET-1
(Plumpton et al., 1996). Importantly this is not simply
the result of displacement of ET-1 release from the
endothelium that would otherwise have bound to
vascular ETA receptors, because plasma ET-3 levels
also rise. Increases in plasma ET-1 have also been
reported for mixed antagonists that block both recep-
tors, such as bosentan, where there is a dose-dependent
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rise in plasma ET-1 (see, for example, Williamson et al.,
2000). With mixed antagonists, provided ETA receptors
are blocked it is unlikely that ET-1 will have any
adverse effect, whereas selective blockade of ETB may
potentially be detrimental. In contrast, administration
of the selective ETA antagonists in animals and humans
usually does not increase but in some cases reduce
plasma ET-1 levels compared with nonselective antag-
onists, which have been documented to increase ET-1
levels. For example, in patients with heart failure acute
ETA antagonism by sitaxentan caused selective pulmo-
nary vasodilatation associated with a reduction in
plasma ET-1 (Givertz et al., 2000). Monitoring changes
in plasma ET-1 provides an elegant biomarker of
receptor occupancy of ETB receptors and also a guide
as to the selectivity of antagonists in vivo.
Clearance of ET-1 in humans is very efficient and was
reported to be biphasic. The half-life of the initial phase
was 4 minutes, with a longer late phase that had not
reached basal after 1 hour (Vierhapper et al., 1990). A
biphasic curve was obtained with Big ET-1 with a half-
life of 7 minutes and 23 minutes for the late phase
(Hemsen et al., 1995). By comparison, ET-3 plasma half-
life was 1.7minutes (Weitzberg et al., 1995). In humans,
the lungs (Dupuis et al., 1996), liver (Gandhi et al.,
1996), and kidney (Saito et al., 1991) are important sites
for removal of ET-1. This reflects that these organs are
ETB rich (Fig. 7): Seventy percent of the ET receptors in
both the cortex and medulla of the kidney are ETB and
localize to endothelial cells throughout the renal vascu-
lature consistent with clearing ET-1 (Kuc et al., 1995;
Gariepy et al., 2000). In lung comprising about 50%
ETB, the majority are present on the vascular endothe-
lium. The isolated perfused liver extracts proportionately
more ET-1 than the lungs, with 80% uptake in a single
pass through binding to ETB receptors on hepatic stellate
cells and is reduced in conditions such as cirrhosis (Rockey
and Weisiger, 1996). Plasma levels of ET-1 are increased
in patients with cirrhosis, and elevated concentrations in
the liver are thought to be a consequence of both increased
synthesis and decreased clearance (Hinterhuber et al.,
2004).
The technique of positron emission tomography
(PET) using [18F]-ET-1 allows the dynamic distribution
and uptake to be visualized in all organs (Johnstrom
et al., 2005). This study confirmed the rapid removal
from the circulation within 2 minutes, and the major
sites for clearance of circulating [18F]-ET-1 were the
lungs, the liver, and the kidney (particularly the
glomeruli, cortex, and inner medulla/papilla), with only
low levels of uptake visualized in the thyroid, pitui-
tarym and salivary glands and no binding to the
skeleton or brain, the latter indicating the peptide did
not cross the blood-brain barrier. BQ788 injected before
[18F]-ET-1 significantly reduced clearing in lung and
kidney by 85% confirming the role of the ETB subtype,
although interestingly [18F]-ET-1 significantly increased
in the liver because the label was no longer cleared byETB
receptors and now bound to the ETA subtype. BQ788
injected after [18F]-ET-1 did not displace the radioligand,
consistent with internalization of ET-1 by ETB receptors
and degradation in the lysosome (Bremnes et al., 2000).
[18F]-ET-1 could not be visualized to the heart despite
expressing this organ expressing ETB receptors, but
binding was detected under BQ788 blockade. These
results emphasize the importance of ETB receptors in
maintaining low circulating plasma levels and the poten-
tial for ET-1 levels to rise under pathophysiological
conditions where clearance is reduced. ETB receptors are
expressed by a number of cell types in addition to
endothelial cells including epithelial and smooth muscle
cells. Do these contribute to removal of ET-1? Selective
deletion of endothelial ETB receptors in mice (with other
ETB receptors expressed by other cell types unaffected
with no change in ETA) resulted in impaired clearance of
an intravenous bolus of labeled ET-1 (Bagnall et al., 2006;
Kelland et al., 2010b). [18F]-Big ET-1 was also rapidly
cleared from the circulation of the rat (half-life ;3
minutes) with uptake of radioactivity in three major
organs: the liver and lungs were major sites for
conversion (inhibited by phosphoramidon), whereas
in the kidney [18F]-Big ET-1 was excreted largely
unmetabolized (Johnstrom et al., 2010).
E. Receptor Heterodimers?
GPCRs were originally considered as monomeric
proteins, but it is now well established that GPCRs
are able to form dimers, particularly receptors in
Family C, and there is some evidence for a number of
Class A receptor dimers, e.g., b1 and b2 adrenoceptors,
CCR2 and CCR5 (Pin et al., 2007). NC-IUPHAR has
published a number of criteria that should bemet before
a heterodimer can be established. There should be a
specific pharmacological property, such as a ligand-
specific response of the heterodimer. There should be
evidence for physical association in native tissues or
primary cells; coimmunolocalization using antibodies
recognizing each of the subunits should be used, ideally
by electron microscopy level, energy transfer technolo-
gies, and recombinant fluorescent proteins. Knockout
animals or RNAi technology may also provide key
information on the existence of heterodimeric GPCRs
in vivo.
Gregan et al. (2004) demonstrated that ETA/ETB
heterodimers artificially expressed in HEK293 cells
could be coimmunoprecipitated using ETB-specific an-
tibodies, detected using FLAG-tagged ETA and myc-
tagged ETB receptors and confirmed using fluorescence
resonance energy transfer microscopy. The authors
observed a pharmacological difference in that ETA/
ETB heterodimers internalized more slowly in response
to ET-1 than with BQ3020. If this occurred in native
tissues this could change the number of functional ETB
receptors on the cell surface and also the clearance of
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ET-1. Evans andWalker (2008a,b) explored evidence for
both homo (ETA/ETA, ETB/ETB)- and heterodimers
(ETA/ETB). These studies used energy transfer technol-
ogies and coimmunoprecipitation to show close associ-
ation for each of the dimer pairs and a pharmacological
difference between homodimers that when stimulated
by ET-1 mediated a transient increase in calcium but a
sustained increase was obtained to ET-1 with ETA/ETB
heterodimers. These studies meet some of the required
criteria, but were all done in HEK293 cells. Further
experiments are required in native tissues to determine
whether heterodimers exist, for example, in epithelial
cells where both subtypes are expressed and whether
such dimers have any physiologic or pathophysiological
significance.
IV. Classification of Selective Agonists
and Antagonists
Over the last 20 years the development of agonists and
antagonists of varying degrees of specificity for both
receptors has been extensive, not only as pharmacolog-
ical probes but also for candidate drugs. Themost concise
overview (many compounds from which are discussed
individually in this section) is maintained on the
IUPHAR/BPS Guide to PHARMACOLOGY (GotPdb)
web site (Pawson et al., 2014; Southan et al., 2016). The
entry for ETA antagonists is at guidetopharmacology.org/
GRAC/ObjectDisplayForward?objectId=219 and for ETB
atguidetopharmacology.org/GRAC/ObjectDisplayForward?
objectId=220, where further information on structure-
activity and molecular structures can be downloaded.
Although the GtoPdb entries are an expert-curated core
set, the much larger number of receptor-to-compound
mappings in ChEMBL represents a maximal compilation
extracted from the medicinal chemistry literature (PMID
24214965). Release 20 of ChEMBL (https://www.ebi.ac.
uk/chembl/) specifies 3885 unique chemical structures
mapped to ET receptors, but this includes inactive
compounds and entries are not categorized pharmacolog-
ically as agonist or antagonist. As a triage, these 3885
records were filtered to distinct structures with a reported
affinity greater than 1 mM then mapped to PubChem
Compound Identifiers. This resulted in 1133 chemical
structures with binding data for the ETA receptor, 534 for
the ETB, 456 against both, 677 A-only, and 78 B-only.
Lists for these sets of ChEMBL IDs are available as
supplementary data on figshare (http://dx.doi.org/10.6084/
m9.figshare.1549677).
A comparatively large number of nonpeptide antag-
onists were developed for potential clinical use. ET
receptor antagonists are classified as either selective for
one receptor subtype or alternatively as mixed or
"balanced" antagonists that block both receptors. The
classification is usually made by the company or group
discovering the compound by measuring the affinity at
the two subtypes and calculating a ratio of selectivity,
but there is no agreed definition. We have proposed
ETA-selective compounds should display more than
100-fold selectivity for the ETA subtype and those with
less than 100-fold ETA selectivity should be classified as
mixed antagonists (Davenport and Maguire, 2006).
Similarly, ETB agonists and antagonists should display
100-fold selectivity to be useful research compounds. In
practice, the tool compounds described below display at
least two orders of magnitude selectivity and, provided
appropriate concentrations are chosen, would be
expected to be selective in both in vivo and in vitro
assays. In contrast, a number of antagonists developed
for clinical use display marginal selectivity (Fig. 9).
Bosentan is commercially available and is a mixed ETA/
ETB antagonist. One of the first orally active nonpeptide
antagonists to be discovered, it has been widely used in
in vitro and experimental models.
A. Agonists
ET-1 is equipotent for ETA and ETB andwill therefore
activate both. ET-1 has been widely used in pharmaco-
logical preparations in vitro and in vivo as well as
experimentalmedicine studies in volunteers andpatients.
Most studies characterizing and localizing ET receptors
have used [125I]-ET-1 (directly labeled via Tyr13, a residue
not critical for ligand-receptor interaction) that binds with
the same affinity to both subtypes. This radiolabeled
analog of ET-1 is stable under nonphysiologic binding
conditions with little or no degradation being detected.
ET-1 canalso be labeledwith thepositron emitting isotope
[18F] and used to image and quantify ET receptors in
vivo (Johnstrom et al., 2005). [125I]-ET-2, [125I]-VIC,
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Fig. 9. Comparison of the selectivity of ET ligands for native ETA and
ETB receptors measured in the same competition binding assay against
[125I]-ET-1. This assay uses human heart, which expresses both subtypes,
resulting in a biphasic competition curve. Measurement of the affinity
(the equilibrium dissociation constant or KD) of each compound at the two
receptor sub-types can be accurately determined using non-linear
iterative curve fitting. Comparison of the two affinities provides a
measure of the selectivity for each subtype (Maguire and Davenport,
2012).
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and [125I]-sarafotoxin 6b have also been labeled and
used in saturation assays where they also bind to both
subtypes (Davenport and Morton, 1991; Bacon and
Davenport, 1996; Maguire et al., 1996). Binding
was also detected using [125I]-ET-Big ET-1 labeled
at Tyr13 to follow processing by enzymic cleavage to
the mature labeled peptide, whereas no specific
binding was detected with Big [125I]-ET-1 labeled at
Tyr31, where enzymic activity yielded the inactive
C-terminal fragment (Russell et al., 1998). [18F]-ET-Big
has also been used to quantify and characterize conver-
sion in vivo using PET (Johnstrom et al., 2010).
Some authors preferred to inject Big ET-1 instead of
ET-1 for in vivo studies in the rat designed to charac-
terize antagonists such as bosentan, arguing that the
conversion to themature peptide by the vasculature is a
better representation of the ET signaling pathway
(Clozel et al., 1994). However, in a detailed study that
compared the ability of bosentan to block the actions in
vivo of ET-1 versus Big ET-1, it was clear that the
responses were not the same, with the authors conclud-
ing that ET-1 triggered a covert mesenteric vasodilator
mechanism that was antagonized by bosentan but not
seen with the precursor (Gardiner et al., 1994).
1. Endothelin Receptor A-Selective Agonists. No
ETA-selective agonists, either peptide or nonpeptide,
have been discovered.
2. Endothelin Receptor B-Selective Agonists:
Sarafotoxin 6c, IRL1620, BQ3020, and Radioligands.
Initially receptor subtypes were characterized by their
rank order of affinity for the three ET peptides: ETA:
ET-1 = ET=2 . ET-3 versus ETB: ET-1 = ET-2 = ET-3.
Therefore, ET-3 is the only endogenous ET peptide that
distinguishes the two receptor subtypes. For ligand
binding assays, ET-3 can be radiolabeled at three
positions: Tyr6, Tyr13, and Tyr14. Tyr6 is generally used
because it is more difficult to separate [125I]-ET-3
labeled at the latter two Tyr residues, although all
three ET-3 ligands have similar affinities. In practice,
the selectivity of ET-3 for ETB versus ETA receptors is
often only about two orders of magnitude (Fig. 9), and it
is difficult to precisely delineate the two subtypes in
functional experiments without the use of selective
antagonists. ET-3 has been used in clinical studies, for
example by Haynes et al., (1995a, b).
Four synthetic peptides have become established as
the most highly cited compounds that are selective
agonists at the ETB receptor with greater selectivity
than ET-3, and interpretation of results for these are
unequivocal. Sarafotoxin 6c, one of the four sarafotoxin
isoforms originally identified from the snake venom,
has remarkably high selectivity for rat ETB receptors
(200,000-fold’,Williams et al., 1991), although less so for
ETB human receptors (Fig. 9; Russell and Davenport,
1996). The peptide is resistant to peptidases.
[Ala1,3,11,15]-ET-1 (Saeki et al., 1991) is a linear analog
of ET-1 where substitution of Ala for Cys residues
removes the disulfide bridges, converting the ET-1
structure to an ETB agonist. The most widely used
ETB-selective agonists are IRL1620 (Suc-[Glu
9,
Ala11,15]-endothelin-18-21) (Takai et al., 1992), which is a
truncated linear analog where the N terminus has an
N-succinyl modification that reduces metabolism by non-
specific peptidases, and BQ3020 ([Ala11,15]Ac-ET-l6-21)
(Ihara et al., 1992b). Sarafotoxin 6c has been used in
experimental medicine studies in humans (Haynes et al.,
1995a, b). All four peptides have been radiolabeled to
characterize ETB receptors, although [
125I]-BQ3020 and
[125I]-IRL1620 have been most frequently used (Ihara
et al., 1992b; Molenaar et al., 1992). [125I]-BQ3020 binds
with subnanomolar affinity to theETB receptorwith 1500-
fold selectivity for this subtype over the ETA receptor, and
[18F]-BQ3020 has been used as a selective PET imaging
agent in vivo (Johnstromet al., 2000, 2006). [125I]-IRL1620
is also highly ETB selective (Watakabe et al., 1992).
3. Endothelin Receptor B Agonists in Chemotherapy
and Neuroprotection. ETB agonists have been tested
for clinical application in cancer (Maguire and Davenport
2012; Gulati et al., 2012). A Phase 1 clinical trial of
IRL-1620 (SPI-1620, Spectrum Pharmaceuticals;
(Henderson, Nevada)) was carried out in patients with
recurrent progressive carcinoma and shown to selec-
tively and transiently increase tumor blood flow (Gulati
et al., 2012). The rationale for the study was that
stimulating ETB receptors would cause vasodilatation
to increase the penetration of cytotoxic antitumor
agents into tumors but reduce the concentration in
healthy tissue. This hypothesis was based on the
reports that IRL1620 increased effectiveness of antitu-
mor agents in rat models of prostrate and breast cancer
(Rajeshkumar et al., 2005) as well as improving the
efficacy of radiotherapy (Gulati et al., 2012). Preclinical
studies have suggested IRL1620may also be effective in
animalmodels of stroke and cerebral ischemia (Leonard
et al., 2011, 2012; Leonard and Gulati, 2013). Interest-
ingly, the complementary approach of ETA antagonism
has also been suggested as potential benefit in these
models (Patel et al., 1996).
B. Antagonists
1. Endothelin Receptor A Peptide and Nonpeptide
Antagonists and Radioligands. The most widely cited
ETA-selective peptide antagonists used in vivo and in
vitro are BQ123 (cyclo-[D-Asp-L-Pro-D-Val-L-Leu-D-Trp-],
(Ihara et al., 1992b), originally isolated from fermentation
products of the microorganism Streptomyces misakiensis,
that has low nanomolar affinity for the receptor, followed
by the linear peptide FR139317 (N- [(hexahydro-1-
azepinyl)carbonyl]L-Leu(1-Me)D-Trp-3 (2-pyridyl)-D-Ala;
Aramori et al., 1993) (Figs. 3 and 4). These antagonists
are commercially available and are recommended for
their very high selectivity for ETA, their solubility, and
lack of plasma binding (Fig. 9). Owing to their peptidic
structure they do not have oral bioavailability, are
380 Davenport et al.
administered intra-arterially, and are metabolized or
excreted over comparatively short periods of time.
BQ123 and FR139317 are therefore used for short-term,
acute investigations in both animal models and in
experimental medicine studies. BQ123 in particular has
been used extensively in acute studies in volunteers and
patients with no adverse effects reported at the concen-
trations tested. A second peptide antagonist, the cyclic
hexapeptide TAK-044 (Masuda et al., 1996), also isolated
fromStreptomycesmisakiensiswith amoremodest degree
of ETA selectivity, has also been used in experimental
(Plumpton et al., 1996; Haynes et al., 1996; Ferro et al.,
1997) and clinical studies including renal failure (Dhaun
et al., 2007a) and in an amulticenter, randomized, double-
blind, placebo-controlled trial in patients with subarach-
noid hemorrhage (Shaw et al., 2000).
Key tool compounds for radioligand binding and
autoradiography (using a fixed concentration of ligand)
include [125I]-PD151242 that is recommended to local-
ize ETA receptors. This linear tetrapeptide, based on the
initial FR139317 structure, binds with subnanomolar
affinity to the ETA receptor and has about 10,000 fold
selectivity for this subtype in human (Davenport et al.,
1994a,b) and animal tissues (Peter and Davenport,
1995a,b). A tritiated analog, [3H]-BQ123, has also been
reported to be a highly specific and reversible ETA
radioligand (Ihara et al., 1995), although, as with other
tritiated ligands, it has much lower specific activity
than[125I]-labeled compounds.
2. Endothelin Receptor A-Selective Antagonists in the
Clinic: Ambrisentan and Withdrawal of Sitaxentan.
The majority of experimental studies have used a number
of commercially available experimental ETA antagonists
(Palmer, 2009). These include PD156707 (Maguire et al.,
1997) thathas also beenused to imageETA receptor in vivo
using PET (Johnstrom et al., 2000;Maschauer et al., 2013)
and A127722 (ABT627, atrasentan) (Wessale et al., 2002).
AnonpeptideETA selective ligand, ananalog of PD156707,
has been developed, [125I]-PD164333 (Davenport et al.,
1998), as well as [18F]-PD156707 (Johnstrom et al., 2000).
Preclinical studies characterizing the pharmacology of
ETA small molecule antagonists as well as mixed antag-
onists are shown in Fig. 10.
Ambrisentan (Letairis, Volibris, LU208075, BSF
208075) (Vatter et al., 2003) was approved in 2007 by
the Food and Drug Administration and European
Medicines Authority in 2008 as an orally active, once
daily drug for the treatment of PAH (Table 1). The
compound is a competitive ETA antagonist, although
less ETA selective than sitaxentan, but has good bio-
availability, long half-life with a low incidence of acute
hepatic toxicity, and does not induce or inhibit P450
enzymes, so less likely to affect the pharmacokinetics of
P450-metabolized drugs. Ambrisentan has fewer side
effects, such as an increase in liver enzymes that require
liver function tests that is associated with bosentan, but
nasal congestion and peripheral edema are more prev-
alent (Vizza et al., 2012).
In 2015, clinical trials with ambrisentan (clinical-
trials.gov) included the treatment of portopulmonary
hypertension, hypoplastic left heart syndrome, inoper-
able chronic thromboembolic pulmonary hypertension,
PAH associated with systemic sclerosis, and exercise-
induced PAH. Analysis of clinicaltrials.gov showed that
there were no records for the majority of investigational
ET antagonists with the exception of two compounds.
Zibotentan, the most ETA selective of the small molecule
compounds (Fig. 10) was discontinued from development
by Astra-Zeneca (Cambridge, United Kingdom) after it
failed to show any improvement in survival in Phase III
trials inpatientswith resistant prostate cancermetastatic
to bone (Nelson et al., 2012). The antagonist was made
available to other groups and trials included patients with
intermittent claudication and renal scleroderma. Atra-
sentan (AB 627) is the most extensively studied ETA
antagonist in preclinical studies and has shown promise
in patients with type 2 diabetic nephropathy, reducing
albuminuria, blood pressure, cholesterol, and triglyceride
levels (de Zeeuw et al., 2014), and this has led to the
initiation of a Phase 3 multicenter trial (Sonar) with 4000
patients (clinicaltrials.gov).
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Fig. 10. Spectrum of selectivity of antagonists for ETA versus ETB
receptors as reported by the companies that discovered the compounds
mainly based on measuring affinity constants in separate competition
assays against [125I]-ET-1 using human recombinant ETA versus ETB
receptors. Antagonists are classified as either selective for one subtype or
alternatively as mixed antagonists that block both receptors. The
classification is usually made by the manufacturer, but there is no
agreed definition and there are anomalies. We proposed that antagonists
that are ETA-selective should display more than 100-fold selectivity for
the ETA subtype and those that block both ETA and ETB (mixed
antagonists) should demonstrate less than 100-fold ETA selectivity. The
rational for this classification is based on receptor occupancy where a
concentration can be calculated to block virtually all ETA receptors but
not ETB for in vitro studies. The threshold is indicated by the lower
dashed line. It is difficult to achieve exact plasma concentration in vivo
and to achieve selectivity; compounds with at least two orders of
magnitude are more useful. Bosentan, ambrisentan, and macitentan
are currently approved for clinical use and are highlighted. Note that the
manufacturers of macitentan classify the antagonist as a mixed
antagonist although it displays ETA selectivity. Sparsentan is a dual
ETA/angiotensin II receptor type 1 receptor antagonist (modified from
Maguire and Davenport, 2014).
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Sitaxentan (Table 1; Thelin, TBC11251) (Wu et al.,
1997; Barst et al., 2007) was introduced in 2008 as a
potent, competitive, long-acting, orally active ETA
antagonist, the most highly selective to be approved
for the treatment of PAH. The compound was with-
drawn is 2010 owing to cases of idiosyncratic hepatitis
resulting in acute liver failure (Don et al., 2012).
3. Endothelin B Receptor Peptide and Nonpeptide
Antagonists. Few ETB receptor antagonists have been
developed, reflecting the potential danger of blocking
the beneficial vasodilatation and internalization of ET
mediated by this subtype (Palmer, 2009). The most
extensively used and highly cited is the peptide BQ788
(Ishikawa et al., 1994), although a small number of
papers have reported on other compounds such as the
first small molecule, nonpeptide RO468443 that dis-
played 2000-fold ETB selectivity (Breu et al., 1996) and
A192621. The latter compound has the advantage over
BQ788 because it has good oral bioavailability in a
number of species (Wessale et al., 2002). ETB antago-
nists are generally less potent than ETA antagonists
and display lower selectivity (usually only 1 to 2 orders
of magnitude) for the ETB over the ETA receptor, but
concentrations can be chosen that selectively block the
ETB receptor. Other proposed antagonists should be
avoided, and results are difficult to interpret for com-
pounds such as RES-701-1 that had little or no action,
for example, at human or rat ETB receptors (Tanaka
et al., 1995; Russell and Davenport, 1996) or have low
affinity, such as IRL-2500 (Russell and Davenport,
1996). Radiolabeled ETB antagonists have not been
developed.
C. Mixed Antagonists in the Clinic: Bosentan
and Macitentan
Bosentan is a sulfonamide (Palmer, 2009) and was
the first ET orally active antagonist to be approved for
clinical use in the treatment of PAH (Table 1). It has a
comparatively short half-life but good bioavailability,
and as a competitivemixed antagonist, it will block both
the detrimental effects of ET-mediated via ETA as well
as beneficial actions mediated via ETB. Bosentan is the
most widely usedmixed antagonist in preclinical studies
and has been radiolabeled with tritium (Dashwood et al.,
1995). The mixed antagonist SB209670 has been labeled
with 18F (Johnstrom et al., 2004). In common with other
dual antagonists, bosentan tends to have lower rates of
fluid retention and edema than observed with the ETA
antagonists. However, liver toxicity is a significant side
effect; this is not thought to be as a consequence of
blocking ET receptors but by inhibiting the bile salt
export pump leading to accumulation of cytotoxic bile
salts, resulting in hepatocellular damage. In 2015,
bosentan clinical trials included scleroderma renal crisis,
ischemic optic neuropathy, stable severe chronic obstruc-
tive pulmonary disease, and combined with iloprost in
PAH (clinicaltrials.gov).
Macitentan (Table 1, Opsumit, ACT-064992; Actelion)
is a sulfamide thatwas approved for clinical use in PAH in
2013 (Patel and McKeage, 2014; Sidharta et al., 2015). It
was designed using structure-activity studies to improve
the efficacy and tolerability of bosentan. Macitentan has
been proposed to enter the liver via passive diffusion and
not by active uptake as is the case of bosentan (Treiber
et al., 2014), and, as a result of reduced liver toxicity, doses
do not need to be altered in patients with renal or hepatic
disease (Dingemanse et al., 2014). Macitentan has fewer
interactions with other drugs and reduced edema/fluid
retention compared with bosentan (Bruderer et al., 2012;
Gatfield et al., 2012). The pharmacokinetics are more
complex: it is an insurmountable antagonist that is
metabolized to ACT-132577, which is also active albeit
with a lower potency, but the metabolite reaches a higher
plasma concentration and has a longer half-life than the
parent compoundmacitentan (Iglarz et al., 2008; Sidharta
et al., 2013, 2014). Macitentan is an order of magnitude
more potent than bosentan, as a result of longer receptor
occupancy (17 minutes versus 70 seconds for bosentan
measured by in vitro assays), probably as a result of
interaction with different amino-acid residues in the ET
receptors. Actelion describes the compound as a dual
antagonist but on the basis of their own data measuring
inhibition of [125I]-ET-1 binding to human expressed
receptors it displays ;800 fold selectivity for the ETA
subtype (Pulido et al., 2013). However, plasma ET-1
concentrations were significantly increased (twofold at
TABLE 1
Pharmacodynamic and pharmacokinetic properties of ET receptor antagonists approved for clinical use
Bosentan Macitentan Active Metaboliteof Macitentan Ambrisentan
Sitaxentan (Withdrawn from
Clinical Use in 2010)
Trade name Tracleer, Opsumit Letairis, Volibris Thelin
Chemical Name benzenesulfonamide sulfamide sulfamide benzenepropanoic acid 3-thiophenesulfonamide
Inhibition [125I]-ET-1 IC50 (nM, *Ki)
ETA 5* 0.5 3 0.3 1
ETB 97* 391 185 185 9800
ET plasma levels after administration ↑↑ ↑↑ — ↑ ↓
Bioavailability ;50% Not reported Not reported High 70–100%
Time to max plasma concentration 3–5 4-12 30 1.7–3.3 1–4
Terminal half-life (h) 5.4 16 40.2-65.6 15 10
Excretion in urine (%) ,3 50% — Low 50–60
(Weber et al., 1996;1999; Spence et al., 2008; Opitz et al., 2008; Sidharta et al., 2013)
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the highest dose tested), suggesting blocking ofETBoccurs
at the dose used (Sidharta et al., 2011). In 2015, clinical
trials with macitentan included thromboembolic pulmo-
nary hypertension, portopulmonary hypertension, and
Eisenmenger Syndrome. Perhaps the most intriguing
new target is glioblastoma, where the ET pathway is
upregulated (Harland et al., 1998) in combination with
existing therapy, temozolomide (clinicaltrials.gov).
D. Will Endothelin Agonists and Antagonists Be
Developed in the Future?
The first peptide receptor antagonists were discovered
in 1992 (section IV.B.1). ET receptors continue to be a
challenging drug target. First, the key question as to
whether selective ETA receptor antagonists are clinically
advantageous over dualETA/ETBantagonism is still open.
Second, in a review based on commercial intelligence
sources, up to 2009, only three antagonists were approved
for the clinic, bosentan, sitaxentan, and ambrisentan from
;500 preclinical compounds (Palmer, 2009). These chal-
lenges are reflected in a primary patent literature review
in the same year (Mucke, 2009). The latter concluded that
pharmaceutical companies have reduced ET antagonist
primary patenting (first filings on novel structure activity
series) since ;2000 because most potential therapeutic
applications have already been claimed. Figure 11 shows
that although publications on ET antagonists reached a
peak in 2011, patenting and medicinal chemistry output
was already declining by the late 1990s and only a small
number of patents continue to be filed, most recently in
2015. This latter is a series of phenoxybutanoic acid
derivatives with a lead compound identified as a potent
and selective ETA antagonist with efficacy in animal
models of hypoxia-induced PAH (Cai et al., 2015).
The results show that to date ET agents are chemi-
cally very similar and there is further chemical space to
be exploited. Both Palmer (2009) and Mucke (2009)
commented that although the explored and claimed
chemical space is large (the space spanned by all
potential chemical compounds), the ET antagonists that
have progressed are mostly N-heterocyclic sulfon-
amides of comparable structure and molecular weight
and those that are not sulfonamides (atrasentan,
ambrisentan, darusentan, and enrasentan) still retain
strong similarities with each other and with the sulfon-
amides. One way to examine this characteristic for a set
of molecules is via a three-dimensional alignment using
the ChemAxon Marvin tool. Figure 12 shows antagonists
with a range of ETA selectivity. The overlays imply that
this compact conformational ensemble circumscribes an
antagonist binding pocket (note that the extended orange
side chain is from macitentan). Although such results
should not be over interpreted, the side view suggests that
this pocket is flattened in terms ofwhat conformations can
access it to exert the biologic effects. The analogous results
are presented for the ETB-selective antagonists A-192621,
BQ788, and RO468443 in Fig. 12.
E. Allosteric Modulators
Allosteric modulators bind to a separate region of a
given receptor to the orthosteric agonist binding site that
binds the endogenous ligand, in this case ET-1. Negative
allosteric modulators would be expected to reduce ET-1-
mediated responses. Currently, ET receptor antagonists
carry a black box warning because of the risk of the
embryo-fetal toxicity inferred from ET-1 KO studies in
mice. Allosteric modulation, in reducing but not blocking
ET-1,may have an advantage in lessening this possibility.
Only a limited number of allosteric modulators of the ETA
receptor (Blandin et al., 2000; Talbodec et al., 2000; Farhat
and Allen et al., 2004; Ahmed et al., 2008) have been
reported and none for the ETB subtype. These would all be
classified as negative modulators of ET-1 binding such as
sodium salicylate (Talbodec et al., 2000). This compound
and related molecules normally act as nonsteroidal anti-
inflammatory drugs by inhibiting cyclo-oxygenase activity.
It is thereforedifficult to interpret the results of testing the
action of such compounds in vivo on the cardiovascular
actions of ET-1, because they would also inhibit the
production of vasodilators such as prostacyclin. Acetyl
salicylate has not been reported to interact with any other
G-protein coupled receptors. However, from the limited
set of reports it is not possible to drawany structure-based
conclusions on allosteric modulators. Based on the small
molecular size [for example, molecular weight of 296 for
3,5-dibromosalicylic acid and low potency, Ki ;300 mM
(Blandinetal., 2000)], theusefulness of structures reported
so far for SAR expansion seems limited. Although the
absence of additional results should not be over inter-
preted, given the extent of chemical space, it would seem a
reasonable assumption that there may not be easily
exploitable allosteric effector pockets in these receptors.
Fig. 11. Pipeline of ET receptor antagonists measured by papers in
PubMed (blue bars), papers with ChEMBL entries in Europe PubMed
Central (red bars) and patents (green bars) in PATENTSCOPE with ET
receptor antagonists combined with patent classification C07D (code for
medicinal chemistry) (Bento et al. 2014).
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F. Therapeutic Monoclonal Antibodies: Rendomab-B1
A new strategy to block the action of ET-1 is the
development of a monoclonal antibody, rendomab-B1,
which has subnanomolar affinity at the ETB receptor
and was reported to be more effective than BQ788 in
competing for ET-1 binding. Rendomab-B1 was pro-
posed to function as an antagonist based on the
observed inhibition of ET-1-induced IP3-calcium signal-
ing (Allard et al., 2013). The antibody was not tested in
vivo, and it might be expected, based on experience from
BQ788 experimental medicine studies, to block endo-
thelial ETB receptors and therefore cause vasoconstric-
tion. The rationale for clinical application is unclear
compared with that for a monoclonal antibody against
ETA receptors. However, one advantage could be in
linking the monoclonal to a toxic payload for cancer
treatment of those tumors in which ETB receptors are
overexpressed. The generation ofmonoclonal antibodies
against GPCRs is challenging. However the study
provides proof of principle for the generation of a
pharmacologically active monoclonal against the ETB
receptor. Membrane bound GPCRs are highly favorable
targets for the development of monoclonal antibodies
and these can have advantages over small molecule
antagonist with respect to specificity and prolonged
time course of action of several months.
G. Targeting the Endothelin B Receptor with Cell
Penetrating Peptides
The cell penetrating peptides (CPP) superfamily
comprises several classes of peptides that deliver an
exogenousmoiety to a specific intracellular target. They
include the protein-derived CPPs and pepducins that
are lipidated peptides that remain tethered to the cell
membrane but can interact with an intracellular seg-
ment of a GPCR resulting in activation or blockade of
downstream signaling. Currently there are pepducin
agonists and antagonists for many GPCRs including
chemokine receptors, the b2 adrenoceptor, proteinase
activated receptors, sphingosine-1-phosphate receptors,
and the apelin receptor (for reviews, see Dimond et al.,
2011; O’Callaghan et al., 2012; Zhang et al., 2015).
A CPP has been reported for the ETB receptor
incorporating an amino acid sequence based on the
second intracellular loop of ETB linked to a SynB3
vector derived from the antimicrobial protein protegrin-
1 (Green et al., 2013). This molecule, IC2B, reduced
right ventricular systolic pressure and hypertrophy and
the degree of pulmonary artery muscularization in a rat
model of hypoxia induced PAH without an effect on
blood pressure. In acute studies, 24 hours of hypoxia
increased levels of Akt and ERK in pulmonary artery
smooth muscle, and these were attenuated by injection
of IC2B at the beginning of the hypoxic period. In
isolated pulmonary artery from the same animals, in
the presence of the ETA antagonist BQ123, ET-1 further
activated Akt and ERK phosphorylation and this was
also blocked by ICB2 confirming involvement of the ETB
receptor (Green et al., 2013). These data are somewhat
unexpected because blockade of ETB receptors has
generally been shown to be detrimental in PAH. The
authors suggested that the beneficial effect may result
from a selective blockade of smooth muscle ETB
receptor-mediated vasoconstriction and proliferation
via Akt and ERK signaling that contribute to disease
C
A
D
B
Fig. 12. Three-dimensional alignments shown as a top view (A) and the side view (B) of the 11-molecule cluster of ET antagonists using ChemAxon
Marvin tool at default settings to perform a flexible overlap of atoms via on-the-fly adjustments. The following 11 were selected as having high affinity:
peptide antagonist FR139317 and nonpeptide antagonists, A127722, ambrisentan, avosentan, darusentan, macitentan, PD156707, PD164333,
SB234551, sitaxentan, and zibotentan. Top (C) and side view (D) of a three-molecule cluster of ETB peptide antagonist, BQ788, and nonpeptide
antagonists A192621 and RO468443.
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progression, leaving endothelial ETB-mediated vasodi-
latation for example unaffected; however, this remains
to be confirmed.
H. Biased Signaling
A major development in GPCR research has been the
discovery of "biased ligands" that stabilize the receptor
in a conformation that preferentially activates a subpop-
ulation of the G-protein-dependent and/or -independent
cascades that are normally engaged by an unbiased
natural ligand (for reviews, see Kenakin, 2011; Wisler
et al., 2014). Previously, the assumption had been that
ET-1 acting at the ETA receptor, for example, would elicit
G-protein-dependent effects such as vasoconstriction and
stimulate b-arrestin recruitment to silence the receptor
by desensitization and subsequent internalization. ET
receptors are internalized via b-arrestin and dynamin/
clathrin-dependent mechanisms, but the receptor sub-
types exhibit clear differences; ETA receptors are recycled
to the plasma membrane and are therefore available for
further signaling, whereas, after internalization, theETB
subtype is directed to the lysosomes and degraded
(Bremneset al., 2000). However, it is now apparent that
b-arrestins can also contribute to physiologic and, im-
portantly, pathophysiological responses such as cell
migration and proliferation (for review, see Shukla
et al., 2011). Pathway biased ligands are therefore of
great interest, and the development of biased drugs have
the potential to limit detrimental on-target effects. To
date, agonists have been identified that show either G-
protein bias, for example at the nicotinic acid (Walters
et al., 2009), m opioid (deWire et al., 2013), and apelin
receptors (Brame et al., 2015), or b-arrestin bias, such as
the angiotensin II receptor type 1 (Violin et al., 2010) and
parathyroid hormone receptors (van der Lee et al., 2013).
There have been some limited studies that indicate
that the ET peptides and sarafotoxins show some
pathway bias at the ET receptors, at least in vitro, in
some assays. Compeer et al. (2013) proposed that ET-1
and ET-2 activate different signaling mechanisms to
elicit and maintain vasoconstriction that were depen-
dent on the vascular bed investigated. It is now
recognized that signaling bias is best demonstrated by
comparing the relative potencies of agonists to a
standard, preferably an endogenous agonist, in assays
that interrogate multiple G-protein-dependent and
-independent pathways that have relevance to ET
physiology or pathophysiology. One study (Maguire and
Davenport, 2012) has reported that the endogenous ET
peptides show similar rank order of potencies and
maximum responses in both a G-protein-dependent
constrictor assay and cell-based b-arrestin recruitment
assay, whereas sarafotoxin 6b was a full agonist in the
constrictor assay but a partial agonist in the b-arrestin
assay, suggesting the potential to generate biased ET
agonists. It is interesting to speculate that a reduction
in the ability of the toxin to trigger receptor desensitization
may have been a result of evolutionary selection to prolong
the effect on prey of envenomation. Of perhaps more
relevance to the development of improved clinical com-
pounds, it was shown that although bosentan does not
distinguish betweenETA andETB receptors in radioligand
binding assays, this compound exhibited a higher affinity
in the ETA-mediated b-arrestin recruitment assay com-
pared with the ETB-mediated b-arrestin assay.
The potential to develop b-arrestin biased antago-
nists is intriguing because detrimental effects of ET-1,
particularly in cancer, may result from activation of
b-arrestin-mediated signaling. The contribution of the
ET-1/ETA/b-arrestin pathway is well defined in epithe-
lial ovarian cancer and contributes to tumor cell pro-
liferation, invasion, and metastasis. ET-1 induced
activation of nuclear factor kappa-light-chain-enhancer
of activated B cells, a key mediator in oncogenesis, is
dependent on b-arrestin (Cianfrocca et al., 2014), and
b-arrestin-1 is an epigenetic regulator of ET-1-induced
b-catenin signaling, a critical mechanism for controlling
cell division and ovarian cancer progression (Rosanò
et al., 2009, 2013b). Selective activation of the ETA/Gas
pathwaywas recently proposed as an alternative strategy
in this disease (Teoh et al., 2014) because thisG-protein is
linked to tumor-suppressive effects. In this study it was
reported that ETA/Gas stimulated cAMPand subsequent
activation of protein kinase A inhibited the expression of
angiogenic and metastasis genes that are switched on by
ETA-mediated b-arrestin signaling.
I. Pharmacological Targeting of Epigenetic Regulation
of Endothelin Signaling
Epigenetic mechanisms are crucial for normal devel-
opment and maintenance of tissue-specific gene expres-
sion. These mechanisms include DNA methylation and
histone modification, the latter being posttranslational
covalent modification of globular histone proteins by a
range of writers, erasers, and readers that alters the
ability of associated DNA to be transcribed. These
covalent marks are read by specific families of proteins
such as bromodomains that can now be targeted by
small molecule inhibitors, which selectively modulate
gene expression (Prinjha et al., 2012).
Epigenetic regulation is critical to the ET pathway
because transcription is the primary level of regulation
of the endothelin-1 gene by histone modifications and
DNA methylation (Welch et al., 2013). This regulation
can be affected in disease by alterations such as
aberrant DNA methylation in the promoter regions of
the gene. For example, in the cardiovascular system,
ANG II induces cardiac hypertrophy and fibrosis partly
by stimulating ET-1 transcription. This occurs as a
result of an epigenetic complex of chromatin remodeling
proteins and histone methyltransferase being recruited
to the ET-1 promoter region in endothelial cells (Weng
et al., 2015). Conversely downregulation of the ET
pathway may be detrimental in cancer. In rat and
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human colon tumors, hypermethylation of EDN2 and
EDN3 genes resulted in the epigenetic inactivation of
ET-2 and ET-3 mRNA and corresponding protein. Re-
storing ET-2 and ET-3 expression in human cells
significantly attenuated the migration and invasion of
human colon cancer cells (Wang et al., 2013). During
development of tumors, DNA methylation silences the
EDNRB gene and downregulates the receptor protein,
reducing beneficial ETB-mediated apoptosis. Hyperme-
thylation of the EDNRB gene was highly prevalent in
gastric cancer and remarkably related to infiltration
andmetastasis that leads to the tumor progression (Tao
et al., 2012). Epigenetic drugs may have efficacy where
changes in ET signaling are thought to cause some
tumor types such as melanomas and oligodendroglio-
mas (Bagnato et al., 2011).
J. Physiologic Antagonism by Nitric Oxide and Other
Vasoactive Mediators
A key physiologic action of nitric oxide, the endothe-
lium derived relaxing factor, is to activate soluble
guanylate cyclase and generated cGMP to cause re-
laxation. Endothelial nitric oxide synthase is constitu-
tively active, generates NO in response to shear stress
and other physiologic stimuli and can limit the con-
strictor action of ET-1. This has recently been reviewed
(Rapoport, 2014). A number of pathophysiological
conditions are associated with endothelial cell dys-
function and loss of nitric oxide. The balance between
ET and nitric oxide appears critical. In contrast to
nitric oxide, shear stress downregulates the transcrip-
tion of the ET-1 gene and may be related to cell shape
and cytoskeletal change (Malek et al., 1993). It is well
established that inhibitors of NOS increase levels of
ET-1. In rats, in vivo treatment with NOS inhibitor to
cause hypertension resulted in increased ET-1 synthe-
sis in renal microvessels when NO production is sup-
pressed. ET-1 was found to be a major activator of
collagen I formation in renal resistance vessels and in
the development of renal fibrosis (Tharaux et al.,
1999). In humans in vivo, nitric oxide has been dem-
onstrated to be a major component of ETB-mediated
vasodilation (Verhaar et al., 1998, see section III.
D.1 and 3). As noted (section III.D.3) in a study of
human vessels in vitro that tested the potency of four
endogenous directly acting vasodilators, nitric oxide
atrial (ANP), brain, and C-type natriuretic peptides to
oppose the actions of ET-1 (10 nM) in human vessels,
only NO could fully reverse ET-1-mediated constric-
tions in conductance coronary arteries (Wiley and
Davenport, 2000, 2001a, 2002). In human skin, ET-1
caused vasoconstriction at the injection site, but also
vasodilatation in the surrounding area. The latter
response is thought to be mediated by polimodal
nociceptor fibers either releasing nitric oxide directly
or are interconnected with nitrergic fibers innervating
skin microvessels (Wenzel et al., 1998). Nitric oxide is
also able to inhibit ET synthesis, and release from
the vascular endothelium of porcine conduit vessels
(Boulanger and Luscher, 1990) opposes the vasocon-
strictor actions of ET-1 in small and resistant vessels of
rabbits (Ito et al., 1991).
Other vasodilators also act as physiologic antago-
nists. For example, pressor responses to circulating and
locally produced ET-1 were found to be terminated by a
regionally selective effect of calcitonin gene-related
peptide though cyclic nucleotide-independent relaxa-
tion of vascular smooth muscle (Meens et al., 2011;
Labruijere et al., 2013). The apelin family of peptides
potently reverses ET-1-induced vasoconstriction in iso-
lated human vessels (Maguire et al., 2009). The apelin
signaling pathway is downregulated in pulmonary
arterial hypertension, suggesting it may be an impor-
tant mechanism counteracting the pathophysiological
actions of ET.
V. Phenotypes of Global Genetic Modifications
Over the past 20 years, there has been an explosion
of genetic manipulation tools that have been used to
generate transgenic mice and rats. By using homolo-
gous recombination in embryonic stem cells (Evans
and Kaufman, 1981; Smithies et al., 1985; Doetschman
et al., 1987; Thomas and Capecchi, 1987), whole body
knockout (KO) models have been developed. However,
a limitation to this approach is that the target of
interest is knocked out during all of development and
may result in developmental disorders and a lethal
phenotype, as is the case for ET-1, ECE-1, ETA, and
ETB. To circumvent this obstacle, there are a number
of genetic approaches including loxP/Cre (Sternberg
andHamilton, 1981; Lakso et al., 1992; Gu et al., 1993)
or Flp/FRT (O’Gorman et al., 1991) that can be used to
manipulate genomes in a cell-specific manner. These
technologies have resulted in a large number of
murine models. More recently, zinc finger nucleases
have been used to edit genomes in a variety of animals,
including rats (see Urnov et al., 2010), and dramatic
progress has been made with the use of clustered
regularly interspaced short palindromic repeats/Cas9
(Cong et al., 2013). There are now technologies that
can be used to either knock down or knock in a target of
interest, and these studies have been critical in
furthering our understanding of the physiologic role
of the ET axis. This review focuses on how global and
cell-specific genetic modifications have been used to
delineate the biologic function of components of the ET
system.
A. Endothelin-1/-2/-3
1. Global Overexpression of Human Endothelin-1.
Whole body ET-1-overexpressing mice were generated
by microinjecting linear human preproET-1 genomic
DNA into single-cell embryos (Hocher et al., 1997).
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These hemizygous ET-1 transgenic mice (ET-1+) had
normal circulating ET-1 concentrations but signifi-
cantly higher ET-1 expression in the brain, lungs, and
kidney. Furthermore, ET-1 concentration from total
kidney extracts was significantly elevated in ET-1+
mice at both 3 months and 14 months of age (Hocher
et al., 1997). As a consequence, ET-1+ mice presented
with a significant increase in the number of renal cysts,
inflammation, an increase in renal interstitial fibrosis,
and glomerulosclerosis, resulting in a decline in renal
blood flow and GFR that was independent of changes in
mean arterial pressure (Hocher et al., 1997; Theuring
et al., 1998; Shindo et al., 2002). ET-1+ mice also have
significantly increased apoptosis of glomeruli, tubular,
and interstitial cells, whereas proliferation was not
different from control mice (Hocher et al., 1998).
Furthermore, part of the increased renal inflammation
and scarring was androgen dependent because castra-
tion of ET-1+ male mice reduced proteinuria, reduced
CD4+ cell expression, and attenuated glomerulosclerosis
and perivascular fibrosis (Kalk et al., 2009). Castration
did not significantly affect GFR or renal CD8+ or
macrophage expression, nor did it significantly affect
renal interstitial fibrosis or media/lumen-ratio of renal
arteries (Kalk et al., 2009).
Interestingly, ET-1+ mice have increased nitric oxide
synthase (NOS)-2 expression in the renal vasculature
and macrophages (Hocher et al., 2004) and increased
urinary nitrite and nitrate (NOx) excretion while on a
standard breeding diet, suggesting that the increased
renal ET-1 may stimulate renal NO production
(Quaschning et al., 2003). However, urinary NOx is
greatly affected by dietary intake, and it is unclear if
ET-1+ mice eat similar amounts of chow compared with
control animals. Nevertheless, ET-1+ mice have a small
but significantly greater aortic dilation in response to
acetylcholine and have blunted constriction to exoge-
nous ET-1 compared with control aortae, suggesting
there is increased NO bioavailability that challenges
the ET-1-induced aortic contraction (Quaschning et al.,
2003). Moreover, intravenous injection of Nv -nitro-L-
arginine methyl ester (L-NAME, 25 mg/kg) resulted in a
significantly greater increase in blood pressure in ET-1+
mice compared with littermate controls (Hocher et al.,
2004). These data suggest that activation of the NO axis
limits ET-1-dependent increases in both acute and
chronic blood pressure regulation in this model.
The interaction between ET-1 and NO is well docu-
mented throughout the literature. In the endothelium,
ET-1 stimulates NOS3-dependent NO production, lead-
ing to vasodilation. In cardiovascular disease, there is
often NO deficiency and elevated ET-1 that may be
related. To determine the pathophysiological mecha-
nisms of NO deficiency coupled with elevated ET-1, the
ET-1+ mouse was crossed with the NOS32/2 KO mouse
(Vignon-Zellweger et al., 2011, 2014). The ET-1+NOS32/2
mice and NOS32/2mice (both males and females) have a
similar increase in systolic blood pressure and a similar
reduction in heart rate compared with wild-type controls
or ET-1+ mice (Vignon-Zellweger et al., 2011). These
investigators used heart catheterization to observe that
NOS32/2 mice have an increase in left ventricular end-
diastolic pressure, and female NOS32/2 mice have re-
duced ventricular relaxation. However, ET-1+NOS32/2
mice had relatively normal left ventricular end-diastolic
pressure and heart relaxation. Female ET-1+NOS32/2
mice develop perivascular fibrosis of intracardiac arteries
more rapidly than males (Vignon-Zellweger et al., 2014).
Female ET-1+NOS32/2 and NOS32/2 mice have reduced
ventricular ET-1 mRNA compared with male ET-
1+NOS32/2 and NOS32/2, which may partially explain
the sex difference in the cardiac fibrosis observed (Vignon-
Zellweger et al., 2014). Using a proteomics approach,
Vignon-Zellweger at al. (2014) determined that ET-
1+NOS32/2 mice had increased cardiac antioxidant
expression, reduced expression of proteins involved in
destabilization of actin, and greater reduction in proteins
that lead to cardiomyocyte hypertrophy compared with
NOS32/2 mice. Thus, increases in ET-1 in the context of
NO deficiency may, under these unique circumstances,
be beneficial for cardiac function, although clear sex
differences exist in this context. A summary of mice
overexpressing the endothelin system is listed in Table 2.
2. Overexpression of Endothelin-2. To determine the
effect of increases in ET-2 expression, a human ET-2
transgene was inserted into the Sprague-Dawley rat
genome (Table 3). These heterozygous rats, termed TGR
(hET-2)37, express the ET-2 transgene in the kidney,
adrenal gland, gastrointestinal tract, spleen, lung, and
brain (Hocher et al., 1996; Liefeldt et al., 1999). Male
hemizygous rats tended to have higher levels of circulat-
ing ET peptide (ET-1 and ET-2 are indistinguishable by
available immunoassays) compared with female TGR
(hET-2)37 (Liefeldt et al., 1999). ET-2 overexpression
resulted in a significantly lower body weight, and heart-
to-bodyweight andkidney-to-bodyweight ratios inmales
only. Basal blood pressure was similar between TGR
(hET-2)37 and control rats and was also similar between
males and females. Infusion of the NO synthase in-
hibitor, L-NAME, resulted in a significantly greater
increase in blood pressure in male TGR(hET-2)37 rats
compared with controls suggesting that overexpression
of ET-2 results in greater NOS activity (Liefeldt et al.,
1999). Male, but not female, TGR(hET-2)37 also had
reduced creatinine clearance compared with controls.
Finally, male TGR(hET-2)37 presented with significant
interstitial and glomerular sclerosis (Liefeldt et al.,
1999). Female hemizygous TGR(hET-2)37 had increased
ET-1 mRNA in the glomeruli, and blood pressure-
independent glomerulosclerosis and proteinuria com-
pared with control rats (Hocher et al., 1996). These
studies suggest that an increase in ET-2 can lead to
organ sclerosis and that this is independent of blood
pressure. In the context of diabetic cardiomyopathy,
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inducing diabetes (streptozotocin) in male TGR(hET-2)
37 rats resulted in severe coronary and intramyocardial
vessel hypertrophy and myocardial interstitial fibrosis
comparedwith diabetic control rats (Liefeldt et al., 2010).
Thus, elevated ET-2 levels can exacerbate organ damage
inmodeled disease states. Whether this is pathologically
relevant to disease has yet to be established.
3. Endothelin-1, -2, -3 Knockout Mice.
a. Endothelin-1 knockout mice. By disrupting exon
2 of the ET-1 gene, a whole body ET-1 KO mouse was
developed (Kurihara et al., 1994). Mice homozygous for
this deletion (ET-12/2) were neonatal lethal. ET-12/2
mice delivered by caesarian at day 18.5 postcoitum all
displayed significant craniofacial and cardiac abnor-
malities, highlighting the critical developmental role of
ET-1 (Kurihara et al., 1994, 1995b). Moreover, ET-12/2
mice have reduced neonatal weight, impaired thyroid
and thymus development (Kurihara et al., 1995a), and
reduced cardiac sympathetic innervation (Ieda et al.,
2004). Mice heterozygous for ET-1 deletion, ET-1+/2,
appeared normal, were fertile, and had reduced lung
and plasma ET-1 concentration; however they pre-
sented with an elevated systolic, diastolic, and mean
arterial blood pressure (Kurihara et al., 1994). Inter-
estingly, ET-2, ET-3, ETA, and ETB expression were
similar in a number of organs among neonatal wild-
type, ET-12/2 and ET-1+/2 mice, suggesting that other
components of the ET system are not regulated by ET-1
in neonatal mice (Maemura et al., 1995).
b. Endothelin-2 knockout mice. ET-2 was targeted
by deletion of exon 1 and exon 2 (which encodes the
mature peptide) (Chang et al., 2013). Although ET-22/2
mice were born at the expected Mendelian frequencies
and were observed nursing normally, at postnatal day
TABLE 2
Summary of the phenotype of mice with genetic overexpression of endothelin-1
Animal Model Site (Cre) Phenotype References
Overexpressing
ET-1+ Whole body Lung: chronic inflammation; normal
pulmonary pressure
Hocher et al., 1997, 2000;
Kidney: increased renal cyst formation;
renal interstitial fibrosis;
glomerulosclerosis; age-dependent
salt-sensitive hypertension
Shindo et al., 2002; Kalk et al., 2009
ET-1+/+/NOS22/2 Whole body increased blood pressure Quaschning et al., 2008
ET-1+/NOS32/2 Whole body elevated blood pressure, reduced heart
rate
Quaschning et al., 2007,
Vignon-Zellweger et al., 2011, 2014
eET-1 Endothelium (Tie2-CRE) Vascular endothelial dysfunction;
vascular remodeling; increased lipid
metabolism gene expression; normal
blood pressure
Amiri et al., 2004; Simeone et al.,
2011
TET-1 Endothelium(Tie1-CRE) Elevated blood pressure; endothelial
dysfunction
Leung et al., 2004
Apoe2/2eET-1 Whole body ApoE knockout,
endothelial ET-1
overexpression
High-fat diet-induced atherosclerosis,
abdominal aortic aneurysms, increase
oxidative stress; increase immune cell
infiltration
Simeone et al., 2011; Li et al., 2013
Inducible
cardiomyocyte ET1+/+
Cardiomyocytes (alpha-myosin
heavy chain -Cre)
Pulmonary and hepatic congestion;
heart inflammation and hypertrophy
Yang et al., 2004
GET-1 Astrocyte (glial fibrillary
acidic protein-Cre)
Normal development; normotensive;
larger infarct size in response to
ischemia/reperfusion injury;
alleviates inflammatory pain
Lo et al., 2005; Hung et al., 2012
ETA
ET-1/+ Where ETA is expressed,
ET-1 will be expressed
Constitutive ETA activation;
mandibular arch instead of maxillary
arch; perinatal death
Sato et al., 2008
ET-1 H/+ Whole body 350% increased expression of ET-1;
decreased plasma volume, heavy stiff
hearts
Hathaway et al., 2015
ApoE, apolipoprotein E.
TABLE 3
Summary of phenotype of rats with genetic alterations of the endothelin system
Animal Model Site (Cre) Phenotype References
TGR(hET-2)37 Whole body ET-2 overexpression males: lower body weight, interstitial
and glomerularsclerosis
Liefeldt et al., 1995, 1999
females: glomerularsclerosis Liefeldt et al., 1999
Homozygous spotting
lethal (sl/sl)
Whole body, natural mutation
in the ETB
aganglionic megacolon; white coat color;
death at an early age.
Gariepy et al., 1996
DbH-ETB:ETB
sl/sl ETB deficient except for nerves
(insertion with dopamine-b-hydroxylase
promoter)
ETB expressed in nerves but absent
elsewhere; coat color spotting;
salt-sensitive hypertension
Gariepy et al., 1998;
Gariepy et al., 2000;
Pollock et al., 2000
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3 they were obviously smaller than ET-2+/+ pups and
died by 3–4 weeks of age. ET-22/2 mice had severe
growth retardation, reduced blood glucose levels but
normal insulin levels, and elevated blood urea nitrogen
and uric acid, suggesting they suffered from internal
starvation (Chang et al., 2013). Moreover, these mice
presented with a reduced body temperature and abnor-
mal lung histology. To determine the effect of ET-2
deletion in adult animals, Chang et al. (2013) also gener-
ated an inducible ET-22/2 mouse (ET2f/f:CAGGCre-ER).
Deletion of ET-2 was induced in both neonates and adults,
and both presented with a mild hypothermia at ambient
temperature and a significant drop in body temperature
when challengedwith cold for 12hours (Chang et al., 2013).
Thus, ET-2 is critical for metabolism and proper growth.
Although ET-2 is highly expressed in the intestine and
central nervous system, cell specific deletion of ET-2
resulted in a normal phenotype (see specifics in sections
VI.B.8 and 9, respectively) and thus cannot explain the
abnormalities observed in the global knockouts. What
effect ET-2 deficiency has on other physiologic pathways,
such as blood pressure control, remain to be determined.
c. Endothelin-3 knockout mice. Whole body ET-3
KOmice were produced in a similar manner as the ET-1
KO mice: exon 2 of the ET-3 gene encodes for mature
ET-3 and was targeted for deletion using homologous
recombination in embryonic stem cells (Baynash et al.,
1994). ET-3+/2 heterozygous mice were phenotypically
normal and used to breed ET-32/2mice, which also were
born with the expected Mendelian inheritance ratios.
However, these mice only survived for an average of 21
days after birth (Baynash et al., 1994). ET-32/2 mice
have normal tidal volume and breathing frequency
(even in hypoxic, hyperoxic, and hypercapnic environ-
ments) (Nakamura et al., 2001), thus pulmonary dys-
function seems unlikely to explain their early demise.
Blood pressure measurements and baroreflex sensitiv-
ity appear to be normal in ET-32/2 mice at ages 2–3
week compared with wild-type controls (Kuwaki et al.,
2002), suggesting that at least while these mice are
nursing, blood pressure is normal. However, what has
not been tested is whether when challenged with
different salt diets, if ET-32/2 mice maintain normal
blood pressure and baroreflex sensitivity. Because the
ETB receptor is the primary receptor for ET-3, we would
expect the ET-32/2mice to have salt sensitivity similar
to the ETB-deficient rats and CD ETB KO mice (see
sections V.B.4 and VI.B.12, respectively). However, the
ETB receptor does not exclusively bind ET-3, therefore
ET-1 levels may compensate for the loss of ET-3.
ET-32/2 mice presented with 70–80% of their coat
being white (their background was C57blk/6J) but
mainly their heads maintained a black coat. Histologic
analysis of the skin determined the absence of melanin
pigment and melanocytes (piebaldism) (Baynash et al.,
1994), suggesting that ET-3 is critical for melanocyte
melanin production. ET-32/2 mice also present with
aganglionic megacolon (which develops between 1 and
12 weeks of age), with an absence of the myenteric
ganglia in the distal narrow segment of the colon but
normal myenteric ganglion neurons between the
smooth muscle of the proximal colon. From this study,
it was determined that ET-3 is critical for normal
development of vagal neural crest-derived enteric neu-
rons and the trunk neural crest-derived epidermal
melanocytes (Baynash et al., 1994). Moreover, this
study identified ET-3 as the likely candidate gene that,
if mutated, may lead to megacolon (Hirschsprung
disease).
Piebaldism, commonly called lethal spotted (ls), arose
spontaneously in a number of mice, including the C57bl/
6J colony at the Jackson Laboratory. These mice also
have megacolon. To confirm that it was ET-3 deficiency
leading to this pathology, an ET-3 transgene was
introduced into the ls/ls mouse under the control of
the human dopamine-b-hydroxylase (DbH) promoter.
During development of the enteric nervous system,
vagal neural crest cells express DbH (Baetge and
Gershon, 1989; Baetge et al., 1990a,b; Blaugrund
et al., 1996). The ls/ls mice that harbor the DbH-ET-3
transgene had a reduction in piebaldism and were
rescued from megacolon (Rice et al., 2000). Thus, ET-3
deficiency was identified as the mutated gene in the ls/
lsmouse and provided evidence of a novel genetic target
for Hirschsprung disease. A summary of all the endo-
thelin system KO mice is presented in Table 4. Table 5.
4. High and Low Expression of Endothelin-1.
Recently, the Kakoki laboratory developed low-
expressing (L) and high-expressing (H) ET-1 genes
and used these to develop mice with four levels of ET-1
expression: L/L ;20%; L/+ ;65%; +/+ wild-type 100%;
and H/+ ;350% (Hathaway et al., 2015). Young adult
L/L and L/+ mice have dilated cardiomyopathy, hyper-
tension, and increased plasma volumes and reduced
ventricular stiffness. The L allele can be spatiotempo-
rally switched to the H allele by cre-loxP recombination.
Global or cardiomyocyte-specific switching expression
from L to H normalized the abnormalities in the L/L
mice. H/+ mice have decreased plasma volumes and
significantly heavy stiff hearts. These authors con-
cluded that ET-1 is critical for maintaining normal
contractile function and for ensuring that the myocar-
dium has sufficient collagen to prevent overstretching
because even a modest decrease in ET-1 expression is
sufficient to cause cardiac dysfunction (Hathaway et al.,
2015). The epithelial sodium channel (ENaC) blocker
amiloride normalized plasma volume and blood pres-
sure but only partially corrected the cardiomyopathy in
the L/L mice. It is speculated that the reduced ET-1
levels mediated hypertension via increased ENaC
activity, most likely in the renal collecting duct (see
section VI.B.10). Interestingly, H/+ mice displayed re-
duced blood pressure suggesting that the higher level of
ET-1 mediates greater inhibition of ENaC and lower
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TABLE 4
Summary of the phenotype of mice with knockout of the components of endothelin system
Animal Model Site (Cre) Phenotype References
ECE
ECE-12/2 Whole body Craniofacial and cardiovascular defects;
aganglionic megacolon and coat color
spotting; embryonic lethal
Yanagisawa et al., 1998a
ECE-22/2 Whole body No detectable abnormalities Yanagisawa et al., 2000
ECE-12/2 ECE-22/2 Whole body More severe cardiac abnormalities
compared with ECE-12/2 mice
Yanagisawa et al., 2000
ET-1
ET-12/2 Whole body Abnormalities in craniofacial and
cardiovascular system, thyroid and
thymus gland; neonatal lethal
Kurihara et al., 1994,
1995a.b
ET-1-/+ Whole body Mild blood pressure elevation; increased
resting renal sympathetic nerve activity
Kurihara et al., 1994;
Kuwaki et al., 1996;
Ling et al., 1998;
Morita et al., 1998;
Kuwaki et al., 1999
ET-1 L/L or L/+ Whole body 20% and 65% ET-1 expression of a wild
type mouse; dilated cardiomyopathy,
elevated blood pressure, increased
plasma volume
Hathaway et al., 2015
Neuron ET-12/2 Neuron (synapsin I-Cre) Greater sensitivity to acute nociceptive
stimuli
Hasue et al., 2005
Cardiomyocyte ET-12/2 Cardiomyocytes (alpha-myosin
heavy chain -Cre)
Shorter life span; age-associated
reduction in cardiac function
Zhao et al., 2006
Smooth muscle ET-12/2 Smooth muscle protein 22-Cre Normal right ventricular systolic pressure
basally; hypoxia leads to an attenuated
increase in right ventricular systolic
pressure compared with control mice
Kim et al., 2015
VEETKO Endothelium (Tie-2-Cre) Hypotensive to normotensive; ANGII
hypertension is similar to controls but a
reduction in cardiac hypertrophy and
fibrosis; attenuation of oxidative stress,
inflammation and injury following
renal ischemia/reperfusion injury,
hypoxia or high salt feeding
Kisanuki et al., 2010;
Adiarto et al., 2012;
Arfian et al., 2012;
Heiden et al., 2014;
Heimlich et al., 2015
Collecting duct ET-12/2 AQP2-Cre Elevated blood pressure; salt-sensitive
hypertension; impaired ability to
excrete water
Ahn et al., 2004;
Ge et al., 2005a,
2007, 2008b
ET-2
ET-22/2 Whole body Growth retardation; internal starvation;
severe hypothermia; lung dysfunction;
death at an early age
Chang et al., 2013
inducible ET-22/2 knockout Whole body (CAGGCre-ER) Reduced weight gain; reduced lipid
deposition; mild hypothermia
Chang et al., 2013
Intestinal epithelium ET-22/2 Villin-Cre Normal growth and blood glucose level Chang et al., 2013
Neuron ET-22/2 Nestin-Cre Normal core temperature; greater
sensitivity to acute nociceptive stimuli
Chang et al., 2013
ET-3
ET-32/2 Whole body Aganglionic megacolon; coat color
spotting; normotensive and normal
baroreflex sensitivity; death at an early
age
Baynash et al., 1994;
Kuwaki et al., 2002
ls/ls Whole body, natural mutation in the
ET-3 gene
Aganglionic megacolon; white spotting
coat
Rice et al., 2000
ls/ls DbH-ET-3 Naturally ET-3 deficient but ET-3
overexpressed in nerves (insertion
with dopamine-b-hydroxylase
promoter)
Reduction in white spotting coat; rescued
from megacolon
Rice et al., 2000
Piebald lethal s’/s’ Natural deletion of the ETB gene
from the whole body
Aganglionic megacolon; white spotting
coat
Hosoda et al., 1994
ETA
ETA
2/2 Whole body Craniofacial and cardiovascular defects:
lethal minutes after birth
Clouthier et al., 1998
Cardiomyocyte ETA
2/2 Cardiomyocytes (alpha-myosin
heavy chain -Cre)
Normal development and cardiovascular
function; ANGII or isoproterenol-
induced myocardial hypertrophy:
protected from cold stressed-induced
cardiac fibrosis and dysfunction
Kedzierski et al., 2003;
Zhang et al., 2012
Smooth muscle ETA
2/2 Smooth muscle protein 22-Cre Defects of arterial network, mandibular and
thymus structure; death at an early age
Donato et al., 2014
Collecting duct ETA
2/2 AQP2-Cre Normotensive; impaired ability to excrete
water
Ge et al., 2005b
Whole nephron ETA
2/2 Inducible (Pax8-rtTA and LC-1) Normotensive; fluid retention during high
salt intake
Stuart et al., 2012;
Stuart et al., 2013
(continued )
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plasma volume. Varying the expression of ET-1 with
this genetic modification will allow investigators to
further understand and tease apart the consequences
of low and high ET-1 expression.
B. Endothelin Converting Enzyme-1/Endothelin A
Receptor/Endothelin B Receptor
1. Global Knockout of Endothelin Converting
Enzyme. An ECE-1 KO mouse was developed target-
ing the exon upstream of the extracellular zinc-binding
domain exon (Yanagisawa et al., 1998b). Unfortunately,
ECE-12/2mice were embryonic lethal [and begin dying
around embryonic day (E)12.5], although ECE-1+/2
mice were healthy and fertile (Yanagisawa et al.,
1998b). E12.5 embryos of ECE-12/2 mice presented
with congestion and dilation of the atria and peripheral
vessels, pericardial effusion, and generalized edema. A
small percentage of ECE-12/2 mice survived to term;
however, due to severe craniofacial and cardiovascular
abnormalities, these mice died within 30 minutes of
birth (Yanagisawa et al., 1998b). As will be discussed
later in reference to ETB receptor gene deletion models
(sections V.B.3 and V.B.4), it is important to note that
these animals also did not develop enteric nerves. ECE-
1 is critical for converting both Big ET-1 and Big ET-3
into their 21-amino acid active forms (Yanagisawa
et al., 1998b). The ECE-12/2 phenotypewasmore severe
and resulted in earlier death than the ET-12/2 or ETA
2/2
mice, suggesting that active ET-1 and ET-3, by
binding to both ETA and ETB, are necessary for normal
development. Moreover, given ECE-1 has broad sub-
strate specificity (Johnson et al., 1999), it is possible
that cleavage of nonendothelin peptides is also critical
for embryonic development.
ECE-2 is also expressed during development: E10.5
embryos express ECE-2mRNA in the mesenchyme and
neural tube and later in neurons and the developing
heart (Yanagisawa et al., 2000). Knockout of ECE-2
from the whole animal, again targeting the exon that
encodes the extracellular zinc-binding domain, resulted
in no overt phenotype (Yanagisawa et al., 2000).
ECE-22/2mice were healthy, with normal growth rates
and survival, and were fertile. Histologic evaluation of a
number of tissues did not reveal any abnormalities,
which suggested that perhapsECE-1was compensating
for the deletion of ECE-2. To test this hypothesis, the
ECE-22/2 mutation was introduced into the ECE-12/2
mouse. This ECE-12/2/ECE-22/2 mouse had a very
similar phenotype to the ECE-12/2 mouse; however, they
did present with broader and more severe cardiac abnor-
malities. Two interpretations are suggested from thesedata:
(1) ECE-1 can compensate for a lack of ECE-2, resulting in
normal heart development; and (2) ECE-2, which is
expressed in the endocardial cushion of the developing
heart, may lead to local ET-1 production that may limit
cardiac abnormalities when ECE-1 is absent, although
ECE-2 cannot fully compensate for the loss of ECE-1.
2. Global Knockout of Endothelin A Receptor in Mice.
To delineate the physiologic and developmental role of
the ETA receptor, a whole body ETA mouse was created
by deleting exons 5 and 6 from the ETA gene (Clouthier
et al., 1998). ETA
2/2 mice were viable up to parturition
but presented with severe craniofacial deformities
(similar to ET-12/2 mice) and died about 30 minutes
after birth (Clouthier et al., 1998). Specifically, ETA
2/2
mice presented with a maxilla-like structure (upper
jaw) in place of the lower jaw (Ruest et al., 2004).
Interestingly, a specific deletion of ETA from the de-
veloping mandible after neural crest cell patterning was
generated (ETA
flox/flox mice bred with a Dlx5/6-Cre mouse
to induce ETA deletion in the mandibular first arch on
E9.5) and resulted in normal jawdevelopment, suggesting
that ETA is not critical for mandible bone development
(Ruest et al., 2005). However, these studies firmly estab-
lished that ETA signaling is necessary for early neural
crest cell patterning and proper lower jaw development.
TABLE 4—Continued
Animal Model Site (Cre) Phenotype References
ETB
ETB
2/2 Whole body Aganglionic megacolon; white spotting
coat; death at an early age
Hosoda et al., 1994
ETB
-/s’ Whole body, 1 allele naturally
mutated
Systemic ETB deficiency; reduced
incidence of megacolon; 50% white coat
spotting; increased blood pressure;
normal cardiac sympathetic and vagal
activity; reduced brain and lung ETA
Ohuchi et al., 1999;
Davenport and Kuc
2004; Kuc et al., 2006
ETB
2/2+ETB-DbH ETB deficient except for nerves
(insertion with dopamine-
b-hydroxylase promoter)
ETB expressed in nerves but absent
elsewhere; white spotted coat; rescued
from megacolon; elevated blood
pressure; salt-sensitive blood pressure;
endothelial dysfunction
Murakoshi et al., 2002;
Quaschning et al., 2005
ECETB
2/2 Endothelium (Tie-2-Cre) Endothelial dysfunction; normotensive;
red cell congestion of the intrahepatic
branch of portal vein
Bagnall et al., 2006;
Kelland et al., 2010b;
Ling et al., 2012
Collecting duct ETB
2/2 AQP2-Cre Elevated blood pressure; increased ENaC
activity; salt-sensitive hypertension
Ge et al., 2006; Bugaj
et al., 2012
Collecting duct ETA
2/2/ETB
2/2 AQP2-Cre Elevated blood pressure; increased ENaC
activity; salt-sensitive hypertension
Ge et al., 2008a; Bugaj
et al., 2012
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ETA
2/2 mice have a number of neural crest-derived
structure abnormalities, including lack of the malleus,
incus, and tympanic ring of the middle ear; a number of
nerves emanating from the ganglia have abnormal
distal ends; and abnormal cardiac and outflow tract
development (Clouthier et al., 1998). Remarkably,
ETA
2/2 mice had normal peripheral nervous system
development, although many of the nerves failed to
project to the distal aspects of the mandibular arches.
The authors concluded that the absence of ETA does not
significantly affect cranial ganglia patterning (Clouthier
et al., 1998). The most common vessel abnormality in the
ETA
2/2 mouse was an interruption of the aortic arch
between the left common carotid artery and the left
subclavian artery (Yanagisawa et al., 1998a). The mech-
anism(s) of this deformity involves inappropriate regres-
sion of arch arteries 4 and 6, and this is either because of a
lack of proliferation or an increase in apoptosis of the
mesenchymal cells of these arches (Yanagisawa et al.,
1998a). From these studies, it is clear that ETA is critical
for neural crest development.
Normally during development, there are epithelial-
mesenchymal interactions in the first pharyngeal arch
that guide cephalic neural crest cells to ultimately
develop into the jaws. From the ET-1 and ETA null
mice, it was evident that ET-1/ETA is necessary for
lower jaw (mandibular arch) development. Further
evidence came from the activated ET-1/ETA signaling
mouse, whichwasmade by knock in of anET-1 gene into
one allele of the ETA gene (Sato et al., 2008). Thesemice,
ETA
ET-1/+, have constitutive ETA activation. Although
ETA
ET-1/+ died perinatally with severe craniofacial
defects, examination of the early embryos revealed a
dorsal-to-ventral transformation, resulting in a man-
dibular arch instead of the proper maxillary arch (Sato
et al., 2008). In essence, these mice had duplicate lower
jaw structures instead of a proper upper and lower jaw.
This study demonstrates that ET-1-dependent ETA
activation specifies maxillo-mandibular identity. In
summary, ECE-1, ET-1, and ETA are all critical for
neural crest patterning and proper jaw identity and
development and cardiovascular development. Al-
though these whole body KO models are lethal, they
have greatly expanded our understanding of the role of
the ET-1 system in development.
3. Global Knockout of Endothelin B Receptor in Mice.
The ETB receptor was also a candidate gene for causing
Hirschsprung disease. To test this hypothesis, the ETB
TABLE 5
Clinical trials of ET antagonists
Compound Class Company Conditions Studied
Ambrisentan Selective ETA Gilead Sciences Pulmonary arterial hypertension
(licensed in Europe & USA)
LU208075 Scleroderma
BSF208075 Pulmonary fibrosis
Atrasentan ABT-627/ Selective ETA Abbott Prostate cancer
A147627/ Diabetic nephropathy
A127722 Ischemic heart disease
Avosentan Selective ETA Speedel Diabetic nephropathy
SPP301
Bosentan RO470203 Mixed ETA/B Actelion Pulmonary arterial hypertension
(licensed in Europe & USA)
Scleroderma
Hypertension
Chronic heart failure
Melanoma
Clazosentan Selective ETA Actelion Subarachnoid hemorrhage
AXV034343
VML588
Ro611790
Darusentan Selective ETA Gilead Sciences Hypertension
LU125252 Chronic heart failure
BSF135252
Edonentan Selective ETA Bristol-Myers Squibb Chronic heart failure
BMS207940
Enrasentan Mixed ETA/B GlaxoSmithKline Chronic heart failure
SB217242
Macitentan Mixed ETA/B Actelion Pulmonary arterial hypertension
(licensed in Europe & USA)
ACT-064992 Pulmonary fibrosis
Sitaxsentan Selective ETA Selective ETA Encysive (acquired by Pfizer) Pulmonary arterial hypertension
Chronic heart failure
TBC11251 Retrophin Chronic kidney disease
Sparsentan* Hypertension
RE021 Focal & segmental glomerulosclerosis
Tezosentan Mixed ETA/B Selective ETA Actelion AstraZeneca Chronic heart failure
Ro 61-0612 Acute coronary syndrome
Zibotentan Hepatorenal syndrome
ZD4054 Prostate cancer
Ovarian cancer
*Dual ETA and angiotensin receptor antagonist (Murugesan et al., 2005)
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gene was disrupted in exon 3 by insertion of a neomycin
resistance cassette (Hosoda et al., 1994). ETB
+/2 mice
appeared phenotypically normal and were mated to
produce ETB
2/2 mice. ETB
2/2 mice were born and
developed greater than 90% of their fur coat as white
despite being on a hooded mouse background. Although
healthy for the first 2 weeks of life, they became
increasingly sick and died within about 4 weeks
(Hosoda et al., 1994). These mice presented with many
of the same abnormalities as the ET-32/2 mice, in-
cluding severe distension of the intestine consistent
with megacolon. Moreover, histologic analyses revealed
an absence of neurons from the colon. These results led
to the hypothesis that the ETB gene may be deleted or
mutated in another naturally occurring mutated
mouse, the piebald-lethal s9/s9. To confirm this, South-
ern blots for ETB receptors were performed in wild-type
and s9/s9’ mice and revealed that the ETB receptor was
mutated in the lung, heart, and intestine of the s9/s9
mice (Hosoda et al., 1994). Thus, deletion or mutation of
ETB can also lead to Hirschsprung disease. From these
studies with ETB
2/2, ET-32/2, and the naturally occur-
ring mutated s9/s9 mice, it is clear that ET-3/ETB
signaling is critical for development of neural crest-
derived cell lineages, including melanocytes and the
enteric nervous system.
Given that ETB
2/2 mice have a premature death
while s9/s9 mice live longer, these mice were interbred
to produce ETB
-/s9mice to test hypotheses about the role
of ETB receptors in adulthood. Adult ETB
-/s9mice have
increased circulating ET-1 compared with ETB
+/+ mice
and a significant increase in mean, systolic, and di-
astolic pressure compared with ETB
+/+ or ETB
+/s9 mice
(Ohuchi et al., 1999). These mice also lacked a pressor
response to an ETB receptor antagonist, BQ788, that
was observed in ETB
+/+ and ETB
+/s’ mice. However,
ETB
-/s’mice have normal cardiac sympathetic and vagal
activities (Ohuchi et al., 1999). One of the curious
findings in ETB
2/2 mice was a reduction of the brain
ETA receptor (Davenport and Kuc, 2004) and the lung
ETA receptor (Kuc et al., 2006). The mechanism(s)
responsible for ETA downregulation have not been
determined, but could be related to the chronic eleva-
tions in ET-1. Furthermore, the mechanism of the
hypertension in this model is unclear, although it may
be due to a lack of renal ETB receptors.
The lethal phenotype of the deleted ETB receptor can
be rescued in the ETB
2/2mice by driving ETB transgene
expression with the DbH promoter in the enteric nervous
system (Murakoshi et al., 2002). These ETB-deficientmice
(ETB
2/2 + DbH-ETB
+/+) presented with a white coat, but
were rescued from megacolon. Blood pressure measured
in the rescued mice at 14–16 weeks of age was signifi-
cantly elevated and increased further when animals were
placed on a high-salt diet (Murakoshi et al., 2002;
Quaschning et al., 2005). Carotid artery ligation (as a
model of vascular remodeling) resulted in a significantly
larger intimal area, ratio of intimal to medial area, and
stenotic ratio compared with wild-type mice (Murakoshi
et al., 2002). This was coupled with a significant decrease
in carotid nitrite/nitrate (NOx) concentration in the
ETB-deficient mice. Furthermore, ETB-deficient mice
have reduced acetylcholine-mediated aortic relation but
normal sodium nitroprusside-dependent relaxation
whether on normal or high-salt diet, suggesting they
have endothelium-dependent dysfunction (Murakoshi
et al., 2002). Finally, ETB-deficient mice have reduced
ETA-mediated constriction, which is hypothesized to be
due to a decrease in aortic ETA receptor expression
(Murakoshi et al., 2002). These studies suggest that
deletion of the ETB receptor or loss of ETB receptor
signaling accelerates vascular remodeling, reduces NO
production, and leads to endothelial dysfunction.
However, in rat models of diabetes, the protective role
of ETB receptors may depend on the type of vascular
being studied. Although ETB antagonism increased
unwanted remodeling in peripheral vessels there were
a number of technical limitations in their study such as
relatively small number of animals in the control group
and ETB receptors measured indirectly rather than by
ligand binding.
4. Endothelin B Receptor-deficient sl/sl Rats.
Similar to the piebald-lethal mice described above, a
natural mutation called spotting lethal (sl) has been
described in Wistar-Imamichi rats (Ikadai et al., 1979).
Rats homozygous for this mutation present with whit-
ening of their hooded coats and die within a fewweeks of
birth from megacolon. Work by Gariepy et al. (1996)
determined that this spontaneous mutation occurs in
the ETB gene and that megacolon could be prevented by
insertion of the DbH-ETB transgene (Gariepy et al.,
1998). Like in the mice described above, the DbH-ETB
transgene is expressed in the nervous system where it
rescues the homozygous rats (DbH-ETB:ETB
sl/sl) from
megacolon, yet functional ETB receptors are lacking in
all other cell/tissues. As well, DbH-ETB:ETB
sl/sl rats
present with significantly higher circulating ET-1 con-
centrations that increase evenmore when these rats are
fed a high-salt diet (8% NaCl) (Gariepy et al., 2000).
These data suggest that functional ETB receptors play a
role in regulating circulating ET-1 levels.
Both acute and chronic studies determining the
physiology of the ET-1 system in the control of blood
pressure have used the DbH-ETB:ETB
sl/sl model. Acute
intravenous injections of 1 nmol/kg ET-1 result in an
initial decrease in mean arterial pressure followed by a
prolonged pressor response in transgenic control rats
(DbH-ETB:ETB
+/+). In contrast, a prolonged 30 mmHg
increase in mean arterial pressure without the initial
transient hypotension was observed in DbH-ETB:ETB
sl/sl
rats (Gariepy et al., 2000). Furthermore, cumulative dose
response curves to both ET-1 and the ETB agonist
sarafotoxin 6C (S6c) were generated to evaluate the
pressor responses in DbH-ETB:ETB
sl/sl and heterozygous
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DbH-ETB:ETB
sl/+ rats (Pollock et al., 2000). Doses of 0.1
nmol/kg, 0.3 nmol/kg, and 1 nmol/kg of either ET-1 or S6c
resulted in a significant increase in mean arterial pres-
sure in both genotypes. However, the increases in pres-
sure were significantly greater in the DbH-ETB:ETB
sl/sl
rats (Pollock et al., 2000). The significant sarafotoxin
S6c-dependent increase in blood pressure in both hetero-
zygous and DbH-ETB:ETB
sl/sl rats could be prevented by
an ETB antagonist but not an ETA antagonist, suggesting
that ETB-dependent pressor responses still exist in the
ETB-deficient animals (Pollock et al., 2000), presumably a
result of transgene expression in neuronal tissue.
The influence of dietary sodium on chronic blood
pressure control has been extensively studied in the
DbH-ETB:ETB
sl/sl rats. While on a sodium-deficient
diet, mean arterial pressure was similar between trans-
genic control and DbH-ETB:ETB
sl/sl rats; a 3-week diet
of 8% NaCl resulted in a significant (.40 mmHg)
increase in mean arterial pressure in the DbH-ETB:
ETB
sl/sl rats (Gariepy et al., 2000). Thus, lacking functional
ETB receptors in all tissues except the nervous system
results in a severe, salt-sensitive hypertension. Interven-
tion with amiloride, a diuretic that blocks ENaC, pre-
vented the high salt-dependent increase in blood pressure
in the DbH-ETB:ETB
sl/sl rats (Gariepy et al., 2000). These
findings led to the hypothesis that the lack of functional
ETB receptors, likely in the collecting duct, results in
hyperactive ENaC, sodium retention, and an increase in
blood pressure. Interestingly, renal transplant studies
between transgenic controls and DbH-ETB:ETB
sl/sl rats
suggest that extrarenal ETB receptors limit salt-sensitive
hypertension, perhaps through regulation of renal blood
flow, changes in sympathetic tone (Ohkita et al., 2005), or
skin sodium storage.
Intrarenal ET-1 and functional ETB receptors are
very important for regulating natriuresis and diuresis.
Using acute infusion of an ETB agonist into the rat renal
medulla, Nakano et al. (2008) determined that activa-
tion of medullary ETB receptors leads to natriuresis and
diuresis via a mechanism that is NOS1 dependent.
Female and male DbH-ETB:ETB
sl/sl rats on a normal
salt diet have higher blood pressure than genetic
controls, although still within the normotensive range
(mean arterial pressure is approximately 130 mmHg)
(Speed et al., 2015). Nonetheless, there is significantly
higher inner medullary NOS activity in female DbH-
ETB:ETB
sl/sl rats (Taylor et al., 2003) that may provide
an explanation for themore robust ability of female rats
to excrete salt and water (Kittikulsuth et al., 2011,
2013). As well, interstitial intramedullary infusion of
ET-1 resulted in a significant natriuresis in female
DbH-ETB:ETB
sl/sl rats only, and this was dependent on
NOS1 (Nakano and Pollock, 2009). However, 3 week
of high-salt diet (10% NaCl), resulted in a similar
increase in pressure in male and female DbH-ETB:
ETB
sl/sl rats when measured by telemetry (Speed et al.,
2015). High-salt diet resulted in a reduction in NOS
activity in male and female control and DbH-ETB:ETB
sl/sl
rats (Taylor et al., 2003). Moreover, female DbH-ETB:
ETB
sl/sl rats on a high-salt diet (8% NaCl) have signifi-
cantly greater plasma concentrations of ET-1 compared
with male DbH-ETB:ETB
sl/sl rats. In both female DbH-
ETB:ETB
sl/sl rats, tempol (a superoxide dismutasemimetic)
initially attenuated the salt-dependent increase in blood
pressure but after 2 weeks of treatment was ineffective
(Sullivan et al., 2006). These data suggest that reactive
oxygen species (ROS) are critical for the early stages of the
salt-dependent increases in blood pressure, and it is
hypothesized that the female sex does not protect against
hypertension in the DbH-ETB:ETB
sl/sl model similar to
other models of hypertension due to increased circulating
ET-1 and superoxide production (Sullivan et al., 2006).
Taken together, these data suggest that sex differences
exist in DbH-ETB:ETB
sl/sl rats and that these involve an
interaction with dietary salt.
Deoxycorticosterone acetate (DOCA)-salt-induced hy-
pertension is a common model to study mechanisms of
salt-dependent blood pressure control. ETA, as well as
ETA/ETB receptor antagonists, can attenuate the devel-
opment of hypertension in DOCAmodels (Allcock et al.,
1998; Li et al., 1994). In DbH-ETB:ETB
sl/sl rats, DOCA
and salt (1% NaCl in drinking water) resulted in a
significant increase in systolic pressure within aweek of
DOCA implantation, whereas the transgenic and het-
erozygous controls presentedwith an increase in pressure
after 4 weeks (Matsumura et al., 2000c). ETA receptor
antagonism suppressed DOCA-salt-induced hypertension
in DbH-ETB:ETB
sl/sl rats and transgenic control rats
(Matsumura et al., 2000b). After 4 weeks of DOCA-salt,
therewasmarked renal and vascular pathology, including
hypertrophy, but this was attenuated with ETA antago-
nism (Matsumura et al., 2000a). These data suggest that
functional ETB receptors are protective against the devel-
opment of DOCA-salt-dependent hypertension; however
whether this is also true for female rats remains to be
determined.
VI. Phenotypes of Cell-Specific Genetic
Modifications in the Endothelin System
A. Cell-Specific Overexpression of Endothelin-1
In many pathologic states, circulating concentrations
of ET-1 are elevated. For example, ET-1 is elevated in
pulmonary hypertension (Stewart et al., 1991a), myocar-
dial infarction (Stewart et al., 1991b), stroke (Franceschini
et al., 2001; Volpe and Cosentino, 2000), abdominal aortic
aneurysms (Flondell-Site et al., 2010), and chronic kidney
disease patients (Lebel et al., 1994). To test mechanistic
questions about the source of elevated ET-1 levels, a
number of cell-specific overexpression ET-1 transgenic
mice have been developed.
1. Overexpression of Endothelin-1 in Endothelium.
To determine the effects of increasing endothelial ET-1
production on vascular physiology, a transgenic mouse
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overexpressing the human preproET-1 was generated
using the promoter and enhancer regions of the
endothelium-specific tyrosine kinase receptor (Tie-2)
(Amiri et al., 2004). These mice were named TG or eET-1
mice and present with a sevenfold increase in circulat-
ing ET-1 compared with wild-type littermate controls;
however, heart rate and blood pressure were similar to
controls (Amiri et al., 2004). eET-1 mice displayed
endothelial dysfunction, because vasodilation of mes-
enteric resistance arteries was significantly attenuated
that was likely due to an increase in NADPH oxidase
activity and ROS production (Amiri et al., 2004). More-
over, a DNA microarray performed with mesenteric
arteries from eET-1 and control mice determined that
eET-1 mice have increased expression of genes critical
for lipid metabolism (Simeone et al., 2011). This finding
led to the hypothesis that endothelial ET-1 may partic-
ipate in the development of atherosclerosis.
To determine if increases in ET-1 in the endothelium
promotes atherosclerosis, the eET-1 mouse was bred
onto the atherosclerosis prone apolipoprotein E KO
(Apoe2/2) mouse (Li et al., 2013). When placed on a
chronic high-fat diet, eET-1, Apoe2/2, and Apoe2/2eET-1
mice all had an increase in the atherosclerotic lesion size
of the descending thoracic aorta compared with wild-type
control mice; however, Apoe2/2eET-1 mice had a signifi-
cantly higher lesion size compared with eET-1 or Apoe2/2
mice. Further investigation revealed that an increase in
endothelial ET-1 promotes atherosclerosis and abdominal
aortic aneurysms by decreasing high-density lipoprotein,
increasing oxidative stress, and increasing inflammatory
cell infiltration (Li et al., 2013).
A second endothelial cell-specific overexpression of
mouse ET-1 driven by the tyrosine-protein kinase
receptor 1 promoter was also produced. These mice,
named TET-1, have an increase in brain vasculature
ET-1 (as determined by in situ hybridization and semi-
quantitative PCR) compared with nontransgenic litter-
mates (Leung et al., 2004). Interestingly, these mice
also have an elevated systolic and mean arterial blood
pressure (Leung et al., 2004), but similar to the eET-1
mice (Amiri et al., 2004) have aortic and mesenteric
artery endothelial dysfunction. Thus, there are two
unique models that can be used to test mechanistic
questions about elevated endothelial ET-1 production.
In chronic kidney disease patients, plasma ET-1
concentrations are elevated (Lebel et al., 1994). Because
CKD patients are often anemic, erythropoietin is given
to help achieve normal hematocrit levels (Lariviere and
Lebel, 2003; Drueke et al., 2006; Unger et al., 2010).
However, as a consequence, ET-1 levels also are further
increased (Carlini et al., 1993) and thought to perhaps lead
to elevated blood pressure in CKD patients (Barhoumi
et al., 2014). Barhoumi et al. (2014) hypothesized that
exercise may help prevent the increase in blood pres-
sure and vascular pathologies associated with erythro-
poietin treatment in CKD and end stage renal disease
(ESRD). ET-1 mice and controls were given erythropoi-
etin and then either subjected to swimming exercise
training or remained sedentary. Erythropoietin had no
significant effect on blood pressure or vascular function
in the wild-type mice (Barhoumi et al., 2014). In contrast,
the eET-1mice experienced significant increases in systolic
pressure, vascular media/lumen ratio, NADPH oxidase
activity, and ROS production. Interestingly, all of this was
prevented with exercise training, although ET-1 levels
remained elevated (Barhoumi et al., 2014). These data
suggest that exercisemaypreventET-1-dependentadverse
cardiovascular events in CKD and ESRD patients after
erythropoietin treatment. Furthermore, the use of receptor
antagonists for cardioprotection is ESRD patients should
be explored especially because the risk of fluid retention
would not be a serious problem.
2. Overexpression of Endothelin-1 in Cardiomyocytes.
In the setting of congestive heart failure (CHF), circu-
lating ET-1 is elevated (Stewart et al., 1992) along with
increased myocardial expression of ET-1, ETA, and ETB
receptors (Picard et al., 1998; Pieske et al., 1999). To
determine if this increase in the ET-1 axis is pathologic,
a mouse was developed to conditionally overexpress
ET-1 in the myocardium. This mouse was developed
using the a-myosin heavy chain promoter-dependent
cardiac-specific tetracycline-regulated gene expression
system to drive human ET-1 expression (Yang et al.,
2004). Once tetracycline was given to the adult animals
to induce cardiac ET-1 overexpression, there was a
10-fold higher concentration of ET-1 in the heart, but no
significant difference was detected in circulating ET-1
compared with control mice (Yang et al., 2004). These
elevated cardiac ET-1 mice presented with severe heart
inflammation, hypertrophy leading to dilated cardio-
myopathy, CHF, and death within 5 weeks of induction.
Moreover, treatment of these mice with the ETA/ETB
blocker LU420627 (but not the ETA blocker, LU135252),
inhibited leukocyte recruitment and preserved cardiac
function, although this response was only transient and
mice began to die at 8 weeks post-ET-1 overexpression
(Yang et al., 2004). Thus, this study provides evidence
that cardiac ET-1 and potentially the ETB receptor are
putative therapeutic targets in the setting of CHF.
3. Overexpression of Endothelin-1 in Astrocytes.
Stroke patients have elevated plasma and cerebrospi-
nal fluid concentrations of ET-1 (Volpe and Cosentino,
2000; Franceschini et al., 2001). Ischemia/reperfusion
leads to blood-brain barrier injury, including an in-
crease in vascular permeability and edema (Cole et al.,
1991; Yang and Betz, 1994). Furthermore, astrocytes
after hypoxia/reperfusion have elevated levels of ET-1
mRNA (Tsang et al., 2001; Lo et al., 2005); however, it is
unclear whether this could be protective or pathologic.
To answer this question, an astrocyte-specific ET-1
overexpression mouse was created (named GET-1 mice,
using the glial fibrillary acidic protein promoter) (Lo
et al., 2005). These mice develop normally and have a
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normal mean arterial blood pressure under baseline
conditions; however, after middle cerebral artery
occlusion-induced cerebral ischemia, GET-1 mice dis-
played a larger brain infarct size, increased brain swell-
ing, and increased brain water content, although survival
was similar to littermate controls (Lo et al., 2005). Middle
cerebral artery occlusion-induced cerebral ischemia
resulted in a threefold increase in ET-1 in the ipsilateral
hemisphere in the control mice but a 25-fold increase in
ET-1 in the GET-1 mice (Lo et al., 2005). Thus, increases
in astrocyte ET-1 during ischemia/reperfusion leads to
severe blood-brain barrier injury. Likewise, increases in
astrocyteET-1 production results in edemaand vasospasm
after subarachnoid hemorrhage; however, this can be
prevented with ETA and vasopressin V1a receptor
antagonism in GET-1 mice (Yeung et al., 2013).
Chronic pain, for example inflammatory pain or
neuropathic pain, can be caused by or often leads to
tissue injury. Although, in animal models, exogenous
ET-1 has been determined to induce pain peripherally
(Piovezan et al., 2000) or inhibit pain if injected
centrally (Yamamoto et al., 1994); the putative effect
of ET-1 from astrocytes specifically is unclear. Centrally,
astrocyte ET-1 has also been suggested to alleviate
neuropathic pain (Hung et al., 2014). GET-1 and control
mice were subjected to sciatic nerve ligation-induced
neuropathic pain, and pain-related to allodynic and
hyperalgesic behaviors were determined. An increase in
astrocyte ET-1 leads to pain alleviation for over 21 days
after the sciatic nerve ligation-induced neuropathic pain,
and this was likely mediated by the ETA receptor (Hung
et al., 2014). Likewise, astrocyte ET-1, but not endothelial
cell-derived ET-1 (TET-1 mice), can alleviate inflamma-
tory pain (Hung et al., 2012). Taken together these studies
suggest that increases in astrocyte ET-1 may be harmful
in the setting of stroke but may alleviate chronic pain.
B. Cell-Specific Deletion of the Endothelin System
1. Neuron-specific Endothelin-1 Knockout Mice.
To generate a neuron-specific ET-1 KO mouse, ET-1
floxed alleles were deleted by Cre expression driven by
the synapsin 1 promoter (Hasue et al., 2005). Neuron-
specific ET-1 KO mice had a greater sensitivity to acute
nociceptive stimuli, a greater degree of mechanical
allodynia in spinal nerve ligation-induced NP, and
reduced stress-induced analgesia (Hasue et al., 2005).
These data suggest that neuronal ET-1 could also be
involved in suppression of pain. Given the strong
evidence that ET-1/ETA receptors contribute to sensory
nerve pain, the apparent contrast of central versus
peripheral ETA receptors in the pain pathway require
further investigation.
2. Cardiomyocyte Endothelin-1 Knockout.
Cardiomyocyte ET-1 KO mice were produced using an
alpha-myosin heavy chain promoter to drive Cre expres-
sion (Shohet et al., 2004). These mice appear healthy
into adulthood. In isolated cardiomyocytes, there was a
significant 75% reduction in ET-1. To induce cardiac
hypertrophy, littermate control and cardiomyocyte ET-1
KO mice were treated chronically with exogenous tri-
iodothyronine (Shohet et al., 2004). The KO mice had a
57% reduction in cardiac hypertrophy compared with
control mice, suggesting that cardiac ET-1 contributes to
cardiac hypertrophy in his model (Shohet et al., 2004).
Although reduction of ET-1 was beneficial in the
context of cardiac hypertrophy, the same may not be
true in terms of the aging heart. Cardiomyocyte ET-1
KO mice at 2 months of age had normal left ventricular
function compared with controls (Zhao et al., 2006);
however, at 6 months of age, left ventricular systolic
function had declined, and by 11 months many of the
KOmice had died (Zhao et al., 2006). Aged KOmice had
dilated heart chambers and increased cardiac fibrosis
consistent with heart failure. Furthermore, if young KO
mice were challenged with transverse aortic constric-
tion, there was an accelerated development of heart
failure and loss of cardiomyocytes via apoptosis (Zhao
et al., 2006). Thus, from this study, it is evident that
cardiac ET-1 is critical for cardiac function and cardio-
myocyte survival in aging or stressed mice.
3. Cardiomyocyte Endothelin A Receptor Knockout.
Cardiomyocyte ETA KOmice were also developed using
the alpha-myosin-heavy chain promoter to drive Cre
(Kedzierski et al., 2003). These KO mice developed
normally into adulthood and had normal cardiac size
and function. Moreover, when challenged with angio-
tensin II or isoproterenol to induce cardiac stress,
cardiomyocyte ETA KO mice and littermate controls
had similar levels of cardiac hypertrophy, and both
genotypes had a similar increase in peak velocity and
decrease in ejection time (Kedzierski et al., 2003). Thus,
at least in young mice (6- to 7-week-old mice), cardiac
function is normal in mice lacking cardiac ETA recep-
tors. Whether this is also true for aging mice remains to
be determined.
Cold stress, such is experienced during cold winter
months, is associated with oxidative stress and cardiac
dysfunction including hypertrophy. To determine if ETA
receptors are involved in cardiac dysfunction during
cold stress, cardiomyocyte ETA KO mice and controls
were exposed to ambient or 4°C temperatures for 2 and
5 weeks (Zhang et al., 2012). Cardiomyocyte ETA KO
mice were protected against cold stress-induced cardiac
fibrosis and cardiac dysfunction. Moreover, control mice
had an increase in ROS production, caspase-3 activity,
and increased myocardial apoptosis after cold-stress
that was absent in the cardiomyocyte ETA KO mice
(Zhang et al., 2012). These data suggest that an increase
in ETA activation induced by cold stress exposure leads
to cardiac dysfunction.
4. Smooth Muscle Endothelin A Receptor Knockout.
ETA receptors are abundantly expressed throughout the
vascular smooth muscle, where they lead to vasoconstric-
tion. Deletion of ETA receptors from the smooth muscle
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was developed using smooth muscle protein 22-Cre mice
(Donato et al., 2014). These mice had a number of
developmental abnormalities, similar to the whole body
ETA KO mice (above). There was decreased viability,
which may be attributed to growth retardation, mandib-
ular maldevelopment, cranial vascular malformations,
abnormal thymus, pericardial cystic space, and thickened
aortic arch vessels (Donato et al., 2014). However, some
smooth muscle ETA KO (SM-ETAKO) mice managed to
survive into adulthood, and as adults, there were no
differences in body, organ, or adiposemass or blood glucose.
WhenchallengedwithET-1 in thepresence ofETB receptor
blockade, SM-ETAKO mice had blunted femoral artery
vasoconstriction. Althoughbaselinemeanarterial pressure
was similar between the genotypes, floxed controlmice had
a significant increase inmean arterial pressure in response
to a bolus infusion of ET-1 that was absent in the
SM-ETAKO mice (Donato et al., 2014). Thus from this
study it is evident that smoothmuscle ETA receptors are
critical for proper development, and contribute to the
regulation of arterial pressure in adults.
5. Smooth Muscle Endothelin-1 Knockout.
Although the endothelium is a major source of ET-1
production, smooth muscle cells also produce ET-1, and
it is hypothesized that smooth muscle ET-1 (SM ET-1
KO)may be involved in the pathogenesis of PAH. To test
this hypothesis, ET-1 has been deleted from the smooth
muscle using sm22-Cre (Kim et al., 2015). Kim et al.
(2015) did not comment on any developmental abnor-
malities in the SM ET-1KO mice. At baseline, floxed
control and SM ET-1KO mice had similar right ventric-
ular systolic pressure (RVSP); however, exposure to
hypoxia (10% oxygen for 21–24 days) resulted in a
significant increase in RVSP in both genotypes, albeit
it was relatively attenuated in the SM ET-1KO mice
(Kim et al., 2015). Circulating ET-1 levels were in-
creased in a similar manner between the floxed and SM
ET-1 KOmice exposed to hypoxia illustrating that most
circulating ET-1 is from the endothelium and not the
smooth muscle (Kim et al., 2015). Thus, the improved
RVSP in response to hypoxia in the SM ET-1KO mice
suggests that smooth muscle ET-1 plays a role in the
pathogenesis of PAH.
6. Endothelial Endothelin B Knockout. Given that
endothelial ETB receptor activation stimulates NOS3
NO production, one might expect that endothelial cell
ETB deletion would increase blood pressure. To delete
ETB from the endothelium, a Tie2-Cre mouse was used
leading to loxP recombination and deletion of exons
3 and 4 of the ETB receptor (Bagnall et al., 2006).
Endothelial cell ETB KO mice (ECETBKO) had in-
creased circulating ET-1 levels, again confirming the
importance of the endothelial ETB for ET-1 regulating
circulating ET-1 concentrations (Kelland et al., 2010b).
ECETBKOmice also had impaired aortic vasodilation to
the ETB agonist sarafotoxin 6c (S6c) and acetylcholine
that was related to a decrease in NO bioavailability.
Moreover, exposure to hypoxia leads to an exaggerated
muscularization and remodeling of pulmonary arteries
and a greater increase in systolic right ventricular
pressure in ECETBKO mice (Kelland et al., 2010a).
Although endothelial dysfunction was evident in the
ECETBKO mice, they were normotensive and had
similar blood pressures to floxed control mice on chronic
high-salt diets (Bagnall et al., 2006). These data suggest
that endothelial ETB receptors mediate vasodilation
and limit vascular remodeling but may not necessarily
be involved in long-term blood pressure control. How-
ever, these mice were developed on a salt-sensitive
background strain and so both control and ECETBKO
mice became hypertensive on the high-salt diet. Addi-
tional studies on a salt-resistant strain of mouse are
needed.
In humans, the portal vein expresses about 57%:43%
ETA: ETB receptors; however, in portal veins from
cirrhotic livers, there was shift to 90%:10% (Ling et al.,
2012). Thus, the ECETBKO mice may be an appropriate
model to test mechanistic questions about portal hyper-
tension and cirrhosis. The liver of the ECETBKO mouse
had a reduced sinusoid diameter and red blood cell
congestion in the intrahepatic branches of the portal vein
(Ling et al., 2012). Taken together these data suggest that
endothelial ETB receptors tonically dilate the portal vein
and that ETA antagonism may be beneficial in cirrhotic
patients.
7. Endothelial Endothelin-1 Knockout. To further
evaluate thephysiologic role ofET-1 in the endothelium, a
vascular endothelial cell ET-1 KO mouse (VEETKO) was
developed, again using Tie2-Cre to drive ET-1 deletion
from the endothelium (Kisanuki et al., 2010). Deletion of
ET-1 from the endothelium resulted in a 65–80% re-
duction in circulating ET-1 and ET-1 content in the major
organs (Kisanuki et al., 2010). Yet, acute blood pressure
responses to captopril, angiotensin II, phenylephrine,
bradykinin, L-NAME, or ET-1 were similar to floxed
controls, suggesting that the lacking endothelial ET-1
does not affect these paracrine/autocrine signaling sys-
tems (Kisanuki et al., 2010). Although it was initially
determined that VEETKOmice have a significantly lower
blood pressure than floxed controls (Kisanuki et al., 2010;
Adiarto et al., 2012), others have reported that blood
pressure is similar between these genotypes (Heiden
et al., 2014). Thus, it remains controversial if basal blood
pressure is altered by the lack of endothelial ET-1.
However, ANGII infusion leads to a similar increase in
blood pressure between VEETKO and floxed mice, but
cardiac hypertrophy and fibrosis was reduced in the
ANGII-infused VEETKO mice (Adiarto et al., 2012).
Tissue growth factor, TGFb, collagen I and III were
reduced in ANGII-infused VEETKO mice, suggesting
that endothelial-derived ET-1 is a critical mediator in
ANGII-dependent fibrosis (Adiarto et al., 2012). In con-
trast, loss of endothelial-derived ET-1 appears protective
in a transaortic constrictionmodel of cardiac hypertrophy,
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where VEETKO mice with transaortic constriction had
reduced cardiac function (Heiden et al., 2014). The role of
endothelial-derived ET-1 in cardiac hypertrophy likely
depends on a variety of factors, including the level of ET
receptor expression in each cell type.
ET-1 is reported to be increased in acute kidney injury
(AKI) and may be part of the pathogenesis of the
progression of a variety of acute as well as chronic
kidney diseases (Wilhelm et al., 1999). To determine if
elevated ET-1 in AKI is derived from the endothelium,
ischemia/reperfusion injury experimentswere performed
in VEETKO and floxed control mice (Arfian et al., 2012).
Although, ischemia/reperfusion injury resulted in in-
creased oxidative stress, inflammation, and tubular and
small renal artery injury, these pathologies were attenu-
ated in the VEETKO mice (Arfian et al., 2012). Likewise,
exposure to hypoxia or 2 weeks of high-salt diet (4%NaCl)
leads to an increase in glomerular ET-1, oxidative stress,
and kidney injury in floxed control mice, but this was
attenuated in VEETKO mice (Heimlich et al., 2015).
These data suggest that endothelial ET-1 is pathologic
in states of increased oxidative stress including AKI.
8. Intestinal Epithelium-specific Endothelin-2
Knockout. Conditional intestinal epithelium-specific
ET-2 KO mice (driven by Cre expression under the
control of the villin promoter) were born without any
observable abnormalities and had normal survival
(Chang et al., 2013). These intestinal ET-2 KO mice
had normal fat absorption and excretion of fats and
carbohydrates, suggesting that unlike the global ET-22/2
mice that suffered from internal starvation, intestinal
ET-2 derived from epithelial cells is not essential under
normal conditions (Chang et al., 2013). The specific
cellular source of ET-2 that regulates metabolism will
need further investigation.
9. Neuron-specific Endothelin-2 Knockout. Neuron-
specific ET-2 KOmice were produced with Cre driven by
the nestin promoter (Chang et al., 2013). These mice were
born healthy, with no growth defects, and had a normal
core body temperature unlike the ET-22/2mice. Thus, the
body temperature defect displayed by ET-22/2mice is not
due toET-2deletion from thenervous system (Changet al.,
2013), but the precise origin has yet to be determined.
10. Collecting Duct Endothelin-1 Knockout. The
inner medullary collecting ducts have the highest
density of ETB receptors in the body and produce a
large amount of ET-1. To determine the physiologic role
of the collecting duct ET-1 system, a series of studies
were performed by deleting various aspects of this
system from the collecting duct. Mice with lox-P sites
surrounding genes of ET-1, ETA, and ETB receptors
were bred with AQP2-Cre mice (Nelson et al., 1998).
AQP2 is a water channel expressed in the principal cell
of the collecting duct, testes, vas deferens, and epidid-
ymis (Nelson et al., 1998). Thus, breeding floxed mice
with AQP2-Cre-positive dams leads to lines of principal
cell, collecting duct-specific KO mice.
Deletion of ET-1 from the CD resulted in a salt-
sensitive blood pressure phenotype. On a normal salt
diet, CDET-1KO mice had significantly higher systolic
blood pressure compared with floxed controls mice (Ahn
et al., 2004). On a high-salt diet (2% sodium) CDET-1KO
mice had an even greater increase in blood pressure,
whereas floxed controls had no change, demonstrating a
salt-sensitive phenotype. CDET-1KO mice had sodium
retention, and this could be ameliorated with amiloride
or furosemide. However, diuretic treatment only re-
duced the salt-sensitive blood pressure and did not
affect the higher blood pressure while on a normal salt
diet (Ahn et al., 2004). Plasma aldosterone, plasma
renin activity, and plasma ET-1 concentrations were
similar between the genotypes regardless of the salt in
thediet,whichwas surprising considering theCDET-1KO
mice are retaining sodium and it would be expected that
the renin-angiotensin-aldosterone system would be sup-
pressed in these mice. Interestingly, blood pressure is
decreased in the CDET-1KO mice with angiotensin re-
ceptor blockade or mineralocorticoid receptor antagonism
with spironolactone (Ge et al., 2008b). Thus, part of the
hypertension in the CDET-1KO mouse is due to relative
renin-angiotensin-aldosterone system overactivity, and
these data suggest that CD ET-1 may regulate renal
renin production (Ge et al., 2008b).
As expected, CDET-1KO mice had reduced ET-1
excretion, and although ET-1 excretion increased sig-
nificantly in the floxed animals with high-salt diet, this
was not observed in the CDET-1KO mice. These data
suggest that the CD is a major source of urinary ET-1
and that high salt feeding significantly increases CD-
derived ET-1 production and excretion (Ahn et al., 2004).
Given that ET-1 can stimulate CD NO production
(Stricklett et al., 2006; Hyndman et al., 2012), it was
tested whether CDET-1KO mice have an impaired
inner medullary NO system. With both normal salt
and high salt feeding, CDET-1KO mice have reduced
inner medullary NOS1 and NOS3 activity and reduced
urinary nitrite/nitrate excretion (Schneider et al., 2008).
Furthermore, increasing renal perfusion pressure in
anesthetized mice resulted in reduced nitrite/nitrate,
sodium, and water excretion in CDET-1KO mice com-
pared with controls (Schneider et al., 2008), further
demonstrating that CD ET-1 promotes NO production
and natriuresis and diuresis. Thus, the CDET-1 system is
critical for limiting increases in blood pressure under both
normal and high salt feeding.
CD ET-1 also plays a role in the regulation of water
excretion. Floxed control and CDET-1KO mice were
challenged with ddAVP, the vasopressin receptor-2 ago-
nist (Ge et al., 2005a). Chronic ddAVP infusion into
CDET-1KO mice resulted in a greater increase in urine
osmolality for the first 3 days of infusion compared with
floxed controls. Moreover, freshly isolated CDs from
CDET-1KO mice had elevated adenylyl cyclase 5/6 ex-
pression (Strait et al., 2007) and greater AVP-dependent
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cAMPproduction comparedwithCDs from floxed controls
(Ge et al., 2005a). These data suggest that CD ET-1
promotes diuresis.
ET-1 can increase CD PGE2 production that can also
lead to natriuresis and diuresis. Interestingly, CDET-
1KO mice have elevated PGE2 excretion under both
normal and high-salt diets compared with floxed con-
trols (Ge et al., 2007), suggesting that PGE2 is increased
to compensate for the lack of CD ET-1. However,
blocking prostaglandins chronically with indomethacin
resulted in a more concentrated urine from the CDET-
1KO mice compared with littermate control, although
there was a similar increase in blood pressure (Ge et al.,
2007). These data suggest that the compensatory increase
in CD PGE2 promotes diuresis in CD ET-1KO mice but
does not affect blood pressure. It can be concluded that CD
ET-1 is a key regulator for both sodium and water
homeostasis, which is critical for homeostatic regulation
of blood pressure.
11. Collecting Duct Endothelin A Receptor Knockout.
The ETA receptor was deleted from the CD, CDETAKO,
and these mice had normal development and aging (Ge
et al., 2005b). On a normal salt or 2% high sodium diet,
CDETAKO mice and floxed control mice had similar
blood pressure, sodium excretion, plasma creatinine,
and plasma renin activity and concentration (Ge et al.,
2005b). From this it was concluded that the CD ETA
receptor is not critical for regulation of sodium excretion
and blood pressure control. However, CDETAKO mice
had significantly higher plasma AVP concentration,
whereas freshly isolated CDs from CDETAKO mice
had reduced AVP-dependent cAMP production. Fur-
thermore, CDETAKO mice have reduced concentrating
ability when challenged with ddAVP (Ge et al., 2005b).
Interestingly, ETA receptor antagonists can produce
fluid retention, most likely due to renal tubular ETA
receptors, and so together, these data suggest that CD
ETA receptor activation contributes to the urine con-
centrating mechanisms, although the signaling mecha-
nisms are yet to be determined.
12. Collecting Duct Endothelin B Receptor Knockout.
The CD has a very high density of ETB receptors.
Deletion of the ETB receptor from the CD resulted in
an increase in systolic and diastolic blood pressure that
was further increased with high salt feeding (Ge et al.,
2006). CDETBKO mice also had reduced plasma renin
activity and reduced aldosterone excretion, which is
consistent with having sodium retention and possibly
an expanded plasma volume. Moreover, CDETBKO mice
hadadelayednatriuretic response to anacute sodium load.
Although, CDETBKO mice have an elevated blood pres-
sure, it is not as high as CDET-1KO mice, suggesting that
the natriuretic effects of ET-1 may involve non-CD ET
receptors (Ge et al., 2006). ET receptors are also expressed
on the vasa recta and other tubular segments (see Kohan
et al., 2011), thus it is possible that CD ET-1 can act in a
paracrine manner to regulate sodium excretion.
13. Collecting Duct Endothelin A/B Receptor
Knockout. To further determine the contribution of
the CD ET receptors to fluid-electrolyte balance and
blood pressure control, both receptors were genetically
deleted from the CD. CDETA/BKO mice also display an
elevated systolic pressure while on a normal salt diet
that was greater than the CDETBKOmouse but similar
to the CDET-1KO mouse (Ge et al., 2008a). With high
salt diet, there was a significant increase in systolic
pressure compared with floxed control mice, and this
was similar to that observed in CDET-1KO mice but
significantly higher than CDETBKO (;15 mmHg) or
CDETAKO (;1 mmHg) mice (Ge et al., 2008a). Sodium
excretionwas blunted on the first 2 days of high salt diet
feeding, suggesting sodium retention in the CDETA/BKO
mouse compared with controls. From this study, it is
evident that both ETA and ETB activation can lead to
natriuresis/diuresis and that autocrine and paracrine
actions of ET-1 are critical for fluid-electrolyte balance
and blood pressure control.
In the CD, the epithelial sodium channel (ENaC) is a
rate-limiting step in the reabsorption of sodium. Exoge-
nous ET-1 decreases ENaC open probability and activity
(Bugaj et al., 2008), demonstrating a direct tubular action
of ET-1 on sodium homeostasis. To determine which CD
ET receptors may be mediating this ET-1-dependent
decrease in sodium reabsorption, ENaCactivity in acutely
isolated cortical CD was measured in the CDETAKO,
CDETBKO, and CDETA/BKO mice. CDETAKO mice had
similar, low ENaC activity that was not different from
wild-type controls, and as the salt in the diet increased,
therewas a similar expected decrease inENaCactivity. In
essence, CDETAKO mice and controls had the same,
normal suppression of ENaC activity with an increase in
salt intake (Bugaj et al., 2012). In contrast, normal salt fed
CDETBKO and CDETA/BKO mice presented with a
significantly greater ENaCactivity comparedwith control
and CDETAKO mice. Furthermore, increasing dietary
sodium intake did not suppress ENaC activity in these
mice, thus remaining inappropriately high. From this study,
it is evident that CD ETB receptor activation is critical for
inhibiting ENaC activity and thus sodium reabsorption.
Furthermore, this signaling cascade involves CD NOS1
activity, because CDNOS1KO mice fail to suppress ET-1-
dependent ENaC activity (Hyndman et al., 2015).
14. Cardiomyocyte, Smooth Muscle, Nephron, and
Collecting Duct Endothelin A Receptor Knockout.
ETA receptor blockade is proposed to be beneficial in
a number of cardiovascular/renal diseases; however,
there is often significant fluid retention reported with
their use that can be a clinically significant problem. To
further determine if renal epithelial ETA receptors are
critical for promoting diuresis, an inducible nephron
ETA KO mouse was developed using a Pax8-rtTA and
LC-1 transgenic animals. Floxed ETA mice were bred
with Pax8-rtTA/LC-1 mice and deletion of nephron ETA
was initiated by doxycycline treatment in adulthood
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(Stuart et al., 2012). Nephron ETA KO mice had a
modest fluid retention while on a high-salt diet but no
appreciable change in blood pressure or sodium excre-
tion (Stuart et al., 2012). Thus, nephron ETA receptors
likely do not play a predominant role in the regulation of
sodium homeostasis or blood pressure control and
partially contribute to fluid retention seen with ETA
antagonists. Importantly, this study suggests a role for
extra-nephron ETA receptors mediating ETA antagonist-
dependent fluid retention.
To determine which of these potentially extra-nephron
ETA receptors may be contributing to the regulation of
body fluids, a comparative study among the cardiomyo-
cyte ETA KO, SM-ETA KO, nephron ETAKO, CDETAKO,
and floxed ETA control mice was performed (Stuart et al.,
2013). All these mice were fed a high 3.5% sodium diet for
7 days followed by high-salt diet plus 2 weeks of ETA
antagonism (ambrisentan or atrasentan). ETA antago-
nism resulted in a significant increase in body weight,
total body water, and extracellular fluid in the floxed
control and cardiomyocyte ETA KO mice only. Nephron
and CD ETAKO mice were protected to a similar degree
from the ETA-antagonist-dependent fluid retention, sug-
gesting it is antagonism of the CDETA receptor that leads
to fluid retention. The SM-ETAKO mice also were par-
tially protected from this fluid retention. These data
suggest that ETA-antagonist induced fluid retention is
due to CD ETA receptors and SM-ETA receptor, but not
likely cardiomyocyte ETA receptors (Stuart et al., 2013).
15. Podocyte Endothelin A/B Receptor Knockout.
Podocytes have a key role in glomerular function: with
endothelial cells of the glomerular capillary loop and the
glomerular basement membrane they form a filtration
barrier. In mice, podocytes express both receptors.
Diabetic nephropathy was induced experimentally in
mice with podocyte-specific double knockout of both
receptors. This deletion resulted in less albuminuria
and protection from glomerulosclerosis and podocyte
loss (Lenoir et al., 2014). These results suggest that in
mice at least, the ETB receptor may play as important a
role as does the ETA receptor in diabetes, whereas
previous studies have suggested the latter was themain
subtype mediation the deleterious actions of ET-1
(Chandrashekar and Juncos, 2014).
VII. Role of Endothelin in Human Pharmacology
Deduced from Experimental Medicine Studies
A. Clinical Pharmacology of Peptide Endothelin
Receptor Agonists and Antagonists
ET-1 and ET-3 (along with various ET receptor
antagonists) have been most widely used over the years
to define their role and that of the ETA and ETB
receptors in human physiology and disease (Haynes
and Webb, 1994; Haynes et al., 1995a,b; MacIntyre
et al., 2010). The ETB receptor agonist S6c has been
used in a number of clinical studies (Strachan et al.,
1995, 2000; Ferro et al., 2002; Newby et al., 2002) and
probably carries the same risks as those associated with
other agonists.
In humans, brachial artery infusion of ET-1 causes a
sustained, dose-dependent reduction in forearm blood
flow (Clarke et al., 1989; Haynes et al., 1995a,b). Low
doses of the ETB-selective agonists ET-3 and S6c also
produce vasoconstriction when infused into the brachial
artery in keeping with vascular ETB receptors mediating
at least part of the functional response to ET-1 in these
vessels (Haynes et al., 1995a,b). ETB receptor agonists can
also produce transient forearm vasodilation that is NO
mediated (Newby et al., 2002).
Both ET-l (Clarke et al., 1989) and S6c (Haynes et al.,
1995a,b) cause a sustained constriction of human dorsal
hand veins in vivo, suggesting that both vascular ETA
and ETB receptors contribute to venoconstriction to ET-1
in humans. This is further supported by the capacity for
the selective ETA receptor antagonist BQ123 to attenuate
the in vivo venoconstriction to ET-l but not S6c (Strachan
et al., 1995). Thus, the part of theET-1 response that is not
inhibited by BQ123 is likely to be ETB receptor mediated.
In addition, venoconstriction to both ET-1 (Haynes and
Webb, 1993) and S6c (Strachan et al., 1995) is markedly
attenuated by endothelial ETB-mediated production of
vasodilator substances, prostacyclin, and NO.
In humans, brachial artery administration of Big ET-1
leads to a dose-dependent forearm vasoconstriction that
is completely blocked by the ECE inhibitor phosphor-
amidon, suggesting that the effects of the precursor are
mediated through its conversion to the mature peptide
by ECE (Haynes and Webb, 1994). The blockade of
constriction to Big ET-l by phosphoramidon is unlikely
to have been due to inhibition of ET receptor binding,
because vasoconstriction to ET-1 was unaffected by
phosphoramidon and because conversion to ET-1 and its
C-terminal fragment was confirmed in plasma samples
taken from the veins draining the infused forearm
(Plumpton et al., 1995). As circulating blood exhibits little
ECE activity (Watanabe et al., 1991), conversion of Big
ET-1 in the forearm probably occurs via vascular ECE
situated within the forearm blood vessels. The difference
in potency between Big ET-1 and ET-1 and the ratio of
C-terminal fragment to Big ET-1 in venous blood, both
indicate that local ECE converts ;10% of luminally
presented Big ET-1 to ET-1, consistent with ;10%
conversion of exogenous Big ET-1 by cells expressing the
ECE-1 gene (Xu et al., 1994). To date the therapeutic
strategy of combined ECE/NEP remains and unproven
concept (see section II.A.8), particularly asNEP inhibition
alone is associated with vasoconstriction and has not
proven effective when exploited clinically (Ferro et al.,
1998). Further clinical studies are needed with inhibitors
that are selective for ECE alone.
Such agonist studies have proven valuable in helping
to define the site of production of ET-1 and its mediators
of action. However, they may not adequately represent
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the effects of a hormone, the actions of which are largely
autocrine/paracrine, and inhibition of the production, or
actions of ET-1 may better define its physiologic and
pathologic effects. In this respect, ET receptor antago-
nists have proven to be useful tools in defining the role
of ET in health and disease. The distinction between
selective and mixed antagonists is discussed in section
IV. Highly selective peptide ETA antagonists such
BQ123 and the ETB-selective BQ788 have provided
the clearest evidence for defining the role of the two
receptors. In addition, a number of antagonists have
been studied with a range of relative affinities for ETA
over the ETB subtype or as well as mixed antagonists
such as the orally active bosentan (Dhaun et al., 2007b).
There now exist a number of ET receptor antagonists
that have or are being explored in a variety of clinical
conditions (see Table 1).
With respect to systemic hemodynamics in healthy
man, selective ETA receptor antagonism with BQ123 is
associated with peripheral vasodilation (Verhaar et al.,
1998) and a reduction in blood pressure (BP) (Spratt
et al., 2001) and selective ETB receptor antagonism
(BQ788) with peripheral vasoconstriction (Verhaar
et al., 1998) and a pressor response (Strachan et al.,
1999). This suggests that endogenous ET-1 contributes
to the maintenance of vascular tone and BP via the ETA
receptor and the balance of ETB receptor function favors
activation of the endothelial over the vascular smooth
muscle ETB receptor.
B. Clinical Application of Nonpeptide Endothelin
Receptor Antagonists
1. Chronic Heart Failure. Many of the early trials
using ET receptor antagonists were carried out in
patients with chronic heart failure (CHF; Table 5).
These were based on compelling preclinical (Sakai
et al., 1996; Kobayashi et al., 1999) and clinical data
(Pieske et al., 1999) that showed an upregulation of the
ET system in CHF. Furthermore, the high blood levels
of ET-1, observed in both animal models and patients
with CHF, correlated with poor functional state and
lower survival (Motte et al., 2006). Although the initial
acute dosing studies using both selective ETA andmixed
ETA/B approaches were encouraging (Kiowski et al.,
1995; Cowburn et al., 2005), these used hemodynamic
end points, which are a poor surrogate of benefit on
clinical outcomes. Longer term outcome studies have been
disappointing in respect to both of these approaches.
To date, four large multicenter double-blind trials
have been completed. Bosentan was evaluated in both
the REACH-1 and ENABLE studies. The former was
terminated early because of side effects (elevated liver
enzymes) attributed to the high dose of drug used (up to
500mg twice daily). Consequently, the latter study used
a lower dose of drug (125 mg twice daily) with a longer
follow-up period. No benefits of bosentan treatment
were observed, with an excess of adverse events in the
treatment arm. Similarly disappointing results were
seen with the mixed antagonist enrasentan (;100-fold
ETA selective) in the ENCOR study (Battistini et al.,
2006), and the EARTH study, which used the borderline
ETA-selective antagonist darusentan (;130-fold ETA
selective) (Anand et al., 2004). Fluid retention leading to
worsening heart failure was a common feature of
treatment in these studies. Whether this was due to
unnecessarily high doses of drug used or concomitant
ETB in addition to ETA receptor blockade, and, indeed,
whether this could be managed with an appropriate
diuretic regimen would not become apparent until the
trials a decade later in hypertension and chronic kidney
disease (CKD).
Unfortunately, of these four trials, only the EARTH
study has been published in more than abstract form
(Mylona and Cleland, 1999; Abrahams, 2001; Teerlink,
2002). Until the full dataset from all of these studies is
put into the public domain there cannot be a full
independent analysis of the results from which patients
may potentially benefit. Of the four studies described, it
is clear that only one (EARTH) measured the critically
important biomarker of significant ETB receptor block-
ade, plasma ET-1 (MacIntyre et al., 2010). This rose in
EARTH and other studies (Luscher et al., 2002; Anand
et al., 2004), suggestive of significant ETB receptor
blockade. Therefore, it may well be that a truly ETA-
selective approach has not yet been studied in patients
with CHF, and there is no trial of ETA versus ETA/B
receptor antagonism. Unfortunately, given the negative
findings to date, it is unlikely that clinical trials will be
conducted in the future. However, heart failure is a
heterogeneous condition and diastolic heart failure and
cor pulmonale are two conditions where the potential
benefits of ET receptor blockade remain unstudied.
2. Primary Hypertension. Based on its vasoconstric-
tor and pressor effects Yanagisawa and colleagues first
speculated that ET-1 might be involved in the patho-
genesis of hypertension (Yanagisawa et al., 1988).
Vascular production of ET-1 is increased in most salt-
sensitive animal models of hypertension (Schiffrin,
2005), and the hypertensive effects of ET-1 appear to
be at least partly dependent on salt, as chronic infusion
of ET-1 only increases blood pressure (BP) when
combined with a normal or high-sodium diet but is
absent on a low-sodium diet (Mortensen et al., 1990;
Mortensen and Fink, 1992; Pollock and Pollock, 2001;
Schiffrin, 2005). Both selective ETA receptor and mixed
ETA/B receptor antagonists effectively reduce blood
pressure in models of hypertension that are accompa-
nied by an increase in ET-1 (Moreau, 1998).
Interestingly, Ergul et al. (1996) reported that levels
of immunoreactive plasma ET were increased in
African-American patients (who usually present with
salt-sensitive hypertension) despite being treated with
a range of antihypertensive therapies. Although some
studies have observed increasedplasmaET-1 concentrations
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in hypertensive patients compared with healthy indi-
viduals, this is not always evident (Davenport et al.,
1990; Saito et al., 1990; Schiffrin and Thibault, 1991;
Cody et al., 1992). However, because ET-1 is mainly
secreted abluminally and rapidly cleared from the
circulation by ETB receptors (Fukuroda et al., 1994b),
plasma levels may not be an accurate representation of
ET system activation. Local studies with ET receptor
antagonists have shown that both selective and mixed
antagonists increase forearm vasodilation and reduce
BP in hypertensive patients to a greater extent than in
healthy individuals (Cardillo et al., 1999). In addition,
this response was greater with mixed antagonism than
selective ETA receptor blockade, showing the important
contribution of ETB receptor-mediated vasoconstriction
in hypertension. However, this different response in
hypertensive patients and healthy individuals is not
always evident (Martin et al., 2002).
The first chronic dosing study in humans investigat-
ing the potential of an ET receptor blocker as an
antihypertensive agent administered the mixed receptor
antagonist bosentan as a single agent in ;300 patients
with mild to moderate primary hypertension for 4 weeks
(Krum et al., 1998). A reduction in systolic (28 mmHg)
and diastolic (26 mmHg) BP was achieved with a daily
dose of 500 or 2000 mg bosentan that was similar to that
achieved with an angiotensin converting enzyme inhibi-
tor. In general, the drug was well tolerated.
Although use of a mixed ET receptor antagonist
successfully lowered BP, selective ETA receptor antag-
onists may be as effective. Darusentan, an ET receptor
antagonist that has an ETA:ETB receptor affinity of
;130:1 (Rohmeiss et al., 1998) was administered to
;400 patients with stage 2 primary hypertension
(Nakov et al., 2002). Within 1 week of a daily adminis-
tration of 10, 30, or 100 mg darusentan, a signifi-
cant dose-dependent reduction in systolic BP (10 mg:
26 mmHg; 30 mg: 27 mmHg; 100 mg: 211 mmHg) and
diastolic BP (10mg:24mmHg; 30mg:25mmHg; 100mg:
28mmHg) relative to placebo was observed. This decrease
was maintained throughout the 6 weeks of the study.
Flushing and peripheral edemawere seen in the treatment
arms only and in a dose-dependent manner. Although
these studies show that both selective ETA and mixed ET
receptor antagonism can reduce BP, no studies have made
a direct comparison of the different antagonists.
4. Resistant Hypertension. Resistant hypertension
is hypertension that remains uncontrolled despite
taking three or more antihypertensive agents of dif-
ferent classes (usually including a diuretic) at appro-
priate doses. Darusentan was administered as an
add-on therapy in ;100 of these patients in a random-
ized, double-blind, placebo-controlled trial. Darusentan
was initially administered at 10mg a day and titrated up
to 100 mg over 8 weeks. Compared with placebo, BP
showed a progressive decline with systolic BP 211.5
mmHg and diastolic BP26.3mmHg lower at the end of
the study (Black et al., 2007). Two further clinical trials
reported in patients with resistant hypertension both
administering darusentan at 50, 100, and 300 mg over
14 weeks. In the first of these studies (in 379 patients),
all doses resulted in similar and clinically relevant
decreases in office systolic BP (.15 mmHg) that were
greater than the placebo group, with more patients in
the darusentan groups achieving BP goal (Weber et al.,
2009). However, in the second study, a similar decrease
in systolic BPwas observed in the placebo (214mmHg)
and darusentan (215 mmHg) groups (Bakris et al.,
2010). From these studies in resistant hypertension,
two showed a large placebo effect in office blood
pressure measurements that made interpreting and
analyzing the results challenging (Black et al., 2007;
Bakris et al., 2010). However, in both studies, results
from ambulatory blood pressure monitoring showed a
significant decrease in mean 24-hour systolic BP of
;10 mmHg, which was greater than the placebo groups
(;2 mmHg). In these studies, ambulatory BP monitor-
ing was also able to provide the additional information
that both systolic and diastolic BP reductions with
darusentan were maintained over the 24-hour period,
resulting in an improvement in the diurnal variation in
BP. The primacy of ambulatory BPmeasurement above
office BP measurements, where both are available in
these studies, has been noted (Webb, 2010). Unfortu-
nately, after the failure of the second darusentan study to
meet itsprimaryendpoint of a reduction inofficeBP, further
studies into the chronic administration of darusentan in
resistant hypertension were terminated.
5. Chronic Kidney Disease. The management of
CKD in the clinic focuses onBPandproteinuria reduction,
both key parameters that limit CKD progression and
reduce the associated cardiovascular risk. In addition,
there are a number of other aspects of CKD where there
may be a role for the ET system and so where ET receptor
antagonism may offer beneficial effects—these include
endothelial dysfunction, atherosclerosis, arterial stiffness,
andmineral bone disease. Clinical trials with ET receptor
antagonists using these parameters as end points in CKD
are limited. Other potential clinical applications include
ischemia/reperfusion, which is an important cause of
acute kidney injury, associated with high mortality rates
and the development of CKD. There is an unmet need to
prevent renal injury.Experimental studies in rats (Barrera-
Chimal et al., 2016) and dogs (Krause et al., 1997; Roux
et al., 1999) suggest a major role for ET and potential for
repurposing ET antagonists. Rhabdomyolysis and other
causes of massive myoglobin release are often complicated
by an acute ischemic renal failure. In a rat model of
rhabdomyolysis, bosentan was able to partly block a
number of deleterious parameters including the decrease
in creatinine clearance, increase in proteinuria, and the
tubular necrosis (Karam et al., 1995).
6. Hypertension Associated with Chronic Kidney
Disease. In nondiabetic hypertensive CKD patients,
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the systemic vasodilation seen with acute ETA receptor
blockade (associatedwith a reduction inBPof;10mmHg)
(Dhaun et al., 2009a) is attenuated by concomitant ETB
receptor antagonism (Goddard et al., 2004b), suggesting
that, at least in this disease state, vasoconstrictor ETB
receptor activity is less important than ETB vasodilatory
function. Acute ETA receptor antagonism also improves
renal hemodynamics with a fall in renal vascular
resistance and an increase in renal blood flow (Dhaun
et al., 2009a). These changes are accompanied by no
measurable effect on glomerular filtration rate (GFR).
There is a concomitant fall in the filtration fraction,
suggesting that ET-1 induces an ETA receptor-
mediated vasoconstriction, preferentially affecting
the efferent arterioles, although not excluding effects
on mesangial cells and the filtration coefficient
(Dhaun et al., 2009a).
In a similar nondiabetic proteinuric population,
chronic dosing with a selective ETA receptor antagonist
also reduces BP, albeit to a lesser extent (Dhaun et al.,
2011). In this study, a fall in systolic, diastolic, and
mean BP of;4mmHgwas observed. Of note, in this trial,
patients already had good BP control (;125/75 mmHg)
conforming to current CKD guidelines. Interestingly, in
both these acute and chronic studies (Dhaun et al., 2009a,
2011), the majority of patients studied were already
taking ACE inhibitors. Data from healthy subjects
suggest a synergy between ETA receptor antagonism
and ACE inhibition that is not only dependent on an
unblocked ETB receptor but is also associated with a
significant natriuresis (Goddard et al., 2004a). This is
important clinically because patients with CKD are
generally prescribed ACE inhibitors not only for BP
control but also for their renoprotective effects. There
are currently no studies usingmixed ETA/B antagonism.
However, subgroup analysis of the DORADO study,
which looked at the borderline selective antagonist
darusentan in resistant hypertension and where the
top doses may have led to a degree of ETB receptor
blockade, suggests that a combined ETA/B blocking
strategy may also be of benefit in lowering BP in
nondiabetic CKD (Weber et al., 2009).
In diabetic nephropathy, only one study has shown a
fall in BP. This used the ETA-selective antagonist
atrasentan (ETA:ETB receptor selectivity of ;1200:1),
and patients were dosed for 8 weeks. There was a fall in
systolic BP of ;8 mmHg and diastolic BP of ;6 mmHg
(Kohan et al., 2011a). Although the study of darusentan
in resistant hypertension included a significant propor-
tion of subjects with diabetes (;40%), it is unclear how
many had albuminuria and so coexistent nephropathy.
Interestingly, dual blockade with BQ123 and BQ788 or
selective ETA antagonism improved endothelium-
dependent vasodilatation in an experimental study in
patients with type 2 diabetes and coronary artery
disease but did not differ between the two treatments
(Rafnsson et al., 2014).
7. Proteinuria. Proteinuria is one of the manifesta-
tions of glomerular hypertension and has its origin in
physical destruction of the glomerular filtration barrier.
Albuminuria is incrementally associatedwith increased
cardiovascular risk in both individuals with pre-existing
risk (such as hypertensive patients) (Ibsen et al., 2005)
and in individualswith no known risk factors (Wang et al.,
2005). This is true even in the presence of normal renal
function (Freedman et al., 2005). Importantly, in patients
with hypertension, reduction of albuminuria—at least
with blockers of the renin-angiotensin system—confers
cardiovascular protection (Ibsen et al., 2005).
Both acute (Goddard et al., 2004b; Dhaun et al.,
2009a) and chronic (Dhaun et al., 2011) selective ETA
blockade have been shown to reduce proteinuria in
patients with nondiabetic proteinuric CKD. In the acute
studies, these effects were abolished by concomitant
ETB receptor antagonism (Goddard et al., 2004b). As for
BP reduction, mixed ETA/B antagonism has also been
shown to reduce proteinuria in nondiabetic CKD (Weber
et al., 2009). However, all these subjects had, at most,
microalbuminuria compared with the chronic dosing
study with the selective ETA antagonist (Dhaun et al.,
2011), which included not only a wide range of non-
diabetic proteinuric renal diagnoses (membranous
glomerulopathy, IgA nephropathy, focal segmental
glomerulosclerosis, for example) but also varying pro-
teinuria (0.3–8 g/day).
The largest studies looking at the efficacy of ET
receptor antagonism in reducing proteinuria have been
in patients with diabetic nephropathy. The first of
these was a phase II study investigating the effects of
12 weeks of treatment with avosentan, a relatively
ETA-selective antagonist (ETA:ETB blockade ;300:1),
on albuminuria in 286 patients with diabetic nephrop-
athy already receiving renin-angiotensin system block-
ade. Subjects had a creatinine clearance of ;80 ml/min
and albuminuria of;1500 mg/day (Wenzel et al., 2009).
Avosentan, at all doses used, reduced albuminuria by
20–30%. Fluid retention was a problematic side effect,
however, and was more apparent at the higher doses of
avosentan. Based on their interpretation of the data,
the pharmaceutical company launched a phase III trial
(ASCEND) examining the effects of avosentan on renal
disease progression or death in type 2 diabetic nephrop-
athy (Mann et al., 2010). A total of 1392 patients were
enrolled and avosentan reduced urine albumin-to-
creatinine ratio (ACR) by 40–50% compared with the
10% reduction seen with placebo. However, the trial
was terminated early because of greater serious adverse
cardiovascular events in the avosentan groups, includ-
ing a threefold increase in the incidence of congestive
heart failure. It is likely that the doses of avosentan
used were too high and so blocked the ETB receptor as
well as the ETA, an effect that would be predicted to
promote fluid retention (Kohan et al., 2011b). This was
also confirmed by a study in healthy volunteers that
Pharmacology and Genetic Modification of the ET System 403
showed that increasing doses of avosentan were associ-
ated with sodium retention study (Smolander et al.,
2009), and this was certainly the case at the dose used in
the ASCEND study. Furthermore, the ASCEND trial
involved patients with advanced kidney disease who
may have been more likely to retain fluid.
The failure of the ASCEND trial underscored the
importance of careful patient selection and ET antago-
nist dosing in CKD. A subsequent study evaluated the
effects of doses of atrasentan (more ETA selective than
avosentan) or placebo given for 8 weeks on ACR in 89
subjects with diabetic nephropathy receiving stable
doses of renin-angiotensin system inhibitors (Kohan
et al., 2011a). Atrasentan reduced ACR by ;40% com-
pared with the 11% reduction seen with placebo. The only
adverse event was mild to moderate peripheral edema,
which was dose related.
As yet, it remains unclear as yet to what extent these
effects on proteinuria are explained by BP reduction
alone. In both the acute and chronic dosing studies in
nondiabetic CKD using a selective ETA receptor block-
ing approach, there was, as expected, a correlation
between the changes in BP and proteinuria, with a
greater fall in urinary protein seen in those patients
with the greater fall in BP. However, both studies also
had an active control that matched the reduction in BP
seen with ETA antagonism. Despite a similar fall in BP
with both the active control and the ETA antagonist,
proteinuria fell to a greater extent with the latter
supporting a BP-independent effect. Furthermore, a
renal hemodynamic study after chronic selective ETA
antagonism suggests that falls in both GFR and filtra-
tion fraction are in part responsible for the reduction in
proteinuria (Dhaun et al., 2011). This is similar to the
effects seenwith ACE inhibitors and somay translate to
longer term renoprotection. In the atrasentan study in
diabetic nephropathy the reduction in ACR was evident
after 1 week of treatment and was associated with a fall
in BP, suggesting that the initial antiproteinuric effect
of atrasentan may be hemodynamic.
It is noteworthy that the problem with hyperkalemia
associated with the use of ACE inhibitors, especially in
those with CKD, is not an issue with ET receptor
antagonists. Furthermore, the fluid retention (and
anemia that results secondary to this) consistently
demonstrated in clinical trials with both selective ETA
and mixed ETA/B agents has been shown to be manage-
able (Weber et al., 2009) and to not affect the anti-
proteinuric benefits of these drugs (Kohan et al., 2015).
8. Broader Cardiovascular Risk: Endothelial
Dysfunction, Atherosclerosis, and Arterial Stiffness.
The endothelium is a crucial regulator of vascular tone
(Endemann and Schiffrin, 2004) and its function is
impaired in heart failure, hypertension, and CKD, with
a shift toward reduced vasodilation, associated with a
proinflammatory and prothrombotic state. Endothelial
dysfunction is recognized to be a key early determinant
in the progression to atherosclerosis with the develop-
ment of active vascular microcalcifications (Irkle et al.,
2015) and is now well established to be independently
associated with increased cardiovascular risk (Lerman
and Zeiher, 2005) and GFR loss (Perticone et al., 2004).
Animal models show that ET-1 contributes to endothelial
dysfunction (Amiri et al., 2004), and ET receptor antag-
onism, predominantly with selective ETA antagonists,
improves NO-mediated endothelial function (Barton
et al., 1998; Best et al., 1999; Bauersachs et al., 2000). In
addition to its effects on BP, ET-1 is proinflammatory
(Dhaun et al., 2006) and is implicated in the development
of atherosclerosis. Several animal models have shown
benefit of both selective and mixed ET receptor antag-
onism in the development of atherosclerotic lesions
(Kowala et al., 1995; Barton et al., 1998; Babaei et al.,
2000; d’Uscio et al., 2002). Clinical data are limited but
support a role for the ETA receptor in coronary
vascular tone and endothelial dysfunction in coronary
artery disease (Halcox et al., 2001, 2007). Further-
more, endothelial dysfunction is a feature of aging, and
in these subjects compared with younger ET-1 contrib-
utes to endothelial dysfunction (Westby et al., 2011).
Also, in older subjects with early atherosclerosis long-
term administration of a selective ETA receptor
antagonist improves coronary endothelial dysfunction
(Reriani et al., 2010).
Arterial stiffness is linked to endothelial dysfunction
(Oliver and Webb, 2003) and the two commonly coexist
in patients at increased cardiovascular risk. A number
of interventions that reduce arterial stiffness also
improve endothelial function (Oliver and Webb, 2003).
To date, there have been few studies addressing the
relationship between these two markers of cardiovas-
cular disease after treatment. However, both animal
and human studies suggest that the endothelium is an
important regulator of arterial stiffness. ET-1 increases
arterial stiffness in animals (Amiri et al., 2004) and
humans (Vuurmans et al., 2003). There are only two
studies, one acute (Dhaun et al., 2009a) and one chronic
(Dhaun et al., 2011), both using a selective ETA receptor
antagonist approach in nondiabetic CKD. These show a
reduction in arterial stiffness with treatment, but the
extent to which this is independent of BP is unclear.
Interestingly, in the acute study (Dhaun et al., 2009a),
the reduction in arterial stiffness seen with ET antag-
onism was greater in those taking dual ACE inhibitor/
angiotensin receptor blocker treatment than in those
receiving an ACE inhibitor alone (Dhaun et al., 2009b).
Indeed, there was a similar effect for proteinuria in this
study.
9. Chronic Pain. In 1990 a report was published
that described a deep muscular pain associated with
infusion of intra-arterial ET-1 that was exacerbated
both by touch and muscle contractions (Dahlof et al.,
1990). Since then there has been a significant amount of
research dedicated to the contribution of the ET system
404 Davenport et al.
to pain. This has been comprehensively reviewed recently
by Smith et al. (2014) andwill only be summarized briefly.
ET-1 and its receptors are widely distributed through-
out the central and peripheral nervous system pain
pathways. It is now recognized that not only does ET-1
cause pain directly (Namer et al., 2008) but it also
sensitizes pain pathways to other painful stimuli such
as capsaicin (Piovezan et al., 1998). The pain that ET-1
induces directly is mediated via mechanosensitive
C-nerve fibers, but the neuronal firing pattern is distinct
to that elicited by capsaicin and histamine (Smith et al.,
2014), which give rise to short bursts of activity compared
with longer lasting responses with ET-1. Most of the
studies examining the role of ET-1 in specific types of pain
are preclinical and cover a range of diseases including
arthritis, cancer, diabetes, sickle cell disease, and various
types of neuropathic pain (Smith et al., 2014). It appears
that the ETA receptor is consistently involved in pain
transmission pathways, whereas the role of the ETB
receptor is less clear and varies between organs, the type
of pain, and across species (Smith et al., 2014).
To date, there are only a few published clinical studies
and these are limited to cancer and sickle cell disease.
ET-1 is thought to be involved in a number of aspects of
cancer pathophysiology including pain. This extends to
many different cancers, including, breast, brain, pan-
creatic, prostatic, and colon. Clinical studies are largely
restricted to castration-resistant prostate cancer. Here,
addition of an ET receptor antagonist to standard
therapy allows for a better pain profile in patients with
bony involvement (Albany and Hahn, 2014).
Sickle cell disease is characterized by vasoocclusive
events, which may occur in a wide range of vessels,
ranging from the microvasculature to the muscular
arteries. Cell dehydration is an important step in the
formation of sickle cells, and ET has been suggested to
mediate this action in vitro by activating Ca2+-gated K+
channels via ETB receptors on mouse erythrocytes
(Rivera et al., 1999). In vitro studies have shown that
vascular endothelial cells exposed to sickled erythro-
cytes results in elevations in ET-1 transcripts and
peptide, and it has been speculated that this increase
may contribute to vasoconstriction (Phelan et al., 1995).
In patients with sickle cell disease, plasma ET-1
concentration correlates with pain scores during crises
(Schlenz et al., 2012). Phelan et al. (1995) showed that
exposure of human endothelial cells to sickled sickle
erythrocytes caused an increase in ET-1 transduction
and peptide release, suggesting a cause for vascular
occlusion. In addition, ETwas found to activate Ca2+gated
K+ channels via ETB receptors in mouse erythrocytes and
to cause cell dehydration, an important role in the
pathogenesis of sickle cell disease (Rivera et al., 1999).
At present, however, there are no studies using ET
receptor antagonists in this condition.
10. Subarachnoid Hemorrhage. Cerebral vaso-
spasm constitutes the only medically treatable cause
of disability and death in patients suffering a sub-
arachnoid hemorrhage (SAH). Although ET-1 does not
normally contribute to cerebral vascular tone (Andresen
et al., 2006), its synthesis increases and ET receptors
are upregulated after cerebral ischemia, and this may
contribute to vascular dysfunction and brain injury
(Matsuo et al., 2001; Petrov and Rafols, 2001).
Although the preclinical data favored the use of
selective ETA receptor antagonists in this condition,
the early clinical trials using mixed antagonists were
inconclusive (Chow et al., 2002). Early data with the
selective ETA receptor antagonist clazosentan suggested
that it prevented cerebral vasospasmafter SAH, although
the clinical outcome remained unchanged (Macdonald
et al., 2007). This led on to several larger clinical studies of
longer duration.
A meta-analysis and systematic review published in
2012, which included data from five studies incorporat-
ing 2601 patients, concluded that ET receptor antago-
nists do not affect the functional outcome after SAH,
although they reduce vasospasm (Vergouwen et al., 2012).
This was no different for selective or mixed antagonists.
Furthermore, the use of these agents was associated with
an increased incidence of complications, including fluid
overload and anemia, both recognized side effects of this
class of drug and poor prognostic indicators in SAH. At
present, ET receptor antagonists do not have a role in the
medical management of SAH, but the results of future
studies, perhaps in more defined cohorts using drugs with
an improved side effect profile, are awaited.
11. Cancer. Dysregulation of the ET system is now
recognized to play an important role in the biology of
several solid tumors, including bladder, breast, colon,
lung, ovarian, and prostate cancers (Rosano et al.,
2013a). ET-1 signaling is important in a number of
tumorigenic processes, including disease initiation,
angiogenesis, epithelial to mesenchymal transition,
and metastasis. Expression profiles of ET receptors
differ between cancer types, and these may be classified
into three types (Irani et al., 2014): those that pre-
dominantly express ETA receptors, such as breast,
colon, and prostate; cancers that mainly express ETB
receptors, such as melanoma and several brain tumors
(glioblastoma is one example); and those cancers that
express both ETA and ETB receptors, such as bladder,
lung, and ovary. Of note, there is a correlation between
ET receptor expression and disease outcomes such as
metastasis and, more importantly, patient survival
(Rosano et al., 2013a,b). The mitogenic effects of ET-1
are mediated via ETA receptors in several epithelial
tumors (Grant et al., 2003) and by ETB in nonepithelial
tumors (such as melanoma) (Lahav et al., 2004). ET-1,
through its actions onETB, is alsomitogenic for lymphatic
endothelial cells, and so ETB receptor expression in
cancer is associated with lymphatic spread and ETB
receptor blockade impairs lymphangiogenesis (Spinella
et al., 2010). Similarly, ETA receptor overexpression is
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associated with tumor metastasis (Mai et al., 2006).
Thus, clinical trials of ET receptor antagonists in cancer
have focused on both selective ETA and mixed ETA/B
blocking approaches.
Despite the promising results of ET blocking strate-
gies, used in cell lines and animal models of cancer, the
clinical trials have been less rewarding. The two largest
studies have been in advanced prostate cancer using the
selective ETA antagonists atrasentan (809 patients)
and Zibotentan (Astra Zeneca) (312 patients) (Carducci
et al., 2007; James et al., 2010). A trial in metastatic
melanoma using the mixed ETA/B antagonist bosentan
was also disappointing (Kefford et al., 2007). A similarly
negative study was recently reported using zibotentan
in advanced ovarian cancer (Cognetti et al., 2013).
Given the lack of specific biomarkers that might
predict clinical response to treatment with an ET
receptor antagonist, either as monotherapy or in addi-
tion to standard treatment, it currently remains unclear
if there are specific subgroups of patients that might
benefit. The issue of whether a selective ETA or mixed
ETA/B blocking approach is better is also unresolved,
although this is likely to vary between cancer type.
Furthermore, given the significant crosstalk between
the ET system and other pathways involved in cancer
biology, such as vascular endothelial growth factor and
the epidermal growth factor receptor (Rosano et al.,
2013a,b), it might be that the role of ET receptor
antagonists is in combination with agents targeting
these pathways. Finally, stage of disease may be an
important factor. Many of the clinical trials have been
conducted in late-stage, often metastatic, disease and it
is currently unclear whether specific cancers are more
dependent on ET signaling in the early disease trajec-
tory, which may then be a better target.
VII. Concluding Highlights and Perspectives
Considerable progress has been made during the last
two decades in characterizing the pharmacology of the
ET signaling pathway. This has benefited from the
development of the key tool compounds described in this
review, with remarkably highly selective ETA and ETB
antagonists and selective ETB agonists together with
radiolabeled analogs to accurately and confidently de-
lineate the ET system in humans and animal models. A
surprising omission has been that no ETA agonist has
been reported and remains a mystery. The use of ETB
agonists such as IRL1620 in chemotherapy and neuro-
protection is a particularly intriguing field that war-
rants further investigation (Briyal et al., 2014). New
strategies to block the unwanted actions of ET are
emerging via small molecule epigenetic modulators as
well as the appearance of the first biologic—a monoclonal
to the ETB receptor—although GPCRs remain a challeng-
ing target for the development of pharmacologically useful
monoclonal antibodies. Increasing our understanding of
regulating the ET system via microRNAs (Grant et al.,
2013) may also yield new druggable targets in the future.
Two ET antagonist (bosentan, ambrisentan) are
firmly established in the clinic and have proved success-
ful for the treatment of PAH, with the next generation
antagonist with improved efficacy (macitentan) being
approved for clinical use, although it remains unclear to
what extent ET antagonist modify disease progression.
Surprisingly, PAH remains the only clinical condition
approved for ET receptor antagonists. The use of ET
antagonist in heart failure has not translated from
predictions arising from animal studies, although the
reasons for lack of efficacy are still unclear because the
results of certain clinical trials have not been fully
published. However, clinical trials continue to test the
repurposing of existing antagonists with the most likely
clinical indication as outlined here probably targeting
the kidney, including hypertension associated with
CKD and diabetic nephropathy associated with pro-
teinuria, as well as new potential indications for chronic
pain and SAH. Perhaps the greatest potential for a
paradigm shift is GPCR-mediated targeting of the ET
system in cancer. The second strategy to block the
unwanted actions of ET via ECE inhibition despite 20
years of research has not yet translated into a clinical
application. Further studies are needed to understand
more fully the synthesis and metabolism of ETs and
how current and future putative ECE inhibitors also
impact or alter other peptide transmitter systems.
Key questions remain. What is the precise molecular
mechanism for long-lasting responses to ET-1, particu-
larly in the human vasculature? What is the physiologic/
pathophysiological role of ET3, and will differences
emerge particularly in the CNS between ET-1 and ET-3?
Do homo- or heterodimers of ET receptors exist in native
tissue, and can they be exploited pharmacologically?
Perhaps the greatest revolution in pharmacology is the
discovery of biased ligands. Can these be exploited in the
ET field? For example, a b-arrestin biased antagonist to
block oncogenic pathways in ovarian cancer but spare the
beneficial Ga signaling, which is tumor suppressive.
Currently, we cannot yet distinguish pharmacologi-
cally between an ETA receptor expressed on different
cell types such as a myocyte versus a smooth muscle.
However, many mechanistic hypotheses about the
physiologic and pathophysiological role(s) of the ET
system have been tested with the new technological
tools to knockout, knock in, or alter the levels of gene
expression globally and in specific cell types. We have
highlighted the noteworthy studies and conclusions
from over 100 publications, reporting a remarkable 28
different genetic modifications of the ET system. In
addition, we provide insight for potential areas of
interest for future research.
Global KO of ECE-1, ET-1, and ETA are all embryonic
lethal and found to be critical for neural crest patterning,
proper jaw identity and development, and cardiovascular
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development, thus greatly expanding our understanding
of the role of the ET-1 system in development. Global KO
of ET-3 and ETB led to the demise of pups by 3–4 weeks of
age. This has led to the discovery that ET-3 and ETB
receptors are vital for the development of vagal neural
crest-derived enteric neurons and the trunk neural crest-
derivedepidermalmelanocytes.Theseobservations resulted
in ET-3/ETB being identified as a causative pathway in the
development of intestinal megacolon or Hirschsprung dis-
ease. Rescuing this lethalmegacolon phenotype by insertion
of a functional ETB transgene directed to expression in
neuronal tissue allows the intestine to develop normal yet
dysfunctional ETB receptor expression in all nonneuronal
tissues. The rescued ETB receptor-deficient mouse and rat
established the critical role of ETB signaling in salt-sensitive
hypertension.
A large body of work with a range of genetic modifi-
cations with the ET system in the kidney and endothe-
lium found that collecting duct-specific ET-1, ETB, and
ETA/B KO mice all show a salt-sensitive hypertensive
phenotype. A common side effect of pharmacological ETA
antagonists is edema. Genetic models of cell-specific ETA
KO in the CD, whole nephron, cardiomyocyte, or smooth
muscle pointed toward the collecting duct and smooth
muscle ETA receptors being responsible for the fluid re-
tention. CD ETA receptor activation also contributes to the
urine concentrating mechanisms. ETA and ETA/B antago-
nists are clinical therapeutic agents for PAH in clinical
trials for diabetic nephropathy, thus the elucidation of the
signaling mechanisms of CD and/or smooth muscle ETA
receptor activation would be warranted to study in the
future.
Generally, overexpression of ET-1 or ET-2 peptide
results in increased inflammation and fibrosis in many
tissues, especially the heart. Using a novel hypomorphic
low expressing ET-1 gene and hypermorphic high express-
ing ET-1 gene, it was found that ET-1 is vital for maintain-
ing normal contractile function and for ensuring that the
myocardium has sufficient collagen to prevent overstretch-
ing; even amodest decrease in ET-1 expression is sufficient
to cause cardiac dysfunction. Cardiomyocyte-specific ET-1
KO studies showed that cardiac ET-1 is critical for cardiac
function and cardiomyocyte survival in aging or stressed
mice. Proinflammatory and/or profibrotic diseases, such
as cardiac hypertrophy or acute kidney injury, were
attenuated in endothelial cell ET-1 KO mice. Thus,
selectively antagonizing endothelial-derived ET-1 would
be advantageous to block inflammation and fibrosis in the
heart and kidney.
Pain is one of the most prevalent aliments in many
patient populations. Studies with astrocyte-specific
overexpression of ET-1 suggest that increases in astro-
cyte ET-1 may be harmful in the setting of stroke but
may alleviate chronic pain. Given the strong evidence
that ET-1/ETA receptors contribute to sensory nerve
pain, the apparent contrast of central versus peripheral
ETA receptors in the pain pathway requires further
investigation to determine the viability of ET receptor
antagonists and the cell specificity of the ET system in
the many different paradigms of pain.
In perspective, the use of over 28 different genetic
modificationmodels of the ET systemhas provided clear
determinations of the physiologic significance of the ET
system in development as well as in vascular function,
fluid-electrolyte homeostasis, cardiac function, and
neuronal function in a variety of cell types. These
models have proven to be invaluable to distinguish the
physiologic from the pathophysiological aspects of the
ET system. Newer genetic modification tools that
manipulate the level of expression of the ET system in
various cell types will further our understanding of
molecular mechanisms for therapeutic advantage.
Studies on cell-specific modification in the ET system
in mice provide the proof of principle, for example
collecting duct ETA receptors are responsible for the
unwanted side effect of blocking ETA receptors to cause
fluid retention. The challenge for future in ET pharma-
cology will be to discover biased agonists and antago-
nists that can selective activate or block ET receptors
expressed on different cell types.
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